Weight changes and gamma radiation emissions during the three-week isolation period following administration of radioactive iodine (I131) in cats with hyperthyroidism by Roberts, Emma
  
 
 
 
 
 
 
 
 
Roberts, Emma (2017) Weight changes and gamma radiation emissions 
during the three-week isolation period following administration of 
radioactive iodine (I131) in cats with hyperthyroidism. MVM(R) thesis. 
 
 
http://theses.gla.ac.uk/7916/  
 
 
 
 
Copyright and moral rights for this work are retained by the author 
A copy can be downloaded for personal non-commercial research or study, without prior 
permission or charge 
This work cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author 
When referring to this work, full bibliographic details including the author, title, 
awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
Glasgow Theses Service 
http://theses.gla.ac.uk/ 
theses@gla.ac.uk 
! 
 
WEIGHT CHANGES AND GAMMA RADIATION EMISSIONS 
DURING THE THREE-WEEK ISOLATION PERIOD 
FOLLOWING ADMINISTRATION OF  
RADIOACTIVE IODINE (I131) IN CATS WITH 
HYPERTHYROIDISM 
 
 
Emma Roberts 
BVetMed (Hons) DipECVIM-CA MRCVS 
 
 
Submitted in fulfillment of the requirements for the Degree of Master in 
Veterinary Medicine 
 
  
College of Medical, Veterinary & Life Sciences, University of Glasgow 
 
 
September 2016 
 
 
 
 
 
 
 
 
 
 
 2 
ABSTRACT 
Hyperthyroidism is the most common endocrine disorder seen in cats and is 
frequently associated with weight loss. Following treatment weight gain should 
be seen and therefore weight assessment should form part of the monitoring 
protocol for cats with this condition. Although several treatment options are 
available for hyperthyroidism in cats, radioactive iodine (I131) is the gold 
standard treatment for this condition. I131 is offered by several institutions within 
the United Kingdom (UK); however, this treatment is associated with variable 
hospitalization periods due to the radiation hazards that these cats pose to their 
owners following treatment. Hospitalization length and costs associated with 
this treatment have both been found to have a negative impact on the frequency 
that I131 is offered and utilized by general practitioners and owners respectively. 
 
The aims of the studies presented in this thesis were to assess the weight 
changes of hyperthyroid cats seen during the three-week isolation period 
following I131 administration and assess if an electronic personal dosimeter (EPD) 
could be used to document the levels of gamma (γ) radiation emitted from 
treated cats during the same time period. For the study assessing the weight 
changes in treated cats, weight changes were shown to be useful as an indicator 
of the reversal of biochemical hyperthyroidism; however, factors including the 
gender and age of the cat were not found to affect the weight changes that 
occurred. For the γ radiation emission study, it was also assessed whether the 
current 21-day hospitalization period at the Small Animal Hospital (SAH) could 
be shortened. It was shown that an EPD can be used to measure the γ radiation 
emitted from treated cats and that a reduction of the current isolation period to 
14 days is possible in cats treated with ≤ 200 megabecquerels (MBq) of I131.  
 
Both of these studies have added to our knowledge and understanding of I131 
treatment in cats and have demonstrated the merits of using weight changes in 
the assessment of treatment of hyperthyroidism and the utility of EPDs for 
measuring γ radiation emissions in treated cats. 
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1.1 The thyroid gland and thyroid hormone production 
 
The thyroid gland is located on the lateral aspect of the proximal trachea. It 
develops from the fourth branchial pouch as an invagination in the pharyngeal 
floor and then migrates caudally along the midline of the trachea. The gland is 
bilobed in cats and each lobe is closely associated with two parathyroid glands, 
which secrete parathyroid hormone and are responsible for the control of 
calcium metabolism. The thyroid gland is enclosed by a capsule of connective 
tissue and the major blood supply is provided by the cranial thyroid arteries 
(Ohri et al., 1994, Dyce et al., 2010; Greco & Stabenfeldt, 2013).  
 
The follicular cells of the thyroid gland are responsible for the production of two 
active thyroid hormones, triiodothyronine (T3) and thyroxine (T4). In order to 
make T3 and T4, iodide, which is converted from iodine in the gastro-intestinal 
tract, is taken up by iodide transporters and becomes trapped within the thyroid 
gland. Iodide is then oxidized to iodine and iodination of tyrosine residues in the 
glycoprotein thyroglobulin occurs, forming T3 and T4 (Peterson, 2006). Although 
T4 is the hormone predominantly secreted by the thyroid gland, T3 is more 
metabolically active. The synthesis and secretion of T3 and T4 is predominantly 
stimulated by an increase in thyrotropin (TSH) production from the pars distalis 
of the pituitary gland. In turn, the synthesis and secretion of TSH is stimulated 
by thyrotropin releasing hormone (TRH), which is produced by the 
hypothalamus. Thyroid hormones are transported in the circulation via plasma 
proteins e.g. thyroxine binding globulin and also to a lesser degree by 
lipoproteins. However, only the unbound and metabolically active fraction of T4, 
free T4 (fT4) is able to be taken up by tissues and exert its effects. Although T3 
is synthesized by the thyroid gland, the majority of it is produced by 
deiodination of T4 in the cells of the peripheral tissues, including the kidneys, 
skeletal muscle, liver and skin (Visser, 1996; Mooney & Peterson, 2012).  
 
Thyroid hormones bind to thyroid hormone receptors, which are located in the 
cell nucleus, and result in gene transcription (Bianco & Kim, 2006). Thyroid 
hormones increase the metabolic rate of cells and are responsible for the 
regulation of the metabolism of carbohydrates, lipids and proteins. They 
increase the rate of both glycolysis and lipolysis within cells and the cells uptake 
 19 
of amino acids (Mooney & Peterson, 2012; Greco & Stabenfeldt, 2013). They 
are essential for normal growth and development and thyroid function is 
associated with both body weight and body mass index (Knudsen et al., 2005; 
Fox et al., 2008; Mullur et al., 2014). 
 
The circulating concentrations of thyroid hormones are controlled through a 
negative feedback loop of the hypothalamic-pituitary-thyroid axis, in which 
increases in T4 and T3 result in the suppression of TRH and/or TSH (Connors & 
Hedge, 1981; Yamada et al., 1989).  
  
Thyroid hormones are predominantly metabolised via deiodination by 
iodothyronine deiodinases; however, alternative pathways include conjugation 
of their phenolic hydroxyl group with sulfate or glucuronic acid, oxidative 
deamination and decarboxylation of the alanine side chain and cleavage of the 
ether link (Visser, 1996; Wu et al., 2005; Bianco & Kim, 2006). 
 
1.2 Hyperthyroidism in humans 
 
Hyperthyroidism is a pathological disorder in which thyroid hormones are 
synthesized excessively. The prevalence of hyperthyroidism in humans increases 
with age, with the mean age of patients reported to be between 50 and 59 years 
old (Leese et al., 2008; Abraham-Nordling et al., 2011; De Leo et al., 2016). It is 
a condition more frequently seen in women (De Leo et al., 2016). 
 
The most common cause of hyperthyroidism is Graves’s disease. This is an 
autoimmune condition in which the natural immunotolerance is lost and the 
development of antibodies, which bind to the TSH receptor and stimulate the 
follicular cells of the thyroid, occur (De Leo et al., 2016).  
 
Toxic nodular goiter is also a common cause of hyperthyroidism. In this 
condition, nodules that have developed in the thyroid autonomously produce 
thyroid hormones independent of the influence of TSH. There have been 
mutations documented both in the thyrotropin receptor (TSHR) gene and the 
adenylate cyclase stimulation protein Gsα, which result in constitutive activation 
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of the gene and protein respectively, in many of these patients (De Leo et al., 
2016).  
 
Treatment options for hyperthyroidism include surgery (thyroidectomy), anti-
thyroidal medication and radioactive iodine (I131). In Graves’s disease, all three 
treatment modalities are utilized; however, in patients with toxic nodular 
goiter, anti-thyroidal medication only tends to be used to restore the euthyroid 
state prior to definitive treatment i.e. thyroidectomy or I131 treatment (De Leo 
et al., 2016).  
 
In humans a syndrome of subclinical hyperthyroidism also exists, which is 
classified by a repeatedly low or undetectable serum TSH concentration in the 
face of normal serum fT4 and free T3 (fT3) concentrations. This condition is 
usually picked up on routine screening tests and patients may have either only 
mild signs of hyperthyroidism such as nervousness, heat intolerance and anxiety 
or no clinical signs at all (Biondi & Cooper, 2008). As there have been no 
controlled studies that have shown a benefit of treatment in these cases, 
treatment of this condition is currently controversial. However, if treatment is 
pursued, then I131 is thought to be the most appropriate (Bahn et al., 2011). 
 
1.3 Hyperthyroidism in cats  
 
Feline hyperthyroidism, since being first reported in 1979, has become the most 
common endocrine disorder in cats (Peterson et al., 1979; Peterson, 2012). It is 
clinically and pathologically similar to the condition toxic nodular goiter in 
humans and therefore comparisons between the two conditions can potentially 
be drawn (Kooistra, 2014; Peterson, 2014).  
 
Hyperthyroidism in cats results from the excessive production of T3 and T4 from 
thyroid tissue, independent of TSH production from the pituitary gland. It is a 
disease that affects middle-aged and older cats and the average age of onset is 
12-13 years old. An obvious gender predilection has not yet been found 
(Peterson, 2012; Mooney & Peterson, 2012).  
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In the majority of cases (> 95 %), hyperthyroidism is caused by adenomatous 
hyperplasia of the thyroid glands, with hyperplastic tissue identified on 
histopathological assessment (Hoenig et al., 1982). Both thyroid glands are 
typically affected in cats; however, in some cases the disease can be unilateral 
in origin or even multifocal (≥ three tumour nodules) (Peterson & Broome, 2015). 
Similar to humans with toxic nodular goiter, mutations in the TSHR and the Gsα 
genes have been found in some hyperthyroid cats (Peeters et al., 2002; Watson 
et al., 2005; De Leo et al., 2016). In rare cases, hyperthyroidism can result from 
a thyroid carcinoma; however, not all cases of thyroid carcinoma are 
hypersecretory (Hoenig et al., 1982; Turrel et al., 1988; Naan et al., 2006; 
Hibbert et al., 2009; Peterson & Broome, 2015; Peterson et al., 2016a). Thyroid 
carcinomas can be further classified as follicular, papillary or compact and in 
some cases a mixture of adenomatous and carcinoma tissue can be detected on 
histopathological assessment (Turrel et al., 1988; Hibbert et al., 2009).  
 
Hyperthyroidism is a progressive disease, ranging from a subclinical disease to a 
clinical and symptomatic disease. A low serum TSH concentration combined with 
histological evidence of nodular thyroid disease but a normal serum T4 
concentration demonstrates subclinical disease. This is compared to the clinical 
phase of the disease when T4 is then produced excessively resulting in an 
increased serum T4 concentration (Wakeling et al., 2007). As the duration of 
clinical disease lengthens, there is also further progression of the disease as 
shown by the findings of Peterson et al., (2016a). In the Peterson et al., (2016a) 
study it was shown that the prevalence of multifocal disease, large (4–8 cm3) and 
huge (> 8 cm3) thyroid tumours, thyroid carcinoma and intrathoracic tumours all 
increased with length of disease duration, as well as the median tumour volume 
and median serum T4 concentration when comparing cats with disease duration 
≤ one year to cats with a disease duration > 4 - 6.1 years. 
 
Hyperthyroidism is associated with an array of clinical signs in cats; however, 
none of these are pathognomonic for the condition. Clinical signs include 
polyphagia, weight loss, polyuria/polydipsia, gastro-intestinal signs (vomiting 
and diarrhoea), hyperactivity, irritability and tachypnoea, as well as skin 
changes and coat changes such as alopecia or an unkempt coat. Less common 
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clinical signs can include a decreased appetite, ventroflexion of the neck and 
decreased energy levels (Mooney & Peterson, 2012). 
 
1.4 Prevalence of feline hyperthyroidism 
 
The prevalence of hyperthyroidism in cats has increased over the last few 
decades (Edinboro et al., 2004a). Edinboro et al., (2004a) documented that the 
hospital prevalence of hyperthyroidism increased from 0.1 % during the time 
period 1978 to 1982, to 2 % during the time period 1993 to 1997.  
 
The prevalence of hyperthyroidism may also be affected by geographical 
location. A prevalence of 3.93 % has been documented in cats ≥ 10 years old in 
Hong Kong, compared to a prevalence of 8.7 % in England, in cats of the same 
age group (De Wet et al., 2009; Stephens et al., 2014). An even higher 
prevalence of 12.3 % has been documented in Southern Germany (Kohler et al., 
2016). The Kohler et al., (2016) study did use a different age cut-off of eight 
years old, rather than the age cut-off used in the two former studies and this 
may have affected their prevalence. However, as the age of onset of 
hyperthyroidism is 12-13 years old, this variance in age cut-off is unlikely to 
have significantly affected their findings (Mooney & Peterson, 2012). As the 
prevalence of hyperthyroidism has been found to have increased over time, it is 
also possible that differences in prevalence’s between all these studies could 
have been affected by this, as well as geographical variation due to the studies 
being performed at different times.  
 
1.5 Predictors and risk factors for the development of hyperthyroidism in 
cats 
 
Predictors for the development of hyperthyroidism have included the presence 
of a goiter, serum alkaline phosphatase (ALKP) and TSH concentrations and 
breed. These predictors were identified in a study that evaluated which cats, 
aged nine years and over, did and did not develop hyperthyroidism over a 14-
month follow up period. It was found that those cats that developed 
hyperthyroidism were significantly more likely to have a palpable goiter, a 
higher serum ALKP concentration and non-pure breed status at baseline, as well 
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as having an undetectable serum TSH concentration, when compared to cats 
that did not become hyperthyroid (Wakeling et al., 2011).   
 
Potential risk factors for cats developing hyperthyroidism have been proposed. 
These have included breed, the consumption of canned wet food, the use of cat 
litter, exposure to polybrominated diphenyl ethers (PBDEs) and the use of 
topical ectoparasite preparations (Kass et al., 1999; Dye et al., 2007). A more 
recent study by Wakeling et al., (2009) also found similar risk factors to Kass et 
al., (1999), as well as additional factors that included increasing age and a diet 
that included fish. 
 
1.5.1 Breed 
 
Pure bred cats, including Siamese, Persian, Himalayan and Burmese breeds have 
been documented to have a lower risk of developing hyperthyroidism compared 
to domestic shorthaired cats; however, this has not always been demonstrated 
(Kass et al., 1999; Olczak et al., 2005; De Wet et al., 2009; Wakeling et al., 
2011; Stephens et al., 2014). One study assessed this finding further and 
evaluated whether the metabolism of tyrosine, iodine or selenium was 
associated with coat colour/hyperthyroidism in cats that had light or pointed 
coats, but no associations were noted (Sabatino et al., 2013). 
 
1.5.2 Diet 
 
Cats fed a canned wet food have been documented to be at higher risk for 
developing hyperthyroidism; however, the studies that identified this have been 
associated with limitations such as age differences between the case and control 
groups, which may have affected their findings (Kass et al., 1999; Wakeling et 
al., 2009).  
 
Potential constituents of canned food that may be associated with the link with 
hyperthyroidism include the monomer bisphenol A, which is found in plastics and 
is used to line metal cans, as well as selenium and iodine levels in the diet and 
flavonoids (Kooistra, 2014; van Hoek et al., 2015). 
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1.5.2.1 Bisphenol A   
 
Bisphenol A can act as a thyroid hormone receptor antagonist as it is structurally 
similar to thyroid hormones. It has been shown to alter the transcriptional 
expression of genes involved in thyroid hormone synthesis and the genes 
involved with thyroid transcription factors in rats, as well as inhibiting iodide 
uptake (Wu et al., 2016).  
 
Although exposure to bisphenol A has been proposed as a potential risk factor in 
cats, a direct link with the development of hyperthyroidism has not been 
currently found (van Hoek et al., 2015). 
 
1.5.2.2 Selenium 
 
Selenium has been found to increase the expression and activity of the sodium 
iodide symporter in rats, which then mediates the iodine uptake by the thyroid 
follicular cells (Leoni et al., 2015). Although a selenium deficient diet has been 
found to result in a significant increase in both serum fT4 and T4 concentrations 
in chickens, the effect of selenium has yet to be found as a possible cause of 
hyperthyroidism in cats in studies performed to this date (Foster et al., 2001; 
Sabatino et al., 2013; Huang et al., 2016). 
 
1.5.2.3 Iodine 
 
Cats that are fed a non-iodine supplemented commercial diet have been found 
to be more than four times more likely to develop hyperthyroidism, when 
compared to a population of cats fed an iodine-supplemented diet (Edinboro et 
al., 2004b). A marked variation in the iodine content of canned food has also 
been found and this may contribute to the development of nodular hyperplasia 
and subsequently hyperthyroidism, if diets go from being deficient in iodine to 
excessive (Edinboro et al., 2013).  
 
Iodine deficiency has also been shown to be a risk factor for developing 
hyperthyroidism in humans, as the prevalence of toxic nodular goiter is higher in 
areas that are iodine deficient (De Leo et al., 2016). 
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1.5.2.4 Flavonoids 
 
The feeding of a soy-based diet, which contain isoflavone a type of flavonoid, 
has been found to result in significantly higher serum T4 and fT4 concentrations 
in cats, when compared to cats fed a soy-free diet; however, serum T3 
concentrations were unaffected. It is thought that these changes in thyroid 
hormone concentrations are due to either inhibition of 5’-iodothyronine 
deiodinase or due to enhanced clearance of T3 (White et al., 2004). The highest 
median isoflavone content in cat food has been found to be in the wet 
commercially-prepared foods (Bell et al., 2006). 
 
1.5.3 Cat litter 
 
Cats that use cat litter have been found to have a three-fold increased risk of 
hyperthyroidism (Kass et al., 1999; Wakeling et al., 2009). However, it has been 
suggested that this association between cat litter and hyperthyroidism may 
actually be due to the improved level of care seen in these cats, rather than the 
use of cat litter being a direct cause of hyperthyroidism (Kooistra, 2014).  
 
1.5.4 Polybrominated diphenyl ethers (PBDEs) 
 
Cats have been shown to be highly exposed to PBDEs and it has also been shown 
that hyperthyroid cats have higher levels of PBDEs in their serum compared to 
euthyroid cats (Dye et al., 2007; Norrgran et al., 2015). 
 
Research has suggested that PBDEs result in enhanced excretion of T4 or that 
they competitively bind to T4, preventing it from binding with its receptor, 
therefore interfering with the thyroid hormone transport system (Birnbaum & 
Staskal, 2004). 
 
Suggested exposure routes of cats to PBDEs have included the diet or ingestion 
of house dust, with most studies suggesting the dominant exposure to be from 
house dust (Dye et al., 2007; Guo et al., 2012; Mensching et al., 2012). A recent 
study has also found that cats fed food containing fish flavours are exposed to 
the methoxylated derivatives of PBDEs and that this may explain the previously 
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noted association between cats fed fish flavoured food and a higher incidence 
of hyperthyroidism (Wakeling et al., 2009; Mizukawa et al., 2016). 
 
Although PBDE exposure could be a potential risk factor for hyperthyroidism in 
cats, not all studies have found an association between the two (Guo et al., 
2012; Chow et al., 2015). In humans a link between PBDE exposure and thyroid 
dysfunction has also not been identified, with no effect on thyroid hormone 
levels in children or the development of thyroid cancer demonstrated by PBDE 
exposure (Gascon et al., 2011; Aschebrook-Kilfoy et al., 2015).  
 
1.6 Diagnosis of hyperthyroidism in cats 
 
1.6.1 Physical examination 
 
Physical examination in the vast majority of hyperthyroid cats identifies either a 
unilateral or bilateral palpable goiter; however, goiters are not detected in all 
cases due to the presence of ectopic thyroid tissue e.g. in the thorax, as well as 
the palpation technique. Goiters can also be detected in euthyroid cats and 
therefore goiter detection is not a pathognomonic finding (Norsworthy et al., 
2002; Paepe et al., 2008; Wakeling et al., 2011; Peterson, 2013). Other physical 
examination findings can include poor body condition, muscle wastage, pyrexia, 
tachycardia, a gallop rhythm or arrhythmia and auscultation of a cardiac 
murmur, as well as signs consistent with congestive heart failure such as 
dyspnoea, crackles and muffled thoracic auscultation (Mooney & Peterson, 
2012). 
 
1.6.2 Blood tests 
 
1.6.2.1 Thyroxine (T4) 
 
In hyperthyroidism the production of T4 increases. Therefore, the measurement 
of serum T4 concentration is usually the first diagnostic test pursued when 
hyperthyroidism in a cat is suspected; however, false negative and positive 
results can occur with this test (Peterson et al., 1983; Lurye et al., 2002). In 
mild cases of hyperthyroidism up to 35 % of cases have been reported to have a 
 27 
normal serum T4 concentration (Peterson et al., 1987; Peterson et al., 2001; 
Peterson, 2013). Serum T4 concentration can be measured using multiple 
different assays including radioimmunoassays, chemiluminescent enzyme 
immunoassays, point-of-care enzyme-linked immunosorbent assays (ELISA) and 
enzyme immunoassays (Peterson, 2013). However, results from in-house ELISAs 
should be interpreted with caution as false positive results may be seen (Lurye 
et al., 2002). 
 
The serum T4 concentration has also been shown to alter with disease duration 
in hyperthyroidism with significant increases seen as the duration of disease 
lengthens. This observation was documented in a recent study that assessed 
2096 cats with hyperthyroidism and identified that the median serum T4 
concentration in cats with a disease duration ≤ one year was 100 nmol/l, 
compared to 315 nmol/l in cats with a disease duration of > 4-6.1 years 
(Peterson et al., 2016a). Therefore, in cats with chronic hyperthyroidism, 
testing of the serum T4 concentration is more likely to result in a definitive 
answer compared to the use of this test in hyperthyroid cats with early disease 
(Peterson et al., 1987).       
 
1.6.2.2 Triiodothyronine (T3) 
 
The production of T3 also increases in hyperthyroidism; however, the 
measurement of serum T3 concentration as a screening test for hyperthyroidism 
has been shown to have a poor sensitivity with 42 % of hyperthyroid cats having 
a normal serum T3 concentration in one study (Peterson, 2013). As with serum 
T4 concentrations, serum T3 concentrations have been shown to fluctuate in and 
out of the reference interval in cases of mild hyperthyroidism (Peterson et al., 
1987). This makes measurement of serum T3 concentrations in cases of 
mild/early hyperthyroidism of minimal diagnostic utility, as these cats tend to 
have a serum T3 concentration within the reference interval (Peterson, 2013). It 
is therefore of no additional use over measurement of serum T4 concentration.  
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1.6.2.3 Free T4 (fT4) 
 
The production of fT4 increases in hyperthyroidism and it can be used to help 
diagnose this condition. It is reported to have a high sensitivity, with only 2/100 
hyperthyroid cats documented to have a serum fT4 concentration within the 
reference interval (Peterson, 2013). Despite the high sensitivity of this test, the 
specificity can be poor with a 20 % false positive rate documented in cats with 
chronic kidney disease; however, lower false positive rates (6.3 %) have also 
been reported in non-thyroidal illness (Peterson et al., 2001; Wakeling et al., 
2008). Despite the concerns regarding its specificity, the main utility of fT4 is in 
cases where hyperthyroidism is suspected but the serum T4 or T3 concentrations 
are within the reference interval (Peterson et al., 2001). 
 
1.6.2.4 Canine thyrotropin (cTSH) 
 
In hyperthyroidism due to the excessive production of thyroid hormones, TSH 
production is suppressed (Peterson et al., 2015). Although TSH is measured in 
humans with suspected hyperthyroidism, a commercially available feline TSH for 
the same use is not currently available in cats. However, the measurement of 
cTSH has been shown to have a high sensitivity (98 %) in diagnosing feline 
hyperthyroidism but a poor specificity (69.9 %). One of the main concerns with 
the use of cTSH is that it cannot accurately differentiate between a low-normal 
TSH concentration, which can be found in some euthyroid cats, from a 
low/suppressed concentration present in the vast majority of hyperthyroid cats. 
It is therefore advised to combine cTSH with measurement of either serum fT4 
or T4 concentrations, increasing its specificity to 98.8% (Peterson et al., 2015).   
 
1.6.2.5 T3 suppression test 
 
This test assesses the suppression of serum T4 production following 
administration of T3 and the degree of suppression should be reduced in cats 
with hyperthyroidism compared to non-hyperthyroid cats. This test has been 
evaluated in a study population including cats with hyperthyroidism, cats with 
non-thyroidal illness and healthy cats. It was shown that the mean serum T4 
concentration following the suppression test was significantly higher and the 
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percentage decrease in serum T4 concentration was significantly lower in cats 
with hyperthyroidism, compared to the other two groups. Although suppression 
of serum T4 concentration by > 50 % was only documented in non-hyperthyroid 
cats, there was a small amount of overlap between all three groups if a decrease 
in serum T4 concentration > 35 % was used as a cut-off for excluding 
hyperthyroidism (Peterson et al., 1990). Therefore, this test is predominantly 
now used to exclude the presence of hyperthyroidism, rather than to diagnose it 
(Mooney & Peterson, 2012).  
 
1.6.2.6 Thyrotropin releasing hormone (TRH) stimulation test 
 
This test assesses the response of serum T4 concentrations to the administration 
of TRH and has been evaluated in cats with hyperthyroidism, cats with non-
thyroidal illness and healthy cats. Although the absolute difference between the 
mean basal and TRH stimulated concentrations of serum T4 was significantly less 
in cats with hyperthyroidism than the other two groups, there was a large 
amount of overlap, limiting the usefulness of this test (Peterson et al., 1994). A 
later study also showed that the ability of this test to differentiate between cats 
with hyperthyroidism and cats with severe non-thyroidal illness was poor (Tomsa 
et al., 2001). Due to these findings, this test is now rarely used in the diagnosis 
of hyperthyroidism. 
  
1.6.2.7 Thyrotropin (TSH) stimulation test 
 
This test assesses the response of serum T4 concentrations to administration of 
TSH. This test is not commonly used in cases of suspected feline hyperthyroidism 
as it cannot differentiate cats with mild hyperthyroidism i.e. equivocal baseline 
serum T4 concentrations, from healthy cats (Mooney et al., 1996).  
 
1.6.3 Imaging  
 
1.6.3.1 Thyroid scintigraphy 
 
In cases of clinically suspected hyperthyroidism in which the serum T4 
concentration is within the reference interval, thyroid scintigraphy, if available, 
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may be the next test that is utilized (Peterson, 2013). This imaging modality 
produces a visual display of functional thyroid tissue based on the selective 
uptake of various radionuclides by the thyroid tissue itself, enabling ectopic 
thyroid tissue to also be identified (Broome, 2006; Peterson et al., 2016a).  
 
Pertechnetate (99mTc04-) is the most commonly used radioisotope in thyroid 
scintigraphy. The pertechnetate ions are trapped by the thyroidal iodide 
concentrating mechanism, as they mimic iodide ions; however, they are not 
retained within the thyroid gland. The percentage uptake of 99mTc04- by the 
thyroid gland has been shown to be increased in cases of feline hyperthyroidism 
when compared to euthyroid cats (Mooney et al., 1992; Nap et al., 1994).  
 
Pertechnetate is used in thyroid scintigraphy instead of radioiodine nucleotides 
due to the compared relative in-expense of it, the short physical half-life (six 
hours), the lower associated radiation dose, the shorter scanning time required 
and the shorter time interval required between its administration and the start 
of imaging, which is about 20 minutes (Peterson & Becker, 1984). It can be given 
as an intravenous or a subcutaneous injection (Page et al., 2006; Peterson et 
al., 2016b).  
 
Measurements that can be obtained from thyroid scintigraphy include the 
thyroid to salivary (TS) ratio, the thyroid to background (TB) ratio, the percent 
thyroidal uptake of 99mTcO−4 (TcTU) and the thyroid to thyroid (TT) ratio (Page 
et al., 2006; Peterson et al., 2016b).  
 
Although thyroid lobe asymmetry is found to occur frequently in hyperthyroid 
cats, the TT ratio is not relied on in the diagnosis of hyperthyroidism due to the 
presence of thyroid lobe asymmetry in some euthyroid cats as well (Scrivani et 
al., 2007). Of the other quantitative scintigraphic parameters, a high TB ratio (> 
6.1) was detected in 96.1 % of hyperthyroid cats by Peterson and Broome (2015) 
and the TS and TB ratios and TcTU were all found to be significantly higher in 
cats with hyperthyroidism than in euthyroid or healthy cats by Peterson et al., 
(2016b). All three of these parameters have been found to be both sensitive and 
specific for the diagnosis of hyperthyroidism (Peterson et al., 2016b). Of the 
quantitative scintigraphic parameters, the TS ratio is the most commonly used 
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for differentiating euthyroid from hyperthyroid cats and it has been found to 
have the highest test accuracy (Henrikson et al., 2005; Peterson et al., 2016b). 
The TS ratio is high (> 1.5) in 98.7 % of hyperthyroid cats (Peterson & Broome, 
2015). 
 
In the study by Peterson et al., (2016b), the TcTU was found to have a higher 
correlation with serum T3 and T4 concentrations and estimated thyroid volume 
than the TS ratio. This would suggest that TcTU would be the best parameter to 
use to predict the functional volume of the thyroid gland (Peterson et al., 
2016b).  
 
1.6.3.2 Computed Tomography (CT) 
 
CT has been compared to the use of thyroid scintigraphy in its ability to 
characterise the thyroid lobes in hyperthyroidism. Although CT has been found 
to be a potential alternative modality for determining the more active thyroid 
lobe in hyperthyroid cats, it is not able to differentiate unilateral from bilateral 
disease (Lautenschlaeger et al., 2013). Due to this CT is a less useful imaging 
modality if surgery is being considered as the treatment for hyperthyroidism.  
 
1.6.3.3 Ultrasonography 
 
Ultrasonography has also been directly compared to the use of thyroid 
scintigraphy to assess the size and appearance of thyroid glands. Although an 
85.7 % agreement between scintigraphy and ultrasonography was found in their 
ability to differentiate normal from abnormal thyroid lobes, ultrasonography 
cannot assess for the presence of either ectopic thyroid tissue or metastatic 
lesions which can limit its usefulness (Wisner et al., 1994). 
 
1.6.3.4 Medical infrared thermal imaging 
 
Recently, the use of medical infrared thermal imaging, which records cutaneous 
thermal patterns in the form of a colour map, has also been assessed as a 
screening method for feline hyperthyroidism (Waddell et al., 2015). This 
identified an 87.5 % accuracy of differentiating hyperthyroid cats from euthyroid 
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cats, as long as the hair was clipped over the ventral aspect of the neck prior 
to using this modality. However, as this method has only recently been used and 
the study population did not include cats with non-thyroidal illness, further 
studies will need to be performed to further evaluate the use of it in feline 
hyperthyroidism. 
 
1.7 Treatment 
 
The main treatment options for feline hyperthyroidism include antithyroid 
thionamides [methimazole (thiamazole)(Felimazole; Dechra), carbimazole 
(Vidalta; MSD Animal Health)], surgical thyroidectomy, I131 and an iodine-
restricted diet (Mooney, 1994; Naan et al., 2006; Daminet et al., 2014; Hui et 
al., 2015). 
 
Other treatment options including the use of percutaneous radiofrequency heat 
ablation and percutaneous ethanol injections have also been evaluated (Wells et 
al., 2001; Mallery et al., 2003). Percutaneous radiofrequency heat ablation was 
found to result in a reduction in serum T4 concentration in the nine cats 
included in the study; however, a euthyroid state was only achieved for a mean 
time period of four months and hyperthyroidism recurred in all cats (Mallery et 
al., 2003). The longest period of euthyroidism following the use of percutaneous 
ethanol injections was slightly longer at 27 weeks; however, this modality was 
associated with complications including Horner’s syndrome, laryngeal paralysis 
and dysphonia (Wells et al., 2001). Due to the complications seen in the Wells et 
al., (2001) study and the short period of euthyroidism obtained in both the Wells 
et al., (2001) and Mallery et al., (2003) studies, these treatment modalities are 
not currently widely utilized. 
 
Propylthiouracil (PTU) was also previously used for feline hyperthyroidism. 
However, as methimazole has been found to have better bioavailability than PTU 
and be more potent, and PTU is associated with a high incidence of adverse 
effects, PTU is no longer used (Peterson et al., 1984; Trepanier et al., 1991; 
Trepanier, 2006). 
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1.7.1 Radioactive iodine (I131) 
 
Radioactive iodine was first used to treat hyperthyroidism in humans in 1941 and 
it is now also one of the treatment modalities available for feline 
hyperthyroidism (Sawin & Becker, 1997; Peterson, 2006). Radioactive iodine is 
deemed by many to be the gold standard treatment for this condition in cats 
with ≥ 94 % success rate reported (Mooney, 1994; Peterson & Becker, 1995; 
Peterson, 2006).  
 
Institutions need to have fulfilled specific requirements from their regional 
radiation protection services to be allowed to use I131 as a treatment modality 
for feline hyperthyroidism. This requirement has resulted in this treatment 
modality only being offered at a few institutions in the UK, limiting the 
availability of it. 
 
1.7.1.1 Physical properties of I131 and radiobiology 
 
As the cells of the thyroid gland cannot differentiate between stable iodine and 
radioactive iodine,  ~ 30 % of administered I131 is taken up by the thyroid 
follicular cells via iodide transporters and becomes trapped in the thyroid glands 
(Peterson, 2006; Mumtaz et al., 2009; Wyszomirska, 2012).  
 
Radioactive iodine emits ionising radiation in the form of beta (β) and gamma (γ) 
radiation and it has a physical half-life of 8.1 days (Reiners et al., 2008). Beta 
radiation, which takes the form of either an electron or a positron particle, has 
a mean energy of 191 kiloelectronvolts (keV) and is emitted from I131 atoms first, 
followed by the emission of γ radiation, which consists of photons of energy and 
has major radiations at 364 and 637 keV (Wyszomirska, 2012). The radiation 
emissions from the β particles and γ rays are responsible for 90 % of the radiation 
emitted by I131 (Robbins & Schlumberger, 2005). Due to the higher energy of γ 
radiation it can penetrate tissues easily, compared to β radiation which only 
penetrates two mm into tissue once injected (Kurland & Freedberg, 1951).  
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Once taken up by the thyroid follicular cells, there are three phases of the 
interaction of ionising radiation emitted by I131 with living tissue (Wyszomirska, 
2012): 
• Phase 1: the physical phase. Radiation results in ionisation of cells, which 
results in damage to proteins and DNA within the cells as well as 
disruption of chemical bonds, creating free radicals.  
• Phase 2: the chemical phase. In this phase the created free radicals react 
with components of the cell. 
• Phase 3: the biological phase. During this phase enzymatic reactions occur 
within the cell, aiming to repair the damage done during the chemical 
phase. Cell death occurs in those cells that are impossibly damaged or are 
repaired improperly. 
 
The β radiation emitted from I131 is the clinically useful component in thyroid 
disease as it accounts for 80 % of the radiation dose delivered to the thyroid 
tissue (Wyszomirska, 2012). The β radiation destroys the abnormally functioning 
follicular cells in the adenomatous hyperplastic thyroid tissue, resulting in 
resolution of the autonomous production of thyroid hormones and a gradual 
reduction in the thyroid volume (Mumtaz et al., 2009). As β radiation does not 
penetrate far into tissue the damaging effects are restricted to the thyroid cells, 
with sparing of the adjacent cells (Wyszomirska, 2012).  
 
The γ radiation only accounts for 10 % of the radiation dose of I131. The majority 
of γ radiation leaves the body via the skin surface and can be detected with a 
radiation detector (Robbins & Schlumberger, 2005).  
 
1.7.1.2 Methods of I131 administration 
 
In cats, I131 can be administered either as an intravenous injection, 
subcutaneously or orally (Meric et al., 1986; Malik et al., 1993; Theon et al., 
1994). The injectable route of administration (intravenous versus subcutaneous), 
has not been found to affect the uptake of I131 by the thyroid gland and 
therefore the efficacy of treatment appears to be unaffected by this. However, 
subcutaneous administration has been associated with lower levels of radiation 
exposure to staff (Theon et al., 1994). When I131 is administered orally, higher 
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doses tend to be needed and handling of the tablets can also pose additional 
risks to the handler (Malik et al., 1993). Orally administered I131 has also been 
found to result in a higher chance of treatment failure compared to the use of 
I131 intravenously (Forrest et al., 1996). Therefore, due to the lower levels of 
radiation that personnel are exposed to and the lower dose of I131 required, the 
subcutaneous route of administration of I131 is advised (Malik et al., 1993; Theon 
et al., 1994).  
 
In the human field, laser treatment combined with I131 has been assessed 
recently (Chianelli et al., 2014). This combination treatment was found to result 
in a faster and greater improvement in local and systemic symptoms when 
compared to the use of I131 alone. This treatment combination has yet to be 
assessed in cats. 
 
1.7.1.3 Dose of I131 administered in humans 
 
In the human field the dose of I131, in megabecquerels (MBq), which is 
administered to patients with hyperthyroidism can be either a variable 
calculated dose or a fixed dose (Szumowski et al., 2012; Rokni et al., 2014). 
 
When using a variable dose approach, the administered dose can be calculated 
using Marinelli’s formula (Szumowski et al., 2012). Marinelli’s formula, as shown 
below, takes into account the volume of the thyroid gland and the percentage of 
I131 uptake in the nodules:  
A =      25 x m x D 
            T 24 X Teff    
 
A = I131 therapeutic activity (MBq) 
25 = unit conversion coefficient 
m = volume of thyroid gland calculated from ultrasound of the thyroid in grams 
D = absorbed dose in grays (Gy). D = P x 400 Gy, where P = percentage of I131 
uptake in nodules expressed as a common fraction. 400 Gy is the maximum 
absorbed dose for autonomous toxic nodule(s) as agreed in the literature. 
T24 = 24 hours I131 uptake (%) 
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Teff = effective I131 half-life in thyroid gland (days) = Tbiolog x Tphys/Tbiolog + Tphys 
where Tbiolog is the rate of iodine excretion from the thyroid and Tphys is the 
physical half-life of I131.   
 
The use of Marinelli’s formula for the calculated dose approach to toxic nodular 
goiter in humans has been found to result in euthyroidism being obtained in  
≥ 90 % of patients and ≤ 4 % of patients becoming hypothyroid in a study that 
included 2190 patients (Szumowski et al., 2012). 
 
There are also simpler calculations for calculating the dose of I131, as 
documented in the study by Alexander & Larsen (2002). In that study the dose of 
I131 was calculated by the equation below with the percentage uptake of I123 
being determined by scintigraphy 24 hours after its administration: 
Dose of I131 = (8 millicurie (mCi) x 100)/(% uptake of I123 at 24 hours). 
 
The efficacy of a fixed dose of I131 in humans has been directly compared to a 
calculated dose (Huysmans et al., 1993). In the study by Huysmans et al., (1993) 
the incidence of resolution of hyperthyroidism was 73 % and the incidence of 
hypothyroidism was 7 % in cases administered a low fixed dose. This was 
compared to an 88 % incidence of resolution of hyperthyroidism and a 7 % 
incidence of hypothyroidism in cases administered a calculated dose. It was also 
demonstrated that humans administered a low dose of I131 needed a significantly 
higher number of I131 administrations than humans dosed using a calculated 
method.  
 
A recent meta-analysis of the human literature that assessed the efficacy of 
different I131 protocols in 669 patients with toxic nodular goiter, found that a 
calculated dose resulted in a 9.6 % higher cure rate then use of a fixed dose and 
only a 0.3 % higher rate of permanent hypothyroidism. The meta-analysis also 
identified that if using a fixed dose of I131, a fixed high dose (which ranged in 
studies from 600 to 1200 MBq) resulted in an 18.1 % higher cure rate but a 23.9 % 
higher rate of developing permanent hypothyroidism compared to the use of a 
low dose (which ranged in studies from 148 MBq to 555 MBq) (Rokni et al., 
2014).  
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The conclusions from the meta-analysis were that a calculated dose of I131 
may be preferred over a fixed method due to the higher cure rate. However, use 
of a calculated method can result in a slightly higher occurrence rate of 
permanent hypothyroidism (Rokni et al., 2014).  
 
1.7.1.4 Dose of I131 administered in cats 
 
The dose of I131 that can be administered to cats with hyperthyroidism can 
depend on local radiation legislation, with some institutions being restricted to a 
fixed dose protocol (Boland et al., 2014). As in humans there has been research 
performed assessing the optimal dose of I131 to administer in cases of feline 
hyperthyroidism (Mooney, 1994; Peterson & Becker, 1995; Forrest et al., 1996). 
 
Forrest et al., (1996) assessed the use of the volume of hyperfunctioning thyroid 
tissue, calculated from thyroid scintigraphy scans using 99mTc04-, as the basis on 
which the dose of I131 was based. Although 71/80 cats were cured using this 
treatment method, it was found that those cats with a larger volume of 
abnormal hyperfunctioning thyroid tissue were more likely to fail treatment. 
This study concluded that basing the dose of I131 on the volume of abnormal 
thyroid tissue alone is inadequate for cases of hyperthyroidism that have large 
volumes of abnormal thyroid tissue (Forrest et al., 1996).  
 
Although Marinelli’s formula or the formula used by Alexander & Larsen (2002) 
are not used in feline hyperthyroidism, there have been studies looking at 
algorithms for calculating a dose of I131 to be administered (Mooney, 1994; 
Peterson & Becker, 1995). Both Mooney (1994) and Peterson & Becker (1995) 
based the dose of I131 that was administered on the results of a scoring system. 
The scoring system in each study was based on the combination of three factors: 
severity of clinical signs, size of the thyroid gland and magnitude of the serum 
T4 concentration. In Mooney (1994) each factor was scored between one and 
five, where as in Peterson & Becker (1995) a score between one and three was 
given. In Peterson & Becker (1995) 524 cats were treated using this system and 
only a 1.5 % rate of continuation of hyperthyroidism and a 2.1 % prevalence of 
clinical hypothyroidism was reported. In Mooney (1994), a slightly lower success 
rate of 94 % was reported but a 0 % prevalence of clinical hypothyroidism. 
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However, only 50 cases were included in the Mooney (1994) study, which may 
have resulted in the differences in the reported success rate and rate of clinical 
hypothyroidism between the two studies. One weakness of the scoring systems is 
the subjective nature of scoring the severity of clinical signs and size of the 
thyroid gland. However, research has shown that despite there being varying 
methods to palpate the size of goiter in a cat, the estimation of the goiter size is 
not affected by palpation technique (Paepe et al., 2008).  
 
The uptake of I131 by the thyroid gland in hyperthyroid cats has been shown to be 
increased by the use of an iodine-restricted diet, the use of recombinant human 
thyrotropin (rhTSH) and recent discontinuation of methimazole (Nieckarz & 
Daniel, 2001; van Hoek et al., 2008a; Scott-Moncrieff et al., 2015). Therefore, 
this may result in a higher thyroidal uptake of I131 than calculated, which could 
potentially lead to a higher occurrence rate of hypothyroidism post-treatment 
(Rokni et al., 2014). However, the advantage of an increased uptake of I131 is the 
possibility that diet, rhTSH and methimazole could be used as methods to lower 
the dose of I131 administered.  
 
1.7.1.5 Radiation hazards 
 
As I131 is a source of ionising radiation, radiation safety monitoring needs to be 
used in both the feline and human fields, as patients treated with I131 can act as 
a source of radiation exposure to their families, staff members and members of 
the general public (Feeney et al., 2003; Pant et al., 2006; Lamb et al., 2013; 
Ostinelli et al., 2015; Vogiatzi et al., 2015). This is especially prudent for staff 
working in close proximity to patients treated with I131, as they are at a higher 
risk of radiation exposure (Happel et al., 2013).   
 
I131 can act as both an internal and external potential hazard. External radiation 
hazards are hazards that arise from a source of radiation outside of the body and 
internal radiation hazards are due to radioactive material entering the body, 
either through injection, inhalation, ingestion or absorption across the skin 
(Lamb et al., 2013). The main external radiation hazard to personnel from cats 
treated with I131 is from the γ radiation emitted from the internalized I131 
trapped in the thyroid gland and this γ radiation can be measured by radiation 
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detectors (Feeney et al., 2003). Up to 75 % of the injected dose of I131 is 
reported to be excreted in the urine and faeces of treated cats and it has also 
been detected in the saliva of treated cats as well (Chalmers et al., 2006; Lamb 
et al., 2013). Therefore, urine, faeces and saliva can act as internal radiation 
hazards, should they be ingested. 
 
Due to concerns regarding ionising radiation, there are dose limits on the 
effective dose and dose constraints put in place to reduce the radiation risks to 
personnel (Environment Agency, 2012). As there are several terms currently 
utilized when discussing radiation safety these are defined below for further 
information (Environment Agency, 2012):  
• Equivalent dose. This is defined as ‘the absorbed dose in a tissue or 
organ, weighted for the type and quality of the radiation by a radiation 
weighting factor’. This is measured in Sieverts (Sv). 
• Effective dose. This is defined as ‘the sum of the equivalent doses from 
radiation in all tissue and organs of the body, having been weighted by 
their tissue weighting factors’. This is measured in Sv. 
• Absorbed dose. This is defined as ‘the ionising radiation energy absorbed 
in a material per unit mass’ and is measured in Gy. 
• Dose constraint. This is defined as the ‘restriction on annual dose to an 
individual from a single source or site, such that when aggregated with 
doses from all sources excluding natural background and medical 
procedures, the dose limit is not likely to be exceeded.’ The maximum 
dose constraint in the UK is currently 0.3 millisieverts (mSv)/year. 
• Dose limit. This is defined as the ‘maximum permissible dose resulting 
from ionising radiation’ and they apply to the ‘sum of relevant doses from 
external exposures’ during a specified period. The limit in the UK is 
currently one mSv/year.  
 
1.7.1.6 Post-treatment hospitalization of cats 
 
Due to the external and internal radiation hazards posed by cats to hospital staff 
and the public following treatment with I131, they are isolated following 
treatment. However, the isolation time is variable amongst institutions 
nationally, as well as internationally (Boland et al., 2014; Roberts et al., 2015; 
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Kopecny et al., 2016). This is mainly due to local radiation regulations, which 
vary dependent on the location of the institution and the dose of I131 that is 
administered (Lamb et al., 2013; Boland et al., 2014).  
 
The isolation duration will also depend on the effective half-life of I131. This has 
been previously calculated using γ camera dosimetry to be 2.5 ± 0.7 days (Puille 
et al., 2002). The effective half-life of I131 is a combination of the fixed physical 
half-life and the biological half-life, which is variable. The biological half-life 
can be affected by the rate of I131 uptake by the thyroid gland and the excretion 
rates of it into the urine, faeces and also the saliva. It has been shown that the 
level of radiation emitted from urine soaked litter and faeces, from cats treated 
with ≤ 200 MBq of I131 administered subcutaneously does decrease over time. 
However, the radioactivity levels of the urine and faeces are still too high to 
allow them to be disposed of in the general refuse for the first two weeks 
following treatment, as the radioactivity levels are > 0.4 MBq/0.1 m3 (Lamb et 
al., 2013). As saliva can also emit radiation, Chalmers et al., (2006) assessed the 
level of removable radioactivity from cats treated with I131 with daily wipe tests 
using varying sites (the flanks and paws). These wipe tests showed that the level 
of removable radioactivity of these cats exceeded the local state limit of New 
York i.e. > 200 disintegrations per minute/100 cm2, within the first week 
following treatment. This study demonstrated that significant surface 
contamination can occur but this may be a combination of saliva and soiled 
litter. The findings from both Chalmers et al., (2006) and Lamb et al., (2013) 
demonstrate that the radioactivity levels from surface contamination on the 
cats’ coats and from their urine and faeces need to be considered when deciding 
on the length of post-treatment isolation. 
 
Cats that are treated with higher doses of I131 are routinely hospitalized for 
longer durations due to the higher radiation risk they pose to the staff and 
public (Lamb et al., 2013). In the Lamb et al., (2013) study there was one cat 
included that was administered an I131 dose of 1000 MBq and was hospitalized for 
six weeks, which was 50 % longer than cats treated with lower doses i.e. ≤ 200 
MBq. Weichselbaum et al., (2003) showed the effect of I131 dose on the length of 
isolation, by demonstrating that the dose of I131 could be used to calculate the 
number of days that the cat should remain in isolation for using the calculation: 
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days in isolation = 3.2 + [2.66 x mCi of the I131 dose]. In that study the γ 
radiation emission rate at discharge had to be < 2.0 milliröntgen (mR)/hour at 
skin surface at the level of the thyroid gland. The findings in that study clearly 
identified that the dose of I131 administered will have an effect on the length of 
isolation (Weichselbaum et al., 2003). 
 
Although several factors can affect the length of isolation following I131 
treatment, many centres use a γ radiation emission rate cut-off to determine 
the length of time that cats remain in isolation for, which can enable a variable 
isolation period to be used (Feeney et al., 2003; Weichselbaum et al., 2003). 
This is performed by detecting the γ radiation emission at the skin surface at the 
level of the thyroid gland using a Geiger- Müller instrument and has been shown 
to be a valid method to assess isolation lengths (Feeney et al., 2003). However, 
due to differences in local and national radiation legislation, release criteria will 
vary between different states and countries (Weichselbaum et al., 2003; Martin 
et al., 2015).  
 
1.7.1.7 Measuring radiation emission post-treatment in humans 
 
Guidelines in humans by the International Atomic Energy Agency (IAEA), 
recommend that in patients treated with I131 residual activity should be 
determined at hospital discharge (IAEA, 2009). This can be performed by means 
of evaluating the dose rate or determining the amount of residual activity 
combined with other considerations, which are patient based; a single 
measurement of ambient dose equivalent rate at one metre < 0.030 mSv/hour is 
suggested (De Crescenzo et al., 2014). However, the criteria to determine a 
patients release from hospital may vary as in the study by Grigbsy et al., (2000), 
which was based in the United States, patients treated with I131 were deemed 
safe to be discharged home as long as the calculated radiation dose to the 
maximally exposed person was < five mSv. This was determined by measuring 
the total body count recorded by a sodium iodide monitor 3.1 metres from the 
xiphoid process.  
 
A recent study that developed a new procedure to estimate residual I131 activity, 
which was based on a mathematical model and external radiometric assays, has 
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been found to be comparable to performing the measurement of ambient dose 
equivalent rate. Therefore, this could be used as an alternative method and it is 
also simple and reliable (Ostinelli et al., 2015). 
 
Although radioactivity levels need to be assessed in patients at the time of 
discharge, work has also been performed in the patients’ home environment to 
ensure that the radiation exposure to household members and even household 
pets from treated patients is within radiation legislation guidelines (Grigsby et 
al., 2000). In the study by Grigsby et al., (2000), the radiation exposure was 
measured using continuous optically stimulated luminescence dosimeters and it 
was found that both household members and household pets received relatively 
equal radiation exposure during the 10 day period following I131 treatment. 
However, the levels of radiation were below the regulation limit of the United 
States Nuclear Regulatory Commission.  
 
Radiation exposure to humans following I131 has also been assessed with 
electronic personal dosimeters (EPDs) (Barrington et al., 1999; Marriott et al., 
2007). Electronic personal dosimeters continuously monitor for ionising 
radiation, which can include β radiation, γ radiation, neutron radiation and x-ray 
radiation and will alert a user if the preset dose and dose rate thresholds are 
exceeded. They have been used to measure the radiation exposure to caregivers 
from patients treated with I131 on an hourly basis (Marriott et al., 2007). The 
data from the EPDs identified that a third of the radiation exposure occurred 
during the journey home from the hospital; therefore, showing that a large 
proportion of radiation exposure occurs shortly after administration of I131 
(Marriott et al., 2007). 
 
Electronic personal dosimeters have also been provisionally assessed for their 
use in monitoring cage-side radiation exposure from cats treated with I131 in a 
pilot study at the Small Animal Hospital (SAH) of the University of Glasgow 
(Roberts et al., 2015). 
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1.7.1.8 Treatment success and predictors of I131 treatment outcome 
 
Radioactive iodine is associated with a high treatment success rate for 
hyperthyroidism in cats (Mooney, 1994; Peterson & Becker, 1995). However, the 
definition of success in papers differs, with some defining success as the 
induction of euthyroidism and others defining success as the induction of a 
euthyroid or biochemical hypothyroid state i.e. resolution of hyperthyroidism 
(Malik et al., 1993; Mooney, 1994; Theon et al., 1994; Peterson & Becker, 1995; 
Puille et al., 2002). Success is usually dictated by measurement of the serum T4 
concentration following treatment, which is then compared to the reference 
interval to allow classification of treatment as successful (depending on the 
definition of success in the individual study), unsuccessful i.e. treatment failure 
or the induction of a biochemical/clinical hypothyroid state. 
 
Other methods to evaluate treatment success in hyperthyroid cats have also 
been assessed, including ultrasonography of the thyroid glands and the use of 
medical infrared thermal imaging. Ultrasonography can assess the size and 
vascularity of the thyroid glands and at evaluation six months after treatment 
with I131, there was a reduction in median thyroid volume and heterogeneity of 
the thyroid glands, as well as decreased vascularity seen in cats successfully 
treated (Barberet et al., 2010). The use of medical infrared thermal imaging has 
been shown to demonstrate treatment success in 92.86 % of treated cats one 
month after treatment and at three months post-treatment, a 100 % accuracy 
was recorded using this method (Waddell et al., 2015). Although these methods 
can be used as part of the evaluation of treatment success, they have not been 
assessed at the time of hospital discharge, unlike the measurement of serum T4 
concentration and therefore, measurement of serum T4 concentration should 
still be performed (Peterson & Becker, 1995).  
 
In humans with either toxic nodular goiter or Graves’ disease, which are treated 
with a fixed dose of I131, it has been found that gender, age, severity of 
hyperthyroidism and goiter size act as independent prognostic factors for 
achievement of a euthyroid or hypothyroid state following a single treatment of 
I131. Negative prognostic factors for obtaining resolution of hyperthyroidism 
following treatment have included male gender, younger patients (< 40 years 
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old), patients with severe hyperthyroidism and patients with medium and 
large sized goiters (Allahabadia et al., 2001).  
 
Palpation of the goiter to evaluate its size can form part of the calculation to 
determine what dose of I131 should be administered in cats (Mooney, 1994; 
Peterson & Becker, 1995). However, due to the presence of ectopic thyroid 
tissue in some cases of hyperthyroidism, palpation is not always capable of 
accurately defining the thyroid volume and therefore, this could result in a 
suboptimal dose of I131 being administered and a higher rate of treatment failure 
(Peterson & Broome, 2015).  
  
Due to the concern that goiter palpation cannot allow an accurate estimation of 
thyroid volume, other ways to calculate thyroid volume have been assessed, 
including the use of scintigraphy. In a study by Forrest et al., (1996) thyroid 
volume, as calculated by scintigraphy, was reported to influence the outcome of 
hyperthyroid cats treated with a modified fixed dose of I131, with cats with 
larger thyroid volumes being more likely to fail treatment. However, more 
recently thyroid size, again calculated by scintigraphic results, has not been 
found to affect the outcome of treatment; however, a much more variable 
dosing regimen for I131 was used in that study (Volckaert et al., 2016). One 
disadvantage of using thyroid scintigraphy to determine thyroid volume is that 
many of the calculations used result in different thyroid volumes to those 
calculated from ultrasound findings; therefore, raising into question their 
validity (Volckaert et al., 2012). Due to the recent findings that TcTU has the 
best thyroid scintigraphic value accuracy for predicting thyroid volume, further 
work may be warranted to assess if this can be used, not only as a predictor for 
treatment success but also to assess if it can be used to help calculate the dose 
of I131 administered to cats (Peterson et al., 2016b). 
 
Although thyroid volume calculated via scintigraphy cannot be definitively 
associated with treatment outcome, the TB ratio can be. It has been shown that 
the TB ratio is significantly higher in cats that remain hyperthyroid following 
treatment when a fixed dose of I131 (148 MBq) is used, when compared to cats 
that were successfully treated, which in this study was defined as the 
achievement of euthyroidism or hypothyroidism (Wallack et al., 2010). 
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Therefore, if scintigraphy is used pre-treatment, this ratio could potentially 
be used as a predictor for treatment failure and in these cases there should be 
additional consideration as to whether a higher dose of I131 should be used to 
maximize the possibility of achieving treatment success. 
 
In humans, the use of anti-thyroidal medication in the two week period either 
before or after administration of I131 has been shown to result in a significantly 
lower cure rate when using a low fixed dose of 185 MBq; however, the same 
effect was not seen when higher doses were used i.e. 375 MBq (Allahabadia et 
al., 2001).  
 
However, recent use of anti-thyroidal medication in cats has not been shown to 
have an effect on the response to a fixed dose of I131 (148 MBq), as there was no 
significant difference in treatment response when methimazole was 
discontinued either < five days or ≥ five days prior to intravenous I131 
administration (Chun et al., 2002). Despite these findings anti-thyroidal 
medication is still usually discontinued prior to administration of I131 in cats to 
facilitate evaluation of the serum T4 concentration, as this forms part of the 
algorithm when deciding the dose of I131 to administer (Mooney, 1994; Peterson 
& Becker, 1995).  
 
There has also been some concern raised regarding the recent use of iohexol, 
which is used to assess the glomerular filtration rate (GFR) and the success of 
I131 treatment in cats. Iohexol has been found to result in a significant decrease 
in the absorbed dose of I131 if used within 24 hours of I131 administration and a 
higher prevalence of residual hyperthyroidism (Peremans et al., 2008). Although 
only 46 hyperthyroid cats were included in the study, the results would suggest 
that the use of iohexol prior to I131 treatment should be avoided.  
 
1.7.1.9 Delayed successes following I131 treatment 
 
The success of I131 can be delayed in some cases as the induction of euthyroidism 
following treatment may take up to six months in cats (Peterson & Becker, 1995; 
Boag et al., 2007). In the study by Peterson and Becker (1995), 15.3 % of treated 
cats were still hyperthyroid post-treatment but this had reduced to only 1.5 % by 
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six months post-treatment. Due to these findings it would be advised to 
continue to monitor the serum T4 concentration in those cats that are 
biochemically hyperthyroid following treatment to assess for further decreases 
in this parameter, as further treatment for hyperthyroidism may not be required 
in all cases.  
 
1.7.1.10 Development of hypothyroidism following treatment with I131 
 
Treatment with I131 can result in the induction of hypothyroidism that may be 
transient, as the remaining normal thyroid cells return to full function, or it can 
be permanent and subsequently result in cats requiring lifelong treatment with 
levothyroxine supplementation (Peterson & Becker, 1995). Biochemical 
hypothyroidism occurs quite frequently following treatment with I131, with a 
prevalence as high as 56 % reported (Mooney, 1994). However, clinical 
hypothyroidism requiring levothyroxine supplementation is reported to be 
uncommon with Peterson & Becker (1995) only reporting this in 11/524 (2.1 %) 
treated cats. The incidence of biochemical hypothyroidism post-treatment may 
be influenced by the number of thyroid lobes affected as Nykamp et al., (2005) 
identified that cats with bilateral disease, based on thyroid scintigraphic 
findings, were twice as likely to become hypothyroid following treatment with 
I131 compared to cats with unilateral disease.  
 
There is also a concern that the development of a hypothyroid state following 
treatment with I131 could lead to an increased risk of azotaemia due to a decline 
in the GFR. This concern was proposed by the study by van Hoek et al., (2009) 
following their findings that 80 % of cats with a post-treatment azotaemia and 
low GFR (≤ 1.1 ml/minute/kg) also had serum T4 concentrations below the 
reference interval. Due to this concern it would suggest that it is important to 
try to minimize the risks of hypothyroidism occurring in cats post-treatment by 
trying to use the lowest dose of I131 possible, whilst also trying to ensure that 
cases do not receive a dose that is too low to achieve a clinical cure.   
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1.7.1.11 Renal function pre- and post-treatment  
 
Cats with pre-existing renal disease have been found to have significantly 
shorter survival times when treated with I131 than cats that do not have pre-
existing renal disease. However, this finding is not specific to the use of I131 as 
the same finding is also seen in cats treated with methimazole (Milner et al., 
2006). 
 
Following treatment with I131 the GFR in hyperthyroid cats has been found to 
decrease, with the majority of this decrease noted by four weeks post-treatment 
(Rogers et al., 2000; Boag et al., 2007; van Hoek et al., 2008b; van Hoek et al., 
2009). A substantial number of cats can develop azotaemia following treatment 
with 63 % of cats in one study showing biochemical evidence of renal disease at 
the one month point post-treatment (Rogers et al., 2000). However, the 
incidence of post-treatment renal azotaemia does appear to vary between 
studies, with a prevalence of only 28 % also reported (Milner et al., 2006). 
Differences in follow up periods may account for the variation in prevalence 
reported as Milner et al., (2006) did not specify when the post-treatment 
azotaemia was documented. The azotaemia that can develop during the 90 days 
following I131 treatment has been shown to be of a similar magnitude to that 
seen with the treatment modalities of surgery and methimazole (DiBartola et 
al., 1996). 
  
Cats with lower GFRs pre-treatment have been shown to be at higher risk for 
developing post-treatment azotaemia (Adams et al., 1997; Rogers et al., 2000). 
In the Rogers et al., (2000) study, cats that developed renal azotaemia tended 
to have lower GFRs pre- and post-treatment than cats that did not develop renal 
azotaemia; however, specific values of GFR were not discussed. In that study, 
due to a large variance in the pre-treatment GFR, it could not be used to predict 
the occurrence of renal azotaemia occurring post-treatment. In Adams et al., 
(1997), all cats that developed post-treatment renal azotaemia had a pre-
treatment GFR < 2.25 ml/kg/min; however, these results may have been 
affected by the inclusion of nine cats with renal azotaemia pre-treatment. 
Taking the findings of both these studies together, measurement of GFR prior to 
treatment could potentially help but not definitively predict the occurrence of 
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renal azotaemia post-treatment. However, it should also be remembered that 
the use of iohexol to measure GFR within 24 hours of I131 administration could 
result in a higher chance of treatment failure and should therefore be avoided 
(Peremans et al., 2008). 
 
Although the assessment of GFR has been shown to be of potential use in the 
prediction of azotaemia occurring post-treatment, this has not been the case for 
pre-treatment haematological or biochemical parameters (including serum 
creatinine and serum urea nitrogen) or urine specific gravity (USG) (Riensche et 
al., 2008). This was shown by Riensche et al., (2008) that showed that these 
parameters could not predict the development of renal insufficiency (defined as 
azotaemia and inadequate urine concentration) occurring following treatment 
with either I131 or methimazole. This study in particular advised that the finding 
of a USG > 1.035 prior to treatment could not be used as a predictor for a 
reduced risk of renal azotaemia developing. Boag et al., (2007) also showed that 
pre-treatment serum biochemistry parameters and USG could not predict the 
percentage change in GFR post-treatment either.  
 
1.7.1.12 Long-term follow up  
 
Recurrence of hyperthyroidism following treatment with I131 is uncommon. In 
Peterson & Becker (1995), a recurrence of hyperthyroidism was only reported in 
2.5 % of the cases and this occurred between 1.1 and 6.5 years later. An even 
lower prevalence of 0 % was reported in Mooney (1994); however, the follow up 
time in that study was shorter at 32 months.  
 
Median survival times post-treatment have been reported to be between two 
and five years (Peterson & Becker 1995; Slater et al., 2001; Milner et al., 2006). 
In the study by Slater et al., (2001), 231 cats that were treated with I131 were 
followed up and their post-treatment survival was found to range from as little 
as three days to as long as eight years. In that study only age at diagnosis and 
the gender of the cat were predictors of survival, with both increasing age and 
male gender associated with shorter survival times. An even larger study that 
looked at 524 cats treated with I131 found that the percentage of cats alive one, 
two and three years following treatment were 89 %, 72 % and 52 % respectively 
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(Peterson & Becker, 1995). The most recent study assessing long-term 
outcome has shown that median survival times can be as long as four years post-
treatment (Milner et al., 2006).  
 
Many cats treated with I131 will develop further health problems later on 
including renal disease and neoplasia, which is not unexpected in an older 
population of cats (Slater et al., 1994; Slater et al., 2001). In the study by Slater 
et al., (1994), 15-27 % of cats that were euthyroid or hypothyroid post-
treatment were found to develop renal disease on follow up and 9-10 % of them 
were found to develop neoplasia.  
 
1.7.1.13 Concerns of using I131  
 
Although I131 treatment is a highly successful treatment option for 
hyperthyroidism in cats, previous work has highlighted that costs involved with it 
can deter both referring vets in general practice and owners (Boland et al., 
2014; Higgs et al., 2014). However, if costs were not a factor when considering 
treatment options, the number of general practitioners selecting I131 as their 
preferred treatment modality would significantly increase (Higgs et al., 2014; 
Kopecny et al., 2016).  
 
Another concern voiced by owners is the length of hospitalization associated 
with I131 treatment (Boland et al., 2014). Therefore, the length of time that a 
cat is hospitalized for could have a significant effect on whether I131 is pursued 
by the owners of hyperthyroid cats.  
 
Knowledge of this treatment modality may also influence the pursuit of it by 
both clients and veterinarians. In the study by Caney (2013), nearly 30 % of 
clients of hyperthyroid cats had only been offered anti-thyroidal medication as a 
treatment option. This finding has been corroborated by Boland et al., (2014) 
that found that 53.3 % of owners of hyperthyroid cats were not aware of the 
possibility of I131 as a treatment option. These study findings would suggest that 
lack of knowledge about I131 could have a significant effect on the frequency that 
this treatment modality is utilised in hyperthyroidism.  
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Comorbidities can be seen in hyperthyroid cats, including chronic kidney 
disease (27 %), osteoarthritis (5.4 %), diabetes mellitus (4.5 %), alimentary 
lymphoma and chronic enteropathies, which is not surprising given the average 
age of cats affected by hyperthyroidism (Caney, 2013; Puig et al., 2015). In 
some cases these comorbidities can have an effect on whether I131 is pursued due 
to concerns regarding progression of comorbid disease during or after 
hospitalization, or a change in the owners decision following detection of them 
(Puig et al., 2015). 
 
1.7.2 Anti-thyroidal medication 
 
The use of anti-thyroidal medication is an alternative option for treatment of 
hyperthyroidism in cats; however, unlike I131 treatment it does not result in a 
cure of hyperthyroidism and clinical signs will recur when this medication is 
stopped. This medication also does not affect the size of the thyroid tumour 
(Behrend, 2006).   
 
Anti-thyroidal medication has been documented to be the preferred treatment 
modality by general practitioners in the UK and Australia and was reported in 
one study to have been offered to 92 % of owners of hyperthyroid cats (Caney, 
2013; Higgs et al., 2014; Kopecny et al., 2016).  
 
The main anti-thyroidal drugs used in hyperthyroidism include methimazole and 
carbimazole (Bucknell, 2000). Methimazole inhibits the enzyme thyroid 
peroxidase, which is involved in the oxidation of iodide to iodine, the 
incorporation of iodine into thyroglobulin and the formation of T3 and T4 by 
coupling tyrosine residues; carbimazole is the prodrug of methimazole (Peterson 
& Aucoin, 1993; Trepanier, 2006). There appears to be some worldwide variation 
in regards to which of these two drugs is predominantly used, with methimazole 
used more commonly in the UK and carbimazole used more commonly in 
Australia (Caney, 2013; Kopecny et al., 2016).  
 
Methimazole and carbimazole are routinely used as an oral medication; 
however, transdermal forms of methimazole are also available (Hoffmann et al., 
2003; Lécuyer et al., 2006; Boretti et al., 2014).  
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1.7.2.1 Efficacy/safety 
 
The efficacy and safety of methimazole have been assessed in a large study, 
which included 262 cats that received it either as sole therapy or pre-operatively 
prior to thyroidectomy at a dose of 10-15 mg/day. In that study it was found 
that the serum T4 concentration decreased significantly after two to three 
weeks of methimazole treatment, from a mean of 156 nmol/l pre-treatment to a 
mean of 27 nmol/l afterwards. Those cats that remained on treatment long-term 
were found to require a mean dose of 11.9 mg/day (Peterson et al., 1988). The 
high efficacy of methimazole has been corroborated by a later study that found 
the use of oral methimazole to result in 87.5 % of hyperthyroid cats becoming 
euthyroid within two weeks of starting treatment, at a lower dose of 2.5 mg per 
os twice daily (Sartor et al., 2004).  
 
Twice daily administration of methimazole is preferred over once daily use. This 
is due to the findings by Trepanier et al., (2003) that found that serum T4 
concentrations were significantly higher following two and four weeks of 
treatment in cats treated orally once daily versus twice daily and that the 
proportion of cats becoming euthyroid after two weeks of treatment was lower 
in cats treated once daily versus twice daily at 54 % and 87 % respectively. For 
owners of cats treated with anti-thyroidal medication, the use of once daily 
dosing of medication is not ranked as the most important treatment priority and 
so this should not influence the dose frequency chosen (Caney, 2013).  
 
A study comparing oral versus transdermal methimazole found the oral version 
to be more efficacious at the two week mark but this was no longer apparent 
four weeks following the start of treatment (Sartor et al., 2004). However, the 
location of transdermal application can have an effect on the efficacy of the 
product and it is advised to apply it to the internal pinna. This is due to more 
complete absorption from this area when compared to other sites on the body 
such as the groin, neck and thorax; however, variation in absorption can still 
occur between ears (Hill et al., 2015a; Hill et al., 2015b). 
 
Clinical side effects of methimazole including anorexia, vomiting, lethargy, 
icterus caused by a hepatopathy, bleeding diathesis caused by thrombocytopenia 
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and self-induced excoriation of the face and neck can occur, with a 
documented prevalence of 18.3 % (Peterson et al., 1988). Haematological side 
effects including eosinophilia, lymphocytosis and mild leukopenia can also occur 
in 16.4 % of treated cats (Peterson et al., 1988). Less common side effects, 
including the development of generalised lymphadenopathy, pyogranulomatous 
mural folliculitis and myasthenia gravis have also been reported (Niessen et al., 
2007; Bell et al., 2012; Castro Lόpez et al., 2014).  
 
Transdermal application of methimazole can result in fewer gastro-intestinal 
side effects when compared to the oral version, whilst also still being able to 
significantly decrease serum T4 concentration; however, it does not decrease 
the risk of neutropenia, hepatotoxicity or facial excoriation occurring (Sartor et 
al., 2004). Dosing frequency of oral methimazole has not been shown to have an 
effect on the prevalence of gastro-intestinal adverse effects (Trepanier et al., 
2003). 
 
Carbimazole given once daily has been shown to result in significant reductions 
in serum T4 concentrations as well, from a mean of 118 nmol/l prior to 
treatment to a mean of 33 nmol/l after 10 days of treatment in a study that 
included 44 cats. Clinical signs of hyperthyroidism were also found to 
improve/resolve in nearly all treated cats. Suspected adverse reactions, which 
were mainly gastro-intestinal in origin, were noted in 44 % of cases (Frénais et 
al., 2009). Generalised lymphadenopathy has also been reported in association 
with the use of this drug (Atkinson, 2008). 
 
The clinical/biochemical response of hyperthyroid cats seen in clinical studies 
when using anti-thyroidal medication is also mirrored by the views of their 
owners, as they also find this treatment modality to be efficacious. In Caney 
(2013), owners reported that the use of methimazole resulted in a cure or 
substantial improvement in 75 % of cats and in 72.2 % of cats treated with 
carbimazole.  
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1.7.2.2 Monitoring 
 
It has recently been advised by a consensus panel that dosages of anti-thyroidal 
drugs be titrated to obtain a serum T4 concentration in the bottom half of the 
reference range; however, this is not evidence-based (Daminet et al., 2014). A 
recent survey in the UK has confirmed that this practice is followed by the 
majority of general practitioners (Higgs et al., 2014).  
 
The timing of blood sampling to assess the serum T4 concentration of treated 
cats has not been shown to be a significant factor when assessing treatment 
response in cats receiving methimazole (Rutland et al., 2009). Therefore, a 
blood sample can be obtained at any time during the day, making this a 
convenient way to monitor treatment efficacy for both owners and practitioners.   
 
1.7.2.3 Long-term follow up 
 
Median survival times in cats treated with anti-thyroidal medication have been 
reported to be two years, which is significantly lower than the four years 
reported with I131 treatment (Milner et al., 2006). 
 
Treatment with anti-thyroidal medication can result in iatrogenic 
hypothyroidism, with a 35 % occurrence rate over the six months following the 
start of treatment documented by Williams et al., (2010); however, this is 
usually resolved with a dose amendment and is therefore reversible (Boretti et 
al., 2014). The induction of a hypothyroid state has not been found to 
significantly affect survival times, with median survival times of 794 days versus 
625 days reported in euthyroid and hypothyroid cats respectively (Williams et 
al., 2010).  
 
Treatment with methimazole has also been found to result in a significant 
decrease in GFR (Becker et al., 2000). However, earlier studies found 
contrasting evidence as to whether significant increases in serum urea nitrogen 
and creatinine concentrations occur in these patients (DiBartola et al., 1996; 
Becker et al., 2000). In Becker et al., (2000) no significant increases in serum 
urea nitrogen or creatinine concentrations were seen four to six weeks post-
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treatment, compared to DiBartola et al., (1996) in which significant increases 
in both parameters were seen at the 30 and 90 day points post-treatment. These 
differences may have been due to the difference in sample size at 12 cats and 
58 cats respectively, as well as the timing of the blood tests. A more recent 
study by Williams et al., (2010) would tend to support the findings by DiBartola 
et al., (1996), as they documented a 40 % occurrence of azotaemia in cats 
during the six month period following treatment; however, cats included in that 
study were treated with anti-thyroidal medication (methimazole or carbimazole) 
alone, as well as being combined with surgery.  
 
Although azotaemia can occur with the use of anti-thyroidal medication, this 
does not appear to affect median survival times as long as euthyroidism is 
maintained (Williams et al., 2010). In Williams et al., (2010) the median survival 
time of euthyroid cats that developed azotaemia was 728 days, which was not 
significantly different from that of euthyroid cats that did not develop 
azotaemia at a median of 794 days. However, the combination of azotaemia and 
hypothyroidism does appear to have an effect on survival times as these cats 
have significantly shorter survival times than hypothyroid cats that remain non-
azotaemic, with median survival times of 456 versus 905 days respectively 
(Williams et al., 2010). In those cases with a combination of hypothyroidism and 
azotaemia, restoration of euthyroidism may result in an improvement in renal 
function as this has been shown to result in a decrease in the serum creatinine 
concentration and an increase in packed cell volume (Williams et al., 2014). 
 
Although development of azotaemia alone following treatment has not been 
found to affect survival times, pre-existing azotaemia has been (Milner et al., 
2006; Williams et al., 2010). Milner et al., (2006) documented that cats with 
pre-existing renal disease treated with methimazole had significantly shorter 
survival times when compared to cats without pre-existing renal disease; 
however, specific median survival times were not reported.  
 
As anti-thyroidal medication is not a curative treatment and tumour volume and 
magnitude of serum T4 concentration has been shown to increase with the 
duration of the disease, further increases in the doses of anti-thyroidal 
medication may be required over time (Peterson et al., 2016a). Cases of 
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hyperthyroidism may also become refractory to anti-thyroidal medication with 
time, due to the previously reported increased prevalence of thyroid carcinoma 
with increasing length of disease duration (Hibbert et al., 2009; Peterson et al., 
2016a).  
 
1.7.3 Surgical thyroidectomy 
 
Hyperthyroidism can be treated by removal of the affected thyroid tissue and in 
most cases a bilateral thyroidectomy is required (Flanders, 1999). Surgical 
thyroidectomy has been documented to result in 94 % of hyperthyroid cats being 
free of recurrence of hyperthyroidism at the three year mark post-treatment 
(Naan et al., 2006). Surgery is associated with a low complication rate; however, 
damage to the recurrent laryngeal nerve can occur (Naan et al., 2006; 
Trepanier, 2007). There are also risks associated with anaesthetising 
hyperthyroid cats for surgery, as ventricular arrhythmias can occur which can be 
fatal and therefore, it is important to try to stabilize the patient prior to surgery 
with anti-thyroidal medication (Mooney & Peterson, 2012). 
 
Due to the presence of co-existing ectopic hyperfunctional thyroid tissue in some 
cases, a recurrence or a continuation of a hyperthyroid state can occur following 
surgery (Naan et al., 2006; Peterson et al., 2016a). This was shown in the study 
by Harvey et al., (2009) in which 61 % of cats that were referred for recurrent 
hyperthyroidism, having previously undergone either a unilateral or bilateral 
surgical thyroidectomy, were identified to have ectopic hyperfunctional thyroid 
tissue on scintigraphy. Due to the concern that cats with ectopic hyperplastic 
thyroid tissue are more likely to have a recurrence of hyperthyroidism following 
thyroidectomy, the use of thyroid scintigraphy prior to surgery could be 
considered. Thyroid scintigraphy also provides additional benefit in cases that 
will be treated surgically, as it enables the surgeon to assess if the disease is 
unilateral or bilateral in origin, which can influence the surgical procedure 
(Naan et al., 2006).  
 
Post-operative hypocalcaemia can occur following surgery and this can be 
transient or permanent (Flanders et al., 1987; Welches et al., 1989). When 
performing a bilateral thyroidectomy, the surgical technique used has been 
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shown to influence the frequency of post-operative hypocalcaemia occurring, 
with the lowest rate (11 %) seen when a bilateral thyroidectomy is staged three 
to four weeks apart. The highest rate of hypocalcaemia (82 %) was found to 
occur in cats that had a bilateral extracapsular dissection performed (Flanders 
et al., 1987). To aid the normalization of serum calcium levels following a 
bilateral thyroidectomy, it is advised that parathyroid gland autotransplantation 
be performed when parathyroidectomy has occurred; autotransplantation of 
parathyroid glands has also been found to reduce morbidity (Padgett et al., 
1998). 
 
As with other treatment modalities, changes in serum renal parameters can 
occur post-treatment; however, the specific occurrence of post-renal azotaemia 
has not been reported (DiBartola et al., 1996). In the study by DiBartola et al., 
(1996) the mean serum creatinine concentration of hyperthyroid cats treated 
with a bilateral thyroidectomy was found to be significantly higher 30 days post-
treatment at 195 µmol/l, compared to the mean pre-treatment value of 150 
µmol/l. However, this study did not comment on how many cats had a serum 
creatinine concentration above the reference interval post-treatment and 27 % 
of the cats included had a serum creatinine concentration above the reference 
interval pre-treatment.    
 
1.7.4 Iodine-restricted diet 
 
As iodine is required for the synthesis of thyroid hormones, restriction of dietary 
iodine can reduce the synthesis of serum T4 production (Melendez et al., 2011). 
Due to this an iodine-restricted diet has been recently assessed in hyperthyroid 
cats (van der Kooij et al., 2014; Hui et al., 2015; Scott-Moncrieff et al., 2015). 
In the study by van der Kooij et al., (2014), hyperthyroid cats (n = 225) were 
treated with an iodine-restricted diet and serum T4 concentrations significantly 
decreased four weeks into the diet trial. There were also significant 
improvements in the clinical signs of the cats, which had included vomiting, 
polyuria, polydipsia, polyphagia, hyperactivity, weight loss and quality of life. 
However, there were no further significant changes in serum T4 concentrations 
after eight weeks of the diet and only 51/68 cats had a serum T4 concentration 
within the reference interval at this stage. 
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The efficacy of the diet may be affected by the pre-treatment serum T4 
concentration. In the study by Hui et al., (2015), it was found that those cats 
with higher pre-treatment serum T4 concentrations were significantly less likely 
to normalize their serum T4 concentration using the diet alone, compared to 
cats with lower pre-treatment serum T4 concentrations, with 17 % of cats 
continuing to be hyperthyroid 61-180 days following the start of the diet. 
Although these results contradict those of Scott-Moncrieff et al., (2015), in 
which the use of an iodine-restricted diet resulted in resolution of 
hyperthyroidism in 100 % of the cases, this difference may have been due to the 
smaller study size at eight cats and the fact that their study cats had lower pre-
treatment serum T4 concentrations than the 49 cats in the Hui et al., (2015) 
study. 
 
The occurrence rates of azotaemia developing in hyperthyroid cats treated with 
an iodine-restricted diet have not been specifically documented (van der Kooij 
et al., 2014; Hui et al., 2015; Scott-Moncrieff et al., 2015). However, in the van 
der Kooij et al., (2014) and Hui et al., (2015) studies it was found that the 
serum creatinine concentration significantly decreased in cats on the diet, but 
this finding may have been affected by the lack of weight gain documented in 
cats in both studies.    
 
As serum T4 concentrations have been found to increase with the duration of the 
disease and the iodine-restricted diet appears to be less effective in cases where 
severe hyperthyroidism is present, there is a theoretical concern as to whether 
this diet will remain an efficacious treatment in cats treated long-term (Hui et 
al., 2015; Peterson et al., 2016a). The diet may also not be suitable for all 
hyperthyroid cats due to the need to ensure that treated cats do not gain access 
to food sources with non-restricted iodine content, therefore theoretically 
limiting this diet to indoor cats.  
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1.8 Weight changes in patients following treatment for hyperthyroidism 
  
1.8.1 Weight gain in humans  
 
A main concern in humans following treatment for hyperthyroidism is weight 
gain as this can be excessive; this weight gain is commonly reported and occurs 
in children as well as adults (Pears et al., 1990; De La Rosa et al., 1997; Abid et 
al., 1999; Dale et al., 2001; Crocker & Kaplowitz, 2010).  
 
The weight gain experienced by these patients has been found to continue for at 
least six months following achievement of a euthyroid state and in some studies 
it can continue for as long as five years after treatment, with sustained 
increases in body mass index during this time period (De La Rosa et al., 1997; 
Dale et al., 2001; Rathi et al., 2008). A study specifically performed to 
determine the prevalence of obesity following therapy for hyperthyroidism, 
found the prevalence to be as high as 32 %. In that study the main weight gain 
occurred during the first two years following treatment and the main factors 
that contributed to the excess weight gain were poor control of thyroid function 
and the need for replacement thyroxine treatment (Brunova et al., 2003).  
 
Although this weight gain can continue for months to years after treatment for 
hyperthyroidism, the majority (54-67 %) appears to occur in the first three 
months following treatment (Pears et al., 1990). The predominant early cause of 
this weight gain is due to increases in the lean mass of patients (De La Rosa et 
al., 1997; Lönn et al., 1998). This was documented by the finding that 
significant increases in the fat-free mass of patients occur at the three and 12 
month points post-treatment with I131 (Lönn et al., 1998). Fat and bone mineral 
content have also been found to increase over the first year following treatment 
but these occur to varying levels of significance (De La Rosa et al., 1997; Lönn et 
al., 1998).  
 
The early weight gain seen in patients following treatment can be predictive of 
longer term weight gain, with one study showing that body weight changes at 
40-60 days post-surgery were highly predictive of the outcome at nine months 
(Rotondi et al., 2014)."
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Although weight gain is mainly reported following treatment of clinical cases 
of hyperthyroidism, it has also been noted when treating subclinical 
hyperthyroidism as well. Treatment with I131 of subclinical hyperthyroidism 
caused by toxic nodular goiter, has been found to impact the body composition 
of humans > 65 years old. The weight gained by these patients was found to 
reflect increases in both lean and fat mass (Boj-Carceller et al., 2015). 
 
All of the weight gain that occurs following treatment for hyperthyroidism may 
not be directly due to its treatment. A study that followed patients treated with 
I131 and compared them to a control group of euthyroid patients, found that both 
groups gained weight over time. Although the treated patients gained more 
weight than the controls over the first year, there was no significant difference 
in weight gain between the two groups by the three year mark (Scheidhauer et 
al., 2002). These study results therefore raise the question as to whether all 
weight gain following treatment of hyperthyroidism can be solely attributed to 
resolution of their hyperthyroid state.  
  
1.8.1.1 Effect of weight loss prior to treatment 
 
Weight loss prior to definitive treatment of hyperthyroidism in humans may have 
an effect on the weight gain seen in these patients following treatment. This 
was shown in a study that demonstrated the largest weight gain in patients 
during the 12 month period post-treatment, to be experienced by those patients 
that had actually gained the least amount of weight over the preceding 12 
months (Lang et al., 2016). Similar findings were also documented in an earlier 
study that showed weight loss at presentation could predict weight gain 
following treatment (Dale et al., 2001). In Dale et al., (2001) those patients that 
had lost weight prior to presentation gained significantly more weight than those 
patients that had either gained weight or their weight had remained stable. 
 
1.8.1.2 Effect of baseline thyroid test results 
 
Serum fT4 concentrations have been shown to predict weight gain in humans. 
Those patients with higher serum fT4 concentrations prior to treatment have 
been shown to gain substantially more weight than those patients with lower 
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serum fT4 concentrations, with a median weight difference of 4.3 kg at the 
one year point post-treatment reported (Gibb et al., 2013).  
 
Alterations in serum TSH concentrations have also been found to be associated 
with changes in body weight in both male and female patients with 
hyperthyroidism (Lang et al., 2016). However, this finding does not appear to be 
specific to hyperthyroidism as alterations in serum TSH concentrations can also 
affect weight gain in patients without thyroid disease (Bjergved et al., 2014). In 
patients with hyperthyroidism, higher baseline serum TSH concentrations have 
recently been shown to be significant factors of weight gain at the 12 month 
point post-treatment (Lang et al., 2016). However, this finding has not been 
previously reported, with Rotondi et al., (2014) finding no association between 
baseline serum TSH concentrations and weight changes at the nine-month point 
post-treatment. The production of TSH should decrease from excessive thyroid 
hormone production due to negative feedback at the level of the pituitary gland 
(Connors & Hedge, 1981; Yamada et al., 1989). Therefore, it would be expected 
that patients with higher serum fT4 concentrations, who have already been 
found to gain more weight post-treatment than patients with lower serum fT4 
concentrations, would also have lower baseline serum TSH concentrations (Gibb 
et al., 2013). As the results from Lang et al., (2016) contradict this, further 
studies are warranted to further investigate the effect of baseline serum TSH 
concentrations in hyperthyroid patients and subsequent weight changes.  
 
1.8.1.3 Effect of treatment modality used 
 
Weight gain following treatment appears to occur regardless of which treatment 
modality for hyperthyroidism is used. However, there are contradicting results 
as to whether the magnitude of weight change may be affected by treatment 
choice (Pears et al., 1990; Dale et al., 2001). Pears et al., (1990) originally 
documented that there were no significant differences in the amount of weight 
gained by patients between treatment modalities, which included carbimazole, 
surgical thyroidectomy and I131; however, the group size in that study only 
included 65 cases. These preliminary results have now been contradicted by a 
bigger study by Dale et al., (2001) that included 162 patients and found that 
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patients treated surgically gained more weight than patients treated with I131 
or anti-thyroidal medication.  
 
Treatment combination has also been found to affect weight gain as patients 
that underwent a surgical thyroidectomy were found to be less likely to gain 
weight when compared to those patients that had first received I131 and then 
had a surgical thyroidectomy performed (Schneider et al., 2014). However, 
there has been no noted effect of the extent of surgery performed on weight 
gain, as no significant difference was detected between those patients that 
underwent a hemithyroidectomy and those patients that underwent a total 
thyroidectomy (Lang et al., 2016). 
 
1.8.1.4 Effect of gender and race/ethnicity 
 
Weight gain in humans could also be linked to gender and racial/ethnic 
differences; however, there are contradictory findings in regards to gender in 
the literature. Male gender, black race and Hispanic ethnicity were found to be 
independent predictors of weight gain following treatment with I131 in one study 
(Ariza et al., 2010). However, other studies have either found that female 
patients gain more weight or they have found that gender is not actually always 
a predicting factor of weight gain (Dale et al., 2001; Scheidhauer et al., 2002; 
Rathi et al., 2008). 
 
1.8.1.5 Effect of age 
 
It is not clear whether patient age has an effect on the post-treatment weight 
gain in patients treated for hyperthyroidism. Both Dale et al., (2001) and Lang 
et al., (2016) found that weight gain was greater in younger patients, where as 
Ozdemir et al., (2010) found the opposite. The latter paper had a smaller 
sample size and used a different cut-off for old versus young (45 years), 
compared to 30 years in the Dale et al., (2001) paper; a cut-off for age was not 
used by Lang et al., (2016). These variances may account for the difference in 
findings between the papers. 
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1.8.1.6 Effect of post-treatment thyroid hormone concentrations  
 
It has been shown that human patients that become biochemically hypothyroid 
during treatment of hyperthyroidism, gain significantly more weight than those 
patients who remain euthyroid during the treatment period (Dale et al., 2001). 
Dale et al., (2001) also showed that the weight gain seen in these patients was 
significantly more in those that became hypothyroid permanently and required 
T4 supplementation, compared to those patients that either became transiently 
hypothyroid or were never hypothyroid.  
 
Hypothyroid patients have a reduced capacity to excrete water through the 
kidneys, which is demonstrated by both a lower plasma osmolality and lower 
free water clearance in affected patients, which both normalise with treatment 
(Sahun et al., 2001). Other causes of water retention in human hypothyroidism 
have included an increased extravascular mass of albumin as well as inadequate 
lymphatic drainage. These variables have also been found to return to normal 
with treatment of the hypothyroid state (Parving et al., 1979). This increased 
water retention may therefore contribute to the weight gain seen in patients 
with hypothyroidism. 
 
Weight changes associated with hypothyroidism have also been shown to be due 
to alterations in lean mass, which may again be linked to altered water 
excretion, as identified by Karmisholt et al., (2011). In that study, dual-energy 
x-ray absorptiometry (DEXA) scans in hypothyroid patients following 
levothyroxine supplementation, identified that a significant decrease in the lean 
mass sub compartment was seen, with only a minimal decrease in the fat sub 
compartment and no change in the bone mass sub compartment. Lean mass 
identified on DEXA scans is known to include water, proteins, glycogen and 
minerals that are not tied into the bone (Pietrobelli et al., 1996). It was 
therefore concluded that the weight loss observed in these patients following 
treatment, was due to the loss of excess body water, resulting in a decreased 
lean mass sub compartment (Karmisholt et al., 2011).  
 
The findings of the Karmisholt et al., (2011) study combined with findings from 
Lönn et al., (1998), which assessed weight changes in hyperthyroid patients 
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following treatment, both demonstrate that weight changes in thyroid 
dysregulation are associated with changes in the lean mass of the patients. It 
could therefore be speculated that as patients who become hypothyroid 
following treatment for hyperthyroidism gain more weight than those patients 
that become euthyroid, the lean mass increases in the former group would be 
higher (Dale et al., 2001). 
 
The effect of post-treatment serum TSH concentrations on weight gain has also 
been investigated. However, serum TSH concentrations following thyroidectomy 
were not found to be related to weight gain (Rotondi et al., 2014).  
 
1.8.1.7 Causes of weight gain 
 
There have been several other suggested causes of the weight gain seen in 
humans following treatment of hyperthyroidism, apart from changes in lean 
mass/body water described above. They have included: 
1) A reduction in metabolic rate secondary to decreased thyroid hormone 
concentrations (Abid et al., 1999).  
2) An initial increase in food energy intake by patients following treatment, 
in order to maintain their premorbid weight (Abid et al., 1999). 
3) Subnormal levels of 24 hour energy expenditure and spontaneous physical 
activity resulting from thyroid hormone suppression (Jacobsen et al., 
2006). 
 
Increased dietary intake as a cause of weight gain following treatment for 
hyperthyroidism is also supported by the study by Alton & O’Malley (1985). They 
identified weight gain to be lower in patients provided with formal dietary 
advice, who therefore had a lower level of energy intake, compared to patients 
not provided with dietary advice.  
 
1.8.2 Weight gain in cats  
 
Weight gain is also commonly associated with successful treatment of 
hyperthyroidism in cats and monitoring their body weight after treatment should 
form part of the routine monitoring in these cases (Jaillardon et al., 2012; 
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Daminet et al., 2014). However, the amount of weight gained by hyperthyroid 
cats that are treated is not as well documented within the literature as it is in 
humans (Boag et al., 2007; Finch et al., 2012; Jaillardon et al., 2012; Hui et al., 
2015; Scott-Moncrieff et al., 2015).  
 
Weight gain has been documented to occur over a variable time period in cats 
post-treatment, with significant weight gain reported as early as three weeks 
following treatment (Boag et al., 2007; van Hoek et al., 2009; Finch et al., 
2012). The study by van Hoek et al., (2009) tried to assess this post-treatment 
weight gain in more detail by assessing the body weight of cats at one, four, 12 
and 24 weeks post-treatment with I131 and found that weight gain increased 
significantly between week one post-treatment and week 24 post-treatment.  
 
The main cause of the early weight gain seen in hyperthyroid cats treated with 
I131 is thought to be due to increases in fat-free mass (Finch et al., 2012). In the 
Finch et al., (2012) study there was a median increase of fat-free mass by 5 % 
within the first three weeks post-treatment. The fat-free mass was calculated 
using a previously validated feline specific prediction formula: -0.164 + (0.41 x 
body weight in kg) + (0.054 x forelimb height in cm) x (0.098 x right forelimb 
circumference in cm) – (0.028 x hindlimb height in cm). These increases in fat-
free mass resulted in a median weight gain of 0.28 kg and a median percentage 
increase in body weight of 9.66 % (range 5.97-32.8) during the three weeks. 
These findings agree with the similar findings in humans that changes in fat-free 
mass occur early on following treatment of hyperthyroidism (Lönn et al., 1998). 
 
Increases in leptin, an adipocytokine secreted by adipose tissue, have been 
found to occur in the three month period following the start of treatment with 
methimazole (Jaillardon et al., 2012; Cao, 2014). This increase in leptin was also 
found to correlate with body weight changes. As leptin reflects the amount of 
body fat mass this would suggest that increases in fat mass also occur in treated 
cats (Jaillardon et al., 2012). However, this increase in fat mass may occur after 
the initial three-week period due to the findings by Finch et al., (2012).  
 
In the Boag et al., (2007) study, cats treated with I131 were found to gain 0.94 kg 
on average during the six month follow up period. This is suggestive that weight 
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gain continues past the three-week point post I131 treatment documented by 
Finch et al., (2012) and would also be supported by the findings of van Hoek et 
al., (2009). However, as specific values for the weight changes were not 
reported in the van Hoek et al., (2009) study and body weight in that study was 
only presented in diagrammatic form with a box-plot, a direct comparison 
between the Boag et al., (2007) and van Hoek et al., (2009) studies cannot be 
made.  
 
A limitation of the studies that have been performed on weight changes 
following I131 treatment is that only small case numbers have been included with 
27, 21 and 10 cases in the Boag et al., (2007), van Hoek et al., (2009) and Finch 
et al., (2012) studies respectively and therefore this may have affected their 
findings.  
 
1.8.2.1 Effect of treatment modality used 
 
Although weight gain is reported with the use of I131 and anti-thyroidal 
medication in hyperthyroid cats, there have been no studies performed that 
have directly compared the degree of weight changes seen amongst the 
different treatment modalities, as it has been done in humans (Pears et al., 
1990; Boag et al., 2007; Jaillardon et al., 2012).  
 
Cats treated successfully with anti-thyroidal medication (methimazole) have 
been documented to have a median increase in their body weight of 0.7 kg over 
a three month period, compared to a median weight gain of 0 kg in cats 
unsuccessfully treated. Treatment success in that study was defined by a serum 
fT4 concentration ≤ 30 pmol/l (Jaillardon et al., 2012). Although the cats 
treated with I131 in the Boag et al., (2007) study were documented to gain more 
weight than the cats in the Jaillardon et al., (2012) study, the weight changes 
were documented three months later at six months, therefore a direct 
comparison cannot be made between the two studies.  
 
Route of administration and dose frequency of methimazole have been 
investigated as to whether they could have an effect on weight gain in the first 
month of treatment in cats (Trepanier et al., 2003; Sartor et al., 2004). In these 
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studies median weight changes were not significantly different between once 
daily and twice daily administration or between oral and transdermal 
administration of methimazole at either the two or four week points post-
treatment. However, neither study separated the weight changes into groups 
dependent on treatment success, which may have affected their findings.  
 
Despite the weight changes seen with I131 and anti-thyroidal medication, weight 
has not been found to significantly change with the use of an iodine-restricted 
diet (Hui et al., 2015; Scott-Moncrieff et al., 2015). In the studies by Hui et al., 
(2015) and Scott-Moncrieff et al., (2015), cats were followed up for six and two 
month periods respectively, but significant weight changes were not identified 
despite the majority of cats having a serum T4 concentration within the 
reference interval. In the Hui et al., (2015) study, which included 49 cats, 83 % 
of cats had a serum T4 concentration within the reference interval but the mean 
body weight only increased by 0.1 kg, from 3.8 to 3.9 kg after 61-180 days on 
the diet. The same weight change of 0.1 kg was also seen in the Scott-Moncrieff 
et al., (2015) study after eight weeks on the diet, when 87.5 % of cats had a 
serum T4 concentration within the reference interval; however, this study 
included a smaller number of cats with only eight cases. An additional study 
assessing the use of an iodine-restricted diet over a time period of two months 
but in much larger numbers (n = 225), showed that body condition score (BCS) 
did not alter during treatment. This was despite owners reporting their cat’s 
weight loss to have improved in the questionnaire. Unfortunately, weights were 
not available for assessment/comparison in this study (van der Kooij et al., 
2014).  
 
Although one study comparing weight changes in cats treated with the different 
treatment modalities has not been performed, the differences in weight gain 
noted between studies does raise the question as to whether variances may 
occur, especially considering the lack of weight gain seen in studies assessing 
iodine-restricted diets (Hui et al., 2015; Scott-Moncrieff et al., 2015). 
 
The effect of other factors such as age and gender of the patient on weight gain 
post-treatment, which have already been assessed in the human field, have not 
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yet been investigated in feline hyperthyroidism and this remains an area to be 
explored (Dale et al., 2001; Scheidhauer et al., 2002). 
 
1.8.2.2 Effect of post-treatment serum T4 concentration 
 
It is not clear whether the post-treatment serum T4 concentration has an effect 
on the post-treatment weight changes in cats. Jaillardon et al., (2012) 
documented weight gain to be significantly lower in cats with a three month 
post-treatment serum fT4 concentration > 30 pmol/l, compared to cats with a 
serum fT4 concentration lower than this; however, they did not assess if weight 
changes were different between euthyroid and hypothyroid cats. In Hui et al., 
(2015) no effect of post-treatment serum T4 concentration on body weight was 
found; however, they only compared the weight changes of cats with a low-
normal serum T4 concentration to cats with a high-normal serum T4 
concentration, two to six months following treatment. 
 
No studies to date have been specifically performed to assess the effect of post-
treatment serum T4 concentration on weight gain in cats treated with I131, nor 
has a study evaluated whether weight changes following treatment for 
hyperthyroidism are different between cats that become euthyroid, cats that 
become hypothyroid and cats that remain hyperthyroid. 
  
1.9 Aims of the thesis 
 
This literature review has shown that treatment of hyperthyroidism with I131 is 
viewed as either the preferential treatment option or one of the preferential 
treatment options for hyperthyroidism in cats and humans (when caused by toxic 
nodular goiter), respectively. 
 
This thesis assesses two different aspects of monitoring cats during the initial 
three-week isolation period following administration of I131 for treatment of 
hyperthyroidism. The aims of the first part of the thesis will be to assess the 
weight changes that are seen in these cats during the isolation period in a larger 
number of cases than previously reported and to evaluate whether factors such 
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as the gender and post-treatment serum T4 concentrations of the patient have 
an effect on this.  
 
The aim of the second part of the thesis will be to expand the original data set 
used for the study by Roberts et al., (2015), to further assess the emission of γ 
radiation from treated cats during the isolation period using an EPD and evaluate 
if a fixed isolation period could be used at the SAH, University of Glasgow.  
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CHAPTER 2 
2 WEIGHT CHANGES IN CATS DURING THE THREE-WEEK 
ISOLATION PERIOD FOLLOWING ADMINISTRATION OF I131 
FOR TREATMENT OF HYPERTHYROIDISM 
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2.1 Introduction 
 
Weight gain has been found to occur in humans and cats following treatment for 
hyperthyroidism, as discussed in depth in chapter one (Dale et al., 2001; Boag et 
al., 2007; Jaillardon et al., 2012). Although the gold standard treatment for 
hyperthyroidism in cats is I131, weight gain following its administration has not 
been well described in the literature (Boag et al., 2007; van Hoek et al., 2009; 
Finch et al., 2012). Those studies on I131 treatment in cats that have included 
the monitoring of weight changes in their study findings have been associated 
with limitations such as the inclusion of only small case numbers or a lack of 
regular documentation of weight changes during the initial isolation period 
following treatment (Boag et al., 2007; Finch et al., 2012). The largest number 
of cats included in a study assessing weight changes post I131 treatment has been 
27 cats in van Hoek et al., (2009); however, in that study the body weight 
changes were only described diagrammatically with box and whisker plots and no 
specific values were documented in the body of the text.  
 
Although weight gain in cats treated successfully with anti-thyroidal medication 
has been found to be significantly greater than cats unsuccessfully treated, this 
has not yet been investigated when using I131, nor has weight gain been assessed 
to evaluate if it could be used as a predictor of the outcome of I131 treatment 
(Jaillardon et al., 2012).  
 
Successful treatment following administration of I131 has been defined 
differently in previous studies on cats, with some defining it as the achievement 
of a euthyroid state, whilst others defining it as the achievement of a euthyroid 
or hypothyroid state i.e. reversal of biochemical hyperthyroidism (Mooney, 1994; 
Theon et al., 1994). Recently, a consensus statement on anti-thyroidal 
treatment for hyperthyroidism has suggested that for treatment success, a 
reduction of the serum T4 concentration into the lower half of the reference 
interval should be aimed for (Daminet et al., 2014). However, this suggestion 
was not evidence based and the consensus statement did not include a 
discussion on treatment with I131. Despite these differing opinions on the 
definition of treatment success, there have yet to be any studies performed that 
assess if the weight changes between these definitions is different.  
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In humans, it has also been shown that those patients that become 
biochemically hypothyroid following treatment gain significantly more weight 
than those that that remain euthyroid (Dale et al., 2001). The effect of 
induction of a biochemical hypothyroid state on weight gain has yet to be 
evaluated in cats. 
 
Following treatment for hyperthyroidism, azotaemia can occur quite commonly 
and the development of post-treatment hypothyroidism is thought to contribute 
to this (Williams et al., 2010). Only one study has tried to evaluate whether the 
development of renal dysfunction could have an effect on weight gain; however, 
that study included only a small number of cases (van Hoek et al., 2009).  
  
In humans, factors including the gender and age of the patient have also been 
assessed to evaluate whether they can affect the amount of weight gained 
following treatment; however, there have yet to be any studies performed that 
assess these factors in cats (Dale et al., 2001; Ariza et al., 2010; Lang et al., 
2016).  
 
2.2 Aims and hypotheses 
 
The aims of this study were to document the weight changes during the initial 
three-week isolation period following administration of I131 in a larger number of 
cases than included in the Finch et al., (2012) study and to also assess whether 
weight gain could be affected by factors that have been previously evaluated in 
humans such as age of the patient (Dale et al., 2001). The aims are shown in 
more detail below:   
1) To determine the amount of weight gained by cats treated with I131 in the 
three-week isolation period following treatment. 
2) To determine if the weight gain of cats that become biochemically 
euthyroid or hypothyroid following treatment is different to those cats 
that remain biochemically hyperthyroid; to therefore assess whether 
weight gain could be used as a predictor of whether treatment has led to 
reversal of overt hyperthyroidism. It was hypothesised that those cats 
that remain biochemically hyperthyroid will gain less weight than those 
cats that become biochemically euthyroid or hypothyroid, and due to this, 
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weight gain could be used as a predictor of the reversal of overt 
hyperthyroidism.  
3) To determine if the weight gain of cats that become biochemically 
hypothyroid following treatment is different to those cats that become 
biochemically euthyroid. It was hypothesised that weight gain would be 
greater in cats that become biochemically hypothyroid than in those cats 
that become biochemically euthyroid.  
4) To determine if the amount of weight gained by cats treated with I131 is 
affected by variables such as age, gender, previous treatment of 
hyperthyroidism and/or the development of post-treatment azotaemia.  
 
2.3 Materials and methods  
 
This was a retrospective study that included cats that were presented to the SAH 
between January 2010 and September 2013 for I131 treatment of confirmed 
hyperthyroidism. These cats had been previously diagnosed with hyperthyroidism 
in general practice and subsequently referred. Any cat that had been referred 
for I131 treatment of their hyperthyroidism was eligible for inclusion into this 
study.   
 
2.3.1 Exclusion criteria 
 
All cases that were treated with I131 during the allotted time frame were then 
assessed in regards to the exclusion criteria. Any cases that matched one or 
more of the criteria shown below were excluded. 
1) Cats that did not have either a pre- and/or post-treatment weight 
recorded. The pre-treatment weight could have been recorded at any 
time between the day of the primary consultation at the SAH and the day 
they were injected with I131. This time period is typically three to four 
days in duration. The post-treatment weight had to have been recorded 
between the day the cat left the I131 isolation unit and the date of their 
discharge from the SAH. This time period is typically one to two days in 
duration.   
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2) Cats treated with I131 doses > 200 MBq. This was because these cats 
would have had to have remained in the isolation unit longer than the 
standard 21 days following treatment.  
3) Cats with known concurrent illnesses pre-treatment e.g. azotaemia or 
congestive heart failure. Azotaemia in this study was defined as a serum 
creatinine concentration > 180 µmol/l (the high end of our laboratory 
reference interval). This exclusion criterion was included because 
concurrent illnesses may have affected the weight gain of treated cats. It 
should be noted that for this study vomiting and diarrhoea were not used 
as exclusion criteria as gastro-intestinal signs can be reported clinical 
signs in hyperthyroidism.   
 
2.3.2 Additional data collected 
 
For those cases that were not excluded additional data was then collected. This 
data included the cat’s age, gender and breed. Data was also collected on 
whether there had been previous treatment of hyperthyroidism in each case and 
which treatment modality had been used i.e. surgical thyroidectomy, anti-
thyroidal medication, an iodine-restricted diet or a combination of these 
treatment options. 
 
Any cat that had a serum T4 concentration > 50 nmol/l (reference interval 15-50 
nmol/l) after the three-week isolation period was classified as biochemically 
hyperthyroid and subsequently followed up. This was to assess if they were a 
true failure i.e. the serum T4 concentration did not return to normal within the 
six month period after treatment, or whether they became euthyroid during this 
time period, as has been documented previously when using I131 (Peterson & 
Becker, 1995). Those cases that had a serum T4 concentration < 15 nmol/l after 
the three-week isolation period and were classified as biochemically hypothyroid 
were also followed up. This was to assess if their serum T4 concentration 
increased back up into the normal reference interval or if they remained 
hypothyroid.      
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2.3.3 Protocol for I131 treatment at the SAH 
 
As part of the protocol for I131 treatment, the use of either anti-thyroidal 
medication or an iodine-restricted diet were stopped two weeks prior to the 
cat’s primary consultation at the SAH. This was due to two reasons: 
1) The cats serum T4 concentration was used as part of the decision making 
process when deciding on the dose of I131 that each cat received (Mooney, 
1994). 
2) The use of an iodine-restricted diet or cessation of anti-thyroidal 
medication just prior to receiving I131 have both been shown to affect the 
uptake of it (Nieckarz & Daniel, 2001; Scott-Moncrieff et al., 2015). 
  
Following the initial consultation with the owner of each cat, when a full clinical 
history was taken and a physical examination of the cat performed, the 
hyperthyroid cat was then admitted into the hospital. As part of the physical 
examination, the cat was weighed using Soehnle 8310 baby weight scales 
(www.soehnle-professional.com) and their weight recorded. The same scales 
were used for all cases and the scales were calibrated monthly using calibration 
weights. Blood was then collected from each cat by jugular venepuncture and 
this was submitted for a complete blood count, serum biochemistry and serum 
T4 concentration assessment. The serum T4 concentration was measured using a 
chemiluminesence assay (Siemens Immulite 2000; reference interval 15 – 50 
nmol/l with 3.2 nmol/l being the lowest limit of detection), the serum 
biochemistry was run using an Olympus AU640 chemistry analyzer and the 
complete blood count using a Siemens Advia 120. As part of the standardized 
protocol blood was also submitted for detection of feline leukaemia virus (FeLV) 
antigen using an ELISA and feline immunodeficiency virus (FIV) antibodies and 
feline coronavirus antibody titres using immunofluorescent assays. A urine 
sample obtained either by free catch or cystocentesis was submitted for full 
urine analysis. 
 
Cats were then hospitalised within a cat ward for between three and four days 
following the initial consultation prior to I131 being administered. This 
hospitalisation period was to allow the cats to acclimatize to the hospital 
environment before going into the I131 isolation unit. This was to ensure they 
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would eat, drink, urinate and defaecate when placed into isolation. It also 
allowed time for the blood results to be interpreted to ensure there was no 
biochemical or haematological concerns that would preclude treatment with I131, 
and to confirm that the cats were truly hyperthyroid. Following the 
acclimatization period cats were first sedated (with either medetomidine and 
butorphanol or midazolam and ketamine) and then injected subcutaneously with 
varying doses of I131, of between 80 and 200 MBq. The dose administered to each 
cat was adapted from an original scoring system described by Mooney (1994). 
The scoring system used both in the Mooney (1994) study and this study, utilises 
the severity of the cats clinical signs, the size of the thyroid gland and the 
magnitude of the serum T4 concentration to dictate what dose of I131 is injected 
in each case (Table 1).   
 
Following the injection of I131, treated cats were then placed into the I131 
isolation unit for 21 days. The cats were fed a variable but large quantity of food 
once daily during the isolation period, with the aim of achieving ad libitum 
feeding. A mixture of dry and wet cat food was provided, depending on the cats’ 
preference. This was based on a combination of the diet history obtained during 
the primary consultation with the owners and by assessment of their preferred 
food type during the acclimatization period in the SAH.  
 
On exit from the isolation unit all cats had a repeat physical examination and 
repeat jugular venepuncture performed. Blood was submitted for repeat serum 
biochemistry and serum T4 concentration assessment. The cats were then 
weighed using the same scales as before treatment (Soehnle 8310 baby weight 
scales).  
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Score Severity of clinical 
signs 
Serum T4 concentration 
(nmol/l) 
Size of goiter 
One Mild < 80 < 1 cm 
Two Mild to moderate 80 to < 100 1 to < 1.5 cm 
Three Moderate 100 to < 150 1.5 to < 2 cm  
Four Moderate to severe 150 to < 400 ≥  2 cm 
Five Severe ≥ 400 Non-palpable 
 
Table 1. The scoring system for classifying the severity of hyperthyroidism in 
each case. For each column, a score of one to five was assigned depending on 
the individual cats clinical signs, their serum T4 concentration and their goiter 
size. The three scores were then added together to give a total score, with a 
minimum possible value of three and a maximum possible value of 15. Using the 
algorithm, cats with low scores (3-9) were administered ≤ 120 MBq, cats with 
medium scores (10-12) were administered > 120 to ≤ 150 MBq and cats with high 
scores (> 12) were administered > 150 MBq (up to 200 MBq). 
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2.4 Statistical analysis 
 
The pre- and post-treatment weight of each included cat was entered into a 
computer database (Microsoft Excel) and the weight gain or loss was then 
calculated. This was then converted into a percentage weight gain or loss of 
their pre-isolation weight.   
 
The cases were then divided into groups for further statistical evaluation to 
assess if gender, age, dose of I131 administered, pre-referral treatment, post-
treatment serum T4 concentration and development of azotaemia post-
treatment had an effect on the amount of weight gained during the isolation 
period. For any cat that had a serum T4 concentration below the limit of 
detection i.e. < 3.2 nmol/l, its serum T4 concentration was recorded as 3.19 
nmol/l. 
1) For the effect of gender the cases were divided into two groups:  
• Male (entire or neutered).  
• Female (entire or neutered). 
2) For the effect of age the cases were divided into three groups dependent 
on their age at the time of treatment:  
• Group one) < 10 years old.  
• Group two) ≥ 10 years old but ≤ 13 years old. 
• Group three) > 13 years old. 
3) For the effect of I131 dose, the cases were divided into five groups 
dependent on the dose they had been administered: 
• 80 MBq 
• 120 MBq 
• 150 MBq 
• 180 MBq 
• 200 MBq 
4) For the effect of previous treatment of hyperthyroidism on weight gain, 
the cases were divided into five groups: 
• Group a) No previous treatment for hyperthyroidism. 
• Group b) Treatment with anti-thyroidal medication. 
• Group c) Treatment with surgery. 
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• Group d) Treatment with an iodine-restricted diet. 
• Group e) Combination treatment e.g. anti-thyroidal medication and 
surgery. 
5) For the evaluation of the effect of post-treatment serum T4 concentration 
on weight gain, the cases were divided into four groups dependent on 
their post-treatment serum T4 concentration:  
• Group A) Biochemical hypothyroidism: serum T4 concentration < 15 
nmol/l. 
• Group B) Biochemical euthyroidism, low normal: serum T4 
concentration 15-35 nmol/l. 
• Group C) Biochemical euthyroidism, high normal: serum T4 
concentration > 35 but ≤ 50 nmol/l.  
• Group D) Biochemical hyperthyroidism: serum T4 concentration > 
50 nmol/l. 
6) For the effect of the development of acute azotaemia following 
treatment on weight gain, the cases were divided into two groups 
dependent on the serum creatinine concentration three weeks post-
treatment: 
• Azotaemic. Azotaemia was defined as a post-treatment serum 
creatinine concentration > 180 µmol/l, with the laboratory 
reference interval being 91-180 µmol/l.  
• Non-azotaemic. This was defined by a post-treatment serum 
creatinine concentration ≤ 180 µmol/l. 
 
The percentage weight gain variable was tested for normality using the Shapiro 
Wilks test in STATA/SE 12.0 for Windows. The data were not found to be 
normally distributed (P-value = 0.03). Non-parametric tests (Kruskal-Wallis 
equality of populations rank test and two-sample Wilcoxon rank-sum test) were 
employed to investigate any differences in this parameter by gender, age, prior 
treatment of hyperthyroidism, dose of I131 administered, development of 
azotaemia and post-treatment serum T4 concentration.  
 
The absolute change in serum T4 concentration between pre- and post-
treatment bloods (ΔT4) and the relative change of serum T4 concentration 
(ΔT4/pre-treatment serum T4 concentration) were assessed for correlation with 
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percentage weight gain using Pearson’s correlation coefficient. The receiver 
operator characteristics (ROC) procedure was used to assess the calculated 
percentage weight gain three weeks after being treated with I131 as a predictor 
for reversal of overt hyperthyroidism. It was also used for selecting cut-off 
points and calculating corresponding sensitivities and specificities for the 
prediction of reversal of overt hyperthyroidism. P values < 0.05 were considered 
statistically significant for all tests applied. 
 
2.5 Results 
 
2.5.1 Study population 
 
During the time period January 2010 to September 2013, 136 cats were referred 
to the SAH for treatment of their hyperthyroidism with I131. This study 
population was then reviewed in further detail to assess if they were eligible for 
inclusion in the study. 
 
2.5.2 Exclusions 
 
Upon further assessment 22/136 cases had to be excluded, resulting in a study 
population of 114 cats, which were then statistically evaluated. Reasons for 
exclusion from the study included: 
1) Administration of an I131 dose > 200 MBq. One case was excluded due to 
this criterion as they were injected with 1000 MBq of I131 and kept in the 
isolation unit for six weeks. 
2) Absence of a recorded weight post-treatment upon exit from the isolation 
unit (n = 21).  
 
2.5.3 Study group demographics 
 
The median age of the study population was 12 years with a range of 6-16 years. 
The majority of the study cats were domestic short-hairs (n = 103); however, 
other breeds included domestic long-hairs (n = 9) and one each of Siamese and 
Maine Coon cats. The median body weight of the whole study group before 
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treatment was 3.7 kg (interquartile range (IQR) 2.93-4.41) and the median 
serum T4 concentration prior to treatment was 188 nmol/l (IQR 114.5 to 260). 
 
2.5.4 Overall weight gain 
 
The median weight of the study cats following treatment was 4.05 kg (IQR 3.39-
4.87) and the median weight gain of the whole study population was 0.36 kg (IQR 
0.15-0.58). This translated to a median percentage weight gain of 11.35 % (IQR 
3.81-17.38) for the whole study population.  
 
2.5.5 Gender 
 
Of the study group 48 cats were male neutered and 66 cats were female 
neutered; there were no entire cats in the study population. The male neutered 
cats were found to have a median percentage weight gain of 7.3 % (IQR 2.75-
15.68) compared to the female neutered cats that had a median percentage 
weight gain of 12.3 % (IQR 5.43-17.75). The percentage weight gain following 
treatment with I131 was not found to be significantly different between male 
neutered and female neutered cats (P = 0.179). 
 
2.5.6 Age 
 
When the study population was divided into their respective age groups, there 
were 16 cats in group one, 74 cats in group two and 24 cats in group three.  
 
The median age before treatment of those cats with post-treatment serum T4 
concentrations ≤ 50 nmol/l was not significantly different from those cats with 
post-treatment serum T4 concentrations > 50 nmol/l, at 12 years versus 10 years 
respectively. Cats in age group one had a median percentage weight gain of 6.5 
% (IQR 0.68-15.2), cats in age group two had a median percentage weight gain of 
11.6 % (IQR 4.15-18.98) and cats in age group three had a median percentage 
weight gain of 11.1 % (IQR 3.75-14.88). There was no statistical difference 
between the percentage weight gain of cats in the three different age groups (P 
= 0.61) (Figure 1).   
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Figure 1. A box and whisker plot illustrating the distribution of the study 
population by age (x-axis) and percentage weight gain (y-axis). The horizontal 
line in the box reflects the median value. Outliers are depicted by asterisks. The 
width of the boxes is relative to the number of cases in each group. 
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2.5.7 Dose of I131 administered 
 
Nineteen of the cats were injected with 80 MBq of I131, 30 of the cats were 
injected with 120 MBq, 37 of the cats with 150 MBq, four cats with 180 MBq and 
24 cats with 200 MBq. 
 
The median and IQR of percentage weight gain of the study cats dependent on 
the dose of I131 administered were as follows: 80 MBq (8.1 %, 3.05-14.45), 120 
MBq (12.5 %, 6.6-16.83), 150 MBq (11.9 %, 3.6-20.2), 180 MBq (15.05 %, 13.29-
20.95) and 200 MBq (5.5 %, 0.47-20.95). The percentage weight gain of the study 
cats was not found to be significantly different between the doses of I131 that 
had been administered (P = 0.15) (Figure 2).  
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Figure 2. A box and whisker plot illustrating the distribution of the study 
population by dose of I131 administered (x-axis) and percentage weight gain (y- 
axis). The horizontal line in the box reflects the median value. Outliers are 
depicted by asterisks. The width of the boxes is relative to the number of cases 
in each group. 
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2.5.8 Previous treatment 
 
Out of the 114 cats included in this study, 49 cats had not received any previous 
treatment for hyperthyroidism (group a) and had a median pre-treatment serum 
T4 concentration of 148 nmol/l.  
 
Of the remaining 65 cats: 
• There were 58 cats that had been previously treated with anti-thyroidal 
medication (either methimazole or carbimazole) and had a median pre-
treatment serum T4 concentration of 245.5 nmol/l (group b). 
• One cat had been treated surgically prior to referral and had a pre-
treatment serum T4 concentration of 185 nmol/l (group c).  
• No cats had been placed onto an iodine-restricted diet (group d). 
• There were six cats that had been treated with a combination of surgery 
(thyroidectomy) and anti-thyroidal medication (methimazole or 
carbimazole) and had a median pre-treatment serum T4 concentration of 
102 nmol/l (group e). 
 
Those cats in group a had a median percentage weight gain of 12.3 % (IQR 5.1 to 
16.1) and those cats in group b had a median percentage weight gain of 11.5 % 
(IQR 3.7-19.2). The one cat in group c gained 2.6 % of their pre-treatment body 
weight and the cats in group e had a median percentage weight gain of 0.9 % 
(IQR -5.5 to 4.83). Percentage weight gain was found to differ statistically 
between pre-referral treatment, with cats in groups c and e gaining significantly 
less weight than cats in group a and b (P = 0.037) (Figure 3).  
 
To assess pre-referral treatment for hyperthyroidism further, the study 
population was then divided into those cats that had received treatment for 
hyperthyroidism prior to referral (n = 65) and those cats that had not received 
any treatment (n = 49). The median pre-treatment serum T4 concentration of 
those cats that had not received treatment was 148 nmol/l, compared to 234 
nmol/l for those cats that had received prior treatment. With this division of 
cases there was no statistical difference found between the percentage weight 
gain of cats that received pre-referral treatment and the percentage weight gain 
of cats that had not (P = 0.302) (Figure 4).  
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Figure 3. A box and whisker plot illustrating the distribution of the study 
population by pre-referral treatment (x-axis) and percentage weight gain (y- 
axis). The horizontal line in the box reflects the median value. Outliers are 
depicted by asterisks. The width of the boxes is relative to the number of cases 
in each group. As there was only one case that had surgery as its only pre-
referral treatment, this was excluded from this box plot.  
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Figure 4. A box and whisker plot illustrating the distribution of the study 
population by pre-referral treatment (x-axis) and percentage weight gain (y- 
axis). The horizontal line in the box reflects the median value. Outliers are 
depicted by asterisks. The width of the boxes is relative to the number of cases 
in each group.  
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2.5.9 Serum T4 concentration post-treatment 
 
The median post-treatment serum T4 concentration was 4.65 nmol/l, with a 
range of 3.19 nmol/l to 819 nmol/l. The mean post-treatment serum T4 
concentration was 33.7 nmol/l. Following the three-week isolation period after 
treatment with I131, only 13/114 cats had a serum T4 concentration above the 
reference interval with a range of 51.1 to 819 nmol/l, a mean value of 230.68 
nmol/l and median value of 88 nmol/l and were classified as the biochemical 
hyperthyroidism group (group D) (Table 2). Five of these cats failed to gain 
weight during the three-week isolation period. These 13 cases were followed up 
to assess if their serum T4 concentration normalised over the following six 
months. Four of the 13 cases were found to become euthyroid during the 
following six months and therefore became delayed successes and 3/13 cases 
were lost to follow-up following treatment at the SAH. Therefore, there were 
only six cats that were known to be persistently hyperthyroid following 
treatment.  
 
For those cats that had a post-treatment serum T4 concentration ≤ 50 nmol/l, 
their median body weight pre-treatment was 3.8 kg. For those cats that had a 
post-treatment serum T4 concentration > 50 nmol/l, their median body weight 
before treatment was 3.4 kg. This difference was not statistically significant (P > 
0.05).  
 
Once the serum T4 concentration post-treatment of the other study cats had 
been assessed, this resulted in 85 cats being in group A (biochemical 
hypothyroidism), 12 cats being in group B (biochemical euthyroidism, low 
normal) and four cats being in group C (biochemical euthyroidism, high normal). 
The mean and median post-treatment serum T4 concentrations of these three 
groups respectively were: group A (4.83 nmol/l and 3.19 nmol/l), group B (21.23 
nmol/l and 22.2 nmol/l) and group C (230.68 nmol/l and 88 nmol/l). 
 
Cats in group D (n = 13) (Table 2) gained a median of 3.9 % (range -8.6 % to 37.6 
%) of their pre-treatment body weight. This was compared to a median 
percentage weight gain of 12.3 % (range -5.3 % to 43.8 %) in group A, 8.75 % 
(range -0.48 % to 25 %) in group B and 8.25 % (range 3.6 to 13.2 %) in group C. 
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The median percentage weight gain of groups A to C combined was 12.2 %. 
Cats in group D were found to gain significantly less weight than groups A to C 
combined (P = 0.007). However, the differences in percentage weight gain 
between groups A, B and C were not statistically significant (P > 0.05) (Figure 5). 
 
Of the four cats in group D that became euthyroid over the six months following 
treatment, three were found to have gained weight (3.9 %, 6.5 % and 9.35 %) 
during the isolation period and only one cat lost weight (-3.3 %). Of the 101 cats 
in groups A to C, 91 of the cases gained weight during the three-week isolation 
period.  
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2.63 
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 Table 2. See legend on next page.
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Table 2. A table showing the age (in years), gender (male neutered (MN) or 
female neutered (FN)), dose of I131 administered (in MBq), the pre-treatment 
(pre-tx) and post-treatment (post-tx) weights (in kg), the percentage weight 
gain, the pre-treatment (pre-tx) and post-treatment (post-tx) serum T4 
concentration (in nmol/l), the ΔT4 (in nmol/l) and the follow-up treatment for 
the 13 cases that were still biochemically hyperthyroid post-treatment (group 
D). 
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Figure 5. A box and whisker plot illustrating the distribution of the study 
population by post-treatment serum T4 concentration (x-axis) and percentage 
weight gain (y-axis). The horizontal line in the box reflects the median value. 
Outliers are depicted by asterisks. The width of the boxes is relative to the 
number of cases in each group. 
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2.5.10 Additional treatment for biochemically hyperthyroid cats  
post-treatment 
 
Of the six cats that were found to be persistently hyperthyroid during the six 
months following treatment with I131, five cats went on to have further 
treatment for their hyperthyroid state (Table 2). Two of the cats had a second 
treatment of I131 using a 200 MBq dose; however, they both continued to be 
hyperthyroid following this and were subsequently treated with methimazole. 
Both of these cats lost weight during the isolation period with 7.78 % and 7 % 
losses of their pre-treatment weight. Two of the other cats that failed 
treatment were placed onto medical management with anti-thyroidal 
medication. Both of these cats were also found to have lost weight during the 
isolation period, with 8.6 % and 1.1 % losses of their pre-treatment weight. One 
of the six cats underwent a thyroidectomy seven weeks following treatment with 
I131 at the referring practice and subsequently died. This cat gained 9.39 % of 
their pre-treatment weight during the isolation period. The last cat in this group 
did not receive any further treatment for hyperthyroidism due to the owners’ 
wishes and this cat gained 0.9 % of their pre-treatment weight during the 
isolation period. 
 
2.5.11 Biochemical hypothyroidism 
 
Of the 85 cats that had a post-treatment serum T4 concentration <15 nmol/l 
(group A), 53 cases were lost to follow up. Of the 32 cases with follow up, only 
six were found to be persistently hypothyroid and required levothyroxine 
supplementation (Table 3). Unfortunately, assessment of cTSH was only 
available for two out of the six cases, but in both cases in which it was 
measured, it was increased (> 0.15 ng/ml) (Wakeling, 2010). 
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2.5.12 Change in serum T4 concentration (ΔT4) 
 
The ΔT4 of the whole study group was normally distributed and had a mean 
value of 183.14 nmol/l, with a range of 28.6 to 466.3 nmol/l. Only one cat had 
an increase in their serum T4 concentration during the three-week isolation 
period (Case 5, Table 2). There was no correlation detected between the 
percentage weight change of the treated cats and ΔT4 (r =0.098, P = 0.305). 
However, a weak correlation was detected between the percentage weight 
change of the treated cats and the relative change of T4 (r = 0.288, P = 0.02). 
 
2.5.13 Azotaemia/other illnesses 
 
On review of the clinical notes, physical examinations and pre-treatment blood 
work of the cats in the study, no cats were found to be azotaemic pre-
treatment, nor were they known to have any concurrent illnesses e.g. congestive 
heart failure.  
 
Only 8/114 cats were found to be azotaemic at the time of the three-week post-
treatment venepuncture, with the range of serum creatinine concentration of 
those eight cases being 181 to 250 µmol/l. These eight cats had pre-treatment 
serum creatinine concentrations of 81-156 µmol/l and the largest noted increase 
in serum creatinine concentration between pre- and post-treatment 
concentrations was 134 µmol/l (Table 4). All eight of these cats had post-
treatment serum T4 concentrations < 15 nmol/l. These eight cats had a weight 
gain range of 2.6 to 22.6 % with a median percentage weight gain of 11.5 % 
(Table 4) compared to a median percentage weight gain of 11.35 % in the non-
azotaemic cats. The development of azotaemia was not found to have a 
statistically significant effect on weight gain (P = 0.909). 
 
One of the eight cats with post-treatment azotaemia also required treatment for 
hypothyroidism and was started on levothyroxine supplementation one month 
following administration of I131 (Case 5, Tables 3 and 4). Despite levothyroxine 
supplementation resulting in an increase of the serum T4 concentration into the 
reference interval, there was no noted improvement in the level of azotaemia. 
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This cat gained 12.5 % of their pre-treatment body weight during the three-
week isolation period.  
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 Table 4. See legend on next page.
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Table 4: A table showing the age (in years), gender (MN or FN), dose of I131 
administered (in MBq), the pre-treatment (pre-tx) and post-treatment (post-tx) 
weights (in kg), percentage weight change, the pre-treatment (pre-tx) and post-
treatment (post-tx) serum T4 concentrations (in nmol/l) and the 
pre-treatment (pre-tx) and post-treatment (post-tx) serum creatinine 
concentrations (in µmol/l) for the eight cats that were found to be azotaemic 
following treatment. Case number five is also included in table 3, as they 
required levothyroxine supplementation.
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2.5.13.1 Percentage weight gain as a predictor of post-treatment serum  
                    T4 concentration ≤ 50 nmol/l 
 
The ROC analysis of percentage weight gain as a predictor of a serum T4 
concentration ≤ 50 nmol/l had an area under the curve of 0.730 (P = 0.006, 95 % 
confidence interval (CI), 0.64-0.81) (Figure 6). The optimal cut-off point that 
provided a high specificity with reasonable sensitivity was found to be a 
percentage weight gain of 9.39 %, corresponding to a sensitivity and specificity 
of 59.41 % and 84.62 %, respectively. This would suggest that if a cat gained > 
9.39 % of their pre-treatment body weight during the three-week isolation 
period, the probability that overt hyperthyroidism had been reversed was nearly 
85 %. A specificity of 100 % was obtained when a cut-off of 37.6 % weight gain 
was used. 
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Figure 6. Receiver operating characteristic (ROC) curve for percentage weight 
gain when used to distinguish between reversal of overt hyperthyroidism and 
continuation of biochemical hyperthyroidism. The dashed line represents the 
specific cut-off value of 9.39 % weight gain, creating a sensitivity of 59.41 % and 
a specificity of 84.62 % for predicting a post-treatment serum T4 concentration ≤ 
50 nmol/l. 
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2.6 Discussion 
 
The data included in this study adds to the current literature that assesses 
weight gain in hyperthyroid cats following treatment (Boag et al., 2007; Finch et 
al., 2012; Jaillardon et al., 2012). Although previous studies have documented 
weight gain following treatment of the feline hyperthyroid state, this is the 
largest study to date that the author is aware of assessing this in cats treated 
with I131. The finding that hyperthyroid cats gain weight following treatment 
with I131 is not unexpected given previous study findings both in the human and 
feline fields (Lönn et al., 1998; Dale et al., 2001; Boag et al., 2007; van 
Veenendaal & Rivkees, 2011; Finch et al., 2012). However, the results from this 
study have also shown that cats that remain biochemically hyperthyroid at the 
three week point following administration of I131 gain significantly less weight 
than cats who become biochemically euthyroid or hypothyroid (proving one of 
the hypotheses of the study to be correct), and this has not been previously 
evaluated.  
 
Treatment of hyperthyroidism in humans is commonly associated with excessive 
weight gain, with the majority of this occurring in the first three months 
following treatment (Alton & O’Malley, 1985; Pears et al., 1990). This weight 
gain has been shown to be predominantly due to increases in lean mass, with 
significant increases in fat-free mass noted on DEXA scans both at the three and 
12 month points post I131 treatment (De La Rosa et al., 1997; Lönn et al., 1998). 
Similar findings have also been shown in cats treated with I131, with significant 
increases in fat-free mass detected three weeks post-treatment (Finch et al., 
2012). In that feline study the median and range of percentage increase in fat 
free mass during the three weeks was 5 % and –5.22 % to 9.08 %, respectively. 
The 10 cats in that study were also found to gain a median percentage body 
weight of 9.66 %, with a range of 5.97 % to 32.8 %. This percentage body weight 
change is similar to the median percentage weight gain of 11.35 % detected in 
this study. 
 
The weight gain following treatment of hyperthyroidism is thought to be due to 
multiple reasons. One study that assessed this weight gain following I131 
treatment in humans concluded that it was not only due to a reduction in the 
  
101 
metabolic rate of the patients secondary to decreased thyroid hormone 
concentrations but also to an initial increase in food energy intake post-
treatment in order to maintain their premorbid weight (Abid et al., 1999). 
Unfortunately, in this study it was not possible to accurately measure food 
intake during the isolation period due to radiation safety protocols. Therefore, 
the weight gain seen in the study cats cannot be specifically attributed to an 
increase in food intake. 
 
2.6.1 Effect of hypothyroidism on weight gain 
 
In humans, the induction of a biochemical hypothyroid state has been shown to 
have a significant effect on weight gain when compared to those patients that 
remain euthyroid (Dale et al., 2001). Hypothyroid patients have been found to 
have an increased amount of water retention resulting in weight gain due to a 
reduced capacity to excrete water through the kidneys, an increased 
extravascular mass of albumin and inadequate lymphatic drainage; however, this 
excess body water is lost following treatment of hypothyroidism (Parving et al., 
1979; Sahun et al., 2001; Karmisholt et al., 2011).  
 
In the current study a significant difference in percentage weight gain was not 
found between patients that became biochemically euthyroid and those that 
became biochemically hypothyroid. However, the weight changes were only 
assessed over a short time period and the sample size of biochemical euthyroid 
cats was only 16, compared to 85 cases in the biochemical hypothyroid group. 
This difference in sample sizes may have prevented a statistical significance 
from being detected. In addition, the 16 biochemically euthyroid cats were not 
followed over time, potentially resulting in the exclusion of some cases that may 
have become biochemically hypothyroid.  
 
In humans, they have also found an association between the length of 
hypothyroidism following treatment and weight gain (Dale et al., 2001). In Dale 
et al., (2001) the mean weight gain for patients that became transiently 
hypothyroid was 5.37 kg compared to a mean weight gain of 8.06 kg in patients 
that became permanently hypothyroid and required treatment with 
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levothyroxine. These weight gains were compared to a mean weight gain of 
4.57 kg in patients that did not become hypothyroid at any point post-
treatment.  
 
In the current study there were only six cases that required levothyroxine 
supplementation and were classified as cases of permanent hypothyroidism, 
compared to 26 cases in which it was known that the biochemical 
hypothyroidism reversed. Due to the small number of cases of permanent 
hypothyroidism it was not possible to directly compare the percentage weight 
gain of these cases to the percentage weight gain of the cases of transient 
hypothyroidism. However, should larger studies be carried out in the future, the 
effect of transient versus permanent hypothyroidism on weight gain could 
potentially be assessed in more detail.   
 
An association between gender and the incidence of hypothyroidism occurring 
following I131 treatment for toxic nodular goiter in humans has not been noted 
(Kahraman et al., 2012). In the current study five out of the six cats that 
remained hypothyroid and required levothyroxine supplementation were female. 
The predominance of female cats in this group may be a reflection of the overall 
case load in that ~ 60 % of the study cases were female; however, a possible 
association between the gender of the cat and the development of 
hypothyroidism in cats following treatment with I131 cannot be completely 
excluded, and has not been assessed in previous studies on I131 (Peterson & 
Becker, 1995; Nykamp et al., 2005).  
 
The function of normal thyroid tissue is suppressed by the overactive thyroid 
tissue in hyperthyroidism, resulting in a delay of normal thyroid function 
occurring following treatment (Peterson, 2006). However, the serum T4 
concentration of many cats that are biochemically hypothyroid post-treatment 
will increase back into the reference interval over the ensuing months, with only 
a 2.1 % incidence of clinical hypothyroidism noted in a study assessing I131 
treatment in 524 cats (Peterson & Becker, 1995). In the current study, of the 
cases that were not lost to follow up long-term, 6/32 cases that were 
biochemically hypothyroid following treatment remained hypothyroid and 
required levothyroxine supplementation. The serum T4 concentration of the 
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other 26 cases returned to within the reference interval during the six-month 
period post-treatment. Unfortunately, a large number of cases (n = 53) in the 
biochemical hypothyroid group had insufficient follow up to assess if their 
biochemical hypothyroidism resolved, which is the most likely reason why the 
incidence of clinical hypothyroidism in this study was higher than the Peterson & 
Becker (1995) study at 9.8 %. In the vast majority of cases this loss to follow up 
in the current study was due to owners failing to bring their cats back for repeat 
assessment of their serum T4 concentration. 
 
2.6.2 Use of weight gain as a predictor of post-treatment serum T4 
concentration 
 
Blood tests are required following I131 treatment to assess if the treatment has 
been successful, as well as for assessing for the development of renal disease.  
 
This study did document that percentage weight gain during the three-week 
isolation period was significantly higher in cats that obtained either a 
biochemical euthyroid or hypothyroid state, compared to those cats that 
continued to remain biochemically hyperthyroid at the 21-day period following 
treatment. However, it was not possible to identify a clinically relevant cut-off 
value that produced a high enough specificity for predicting a serum T4 
concentration ≤ 50 nmol/l, disproving one of the hypotheses of this study. This 
was due to the finding that a 100 % probability of a post-treatment serum T4 
concentration being ≤ 50 nmol/l was only achieved if a cut-off value of > 37.6 % 
weight gain was used and this would have only given a definitive result in 1/114 
cases in this study. The use of a more relevant cut-off value of > 9.39 % weight 
gain resulted in an 85 % probability of a cat having a post-treatment serum T4 
concentration ≤ 50 nmol/l. Therefore, although percentage weight gain cannot 
be used as a predictor of a post-treatment serum T4 concentration ≤ 50 nmol/l 
at the three week point following treatment, it could be used as an indicator of 
this. 
 
Although percentage weight gain can give an indication of the reversal of overt 
hyperthyroidism, it cannot differentiate cats that have become biochemically 
euthyroid post-treatment from cats that have become biochemically 
  
104 
hypothyroid. Induction of a hypothyroid state post-treatment is thought to 
contribute to the development of azotaemia and therefore should be avoided 
(Williams et al., 2010). As percentage weight gain cannot be used to identify 
cases that have become hypothyroid post-treatment, it should not be used in 
place of the measurement of serum T4 concentration.  
 
2.6.3 Definition of treatment success 
 
Previous studies on feline hyperthyroidism have defined successful treatment 
using I131 as the achievement of a biochemical euthyroid or hypothyroid state 
post-treatment, where as others have defined it as the achievement of a 
euthyroid state only (Malik et al., 1993; Mooney, 1994; Theon et al., 1994). 
However, treatment success in cases treated medically has recently been 
defined as a serum T4 concentration in the lower half of the reference interval 
(Daminet et al., 2014). Using the anti-thyroidal medication guidelines, a serum 
T4 concentration lower than the reference interval would be classified as over-
treatment and a serum T4 concentration in the upper half of the reference 
interval would be classified as suboptimal treatment. For this reason, the cases 
in this study were divided into four different groups for analysis of post-
treatment serum T4 concentration so that these different definitions could be 
assessed. 
 
This study found that there were no significant differences between the 
percentage weight gain in groups A (biochemical hypothyroidism), B 
(biochemical euthyroidism, low normal) or C (biochemical euthyroidism, high 
normal) but there was a difference between groups A, B and C combined when 
compared to group D. Therefore, using this data there was a statistical 
difference in weight gain between treatment failures (using group D as failures) 
and cases of treatment success when assessing all three different definitions of 
success. However, not only can percentage weight gain not be used to 
differentiate between cases of over-treatment (i.e. biochemical hypothyroidism) 
and biochemical euthyroidism, the study also showed that it cannot differentiate 
either of these from suboptimal treatment, if using the definition of treatment 
success according to Daminet et al., (2014).  
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Although the consensus statement by Daminet et al., (2014) advised that a 
reduction of the serum T4 concentration into the upper half of the reference 
interval was not viewed as treatment success, it should be remembered that the 
treatment modality of I131 is different from anti-thyroidal medication in that the 
full effect can be delayed for up to six months (Peterson & Becker, 1995). 
Therefore, for I131 treatment induction of a biochemical euthyroid state i.e. a 
low normal or high normal serum T4 concentration should be aimed for at the 
three-week point post-isolation, in regards to obtaining a treatment success.  
 
2.6.4 Failure to gain weight in cats with post-treatment serum T4  
          concentration ≤ 50 nmol/l 
 
Of the cats that obtained a biochemical euthyroid or hypothyroid state post-
treatment, 10/91 failed to gain weight during the three-week isolation period. 
Potential reasons for this failure to gain weight include: 
1) Stress induced hyporexia.  
Stress in cats can result in variability of their appetite and this has been 
documented previously by Zeiler et al., (2014). That study demonstrated that a 
marked increase in appetite occurred during the first three days of 
hospitalization as cats settled into the hospital environment and their stress 
levels reduced. To try to eliminate this effect of stress on cats presented for I131 
treatment, they are allowed to acclimatise to the hospital environment within 
the cat ward for three to four days before transferring them to the isolation unit 
where they are treated and kept for the following three weeks. However, this 
acclimatization period may not have eliminated the effect of stress in all 
treated cats. Therefore, it is still possible that some study cats were stressed 
and this may have negatively impacted their appetite resulting in a lower 
amount of weight gain being obtained. 
2) Increased activity levels.  
Increased activity levels will result in an increase in energy expenditure; 
however, this factor is unlikely to have caused an effect in this study as the cats 
were confined to a kennel rather than being in a free-roaming environment.  
3) Undiagnosed concurrent disease.  
All cats that are admitted for I131 treatment of their hyperthyroidism undergo 
routine haematology, serum biochemistry, testing for the major feline viruses 
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(FeLV, FIV and feline coronavirus) as well as a full urine analysis being 
performed. This testing should hopefully reduce the chances of concomitant 
disease being missed. However, a recent study by Nussbaum et al., (2015) found 
that 36.1 % of cats referred for I131 treatment had evidence of concurrent 
disease detected by abdominal ultrasonography. This included renal disease in 
22.8 % of cases and neoplasia in 2.4 % of cases. Of the cases with renal disease 
noted on ultrasonography in that study, 96.4 % were classified as stage I 
according to the International Renal Interest Society (IRIS) guidelines and were 
therefore non-azotaemic on blood work (IRIS, 2013). Therefore, the presence of 
concomitant disease as a cause of failure to gain weight could not be definitively 
excluded in this study, especially as abdominal ultrasonography was not 
performed. 
 
2.6.5 Assessment for azotaemia 
 
Post-treatment azotaemia is diagnosed by evaluation of the serum renal 
parameters following treatment. This study did not identify that percentage 
weight gain was affected by the development of post-treatment azotaemia. 
Therefore, percentage weight gain would not be useful as an indicator for the 
development of azotaemia in these cases. The results from this study would 
support those of van Hoek et al., (2009) that found that the body weight of cats 
increased between the time of treatment and four weeks post-treatment, 
regardless of whether they did or did not develop impaired renal function. 
Despite this lack of effect on early weight changes shown in the current study, 
van Hoek et al., (2009) showed that long-term weight gain might be affected by 
renal dysfunction. In the van Hoek et al., (2009) study, only cats that did not 
develop impaired renal function post-treatment continued to gain weight 
between one and six months post-treatment. This longer-term effect was not 
assessed in the current study. 
 
Previous work by Boag et al., (2007) has shown that the maximal changes to the 
GFR in cats treated with I131 occur four weeks following treatment, therefore 
suggesting that assessment of serum renal parameters should potentially be 
delayed until this time-point. Combining these findings with the results of this 
study, percentage weight gain could be used as an indicator of the reversal of 
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biochemical hyperthyroidism at the three week point post-treatment and 
venepuncture for assessment of both serum T4 concentration and renal 
parameters be delayed until four weeks post-treatment. This would avoid the 
need for two separate venepunctures to be performed during the first four 
weeks following I131 treatment in these cases. A reduction in the number of 
blood samples required could also reduce the level of stress experienced by the 
cats (Zeiler et al., 2014).  
 
Although the frequency of blood sampling could be reduced in the early period 
post-treatment using this method, repeat assessment for the occurrence of 
azotaemia should still be continued past the one-month period even if 
azotaemia is not detected at that time point. This is because the serum 
creatinine concentration in these cats has been shown to continue to increase up 
to three months following treatment with I131 and in some cases even up to six 
months (Boag et al., 2007).  
  
2.6.6 Pre-referral treatment for hyperthyroidism 
 
Original analysis found that cats that had been treated surgically or with a 
combination of surgery and anti-thyroidal treatment prior to referral were found 
to gain significantly less weight than those cats that had been treated medically 
or had received no treatment at all. However, this finding is likely a confounding 
factor due to the small number of cases in both the surgery and combination 
treatment groups. 
 
When the study population was split into those cats that had received pre-
referral treatment for hyperthyroidism and those cats that had not, no 
statistical difference in weight gain between the two groups was seen. This lack 
of significance was despite the median pre-treatment serum T4 concentration 
being 234 nmol/l in the former group and 148 nmol/l in the latter group, 
suggesting that the former group may have been more severely affected by their 
hyperthyroidism.  
 
Due to these different findings, definitive conclusions regarding specific pre-
referral treatment and weight gain cannot be currently made.  
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This lack of definitive significance between specific pre-referral treatment 
and weight gain is also likely to have been influenced by the type of 
hyperthyroid cats seen at the SAH. The vast majority of cats that are referred to 
the SAH are referred due to an inability to control their serum T4 
concentrations, whether that is due to difficulties in medicating the cat 
consistently on a daily basis or due to poor control of hyperthyroidism despite 
treatment. Due to this, most cats that are seen at the SAH have never been 
successfully treated, which is the most likely reason why the weight gain of 
those cats that had not received any management prior to referral was not 
significantly different from those cats that had received treatment.  
 
In humans, weight gain following treatment of hyperthyroidism appears to occur 
regardless of the treatment modality used. Significant differences in the amount 
of weight gained by patients between treatment modalities (carbimazole, 
surgical thyroidectomy and I131) were not found by Pears et al., (1990); however, 
the sample size in that study was small with only 65 cases. Later studies have 
shown that treatment modality could have an effect on weight gain in these 
patients, with Dale et al., (2001) finding that more weight gain was seen in 
patients that underwent thyroidectomy than in those patients treated with I131 
or anti-thyroidal medication.  
 
A study assessing weight gain in hyperthyroid cats treated with different 
treatment modalities has not yet been performed as it has been in humans 
(Pears et al., 1990; Dale et al., 2001). Therefore, conclusions on whether 
treatment modality could affect weight gain cannot be drawn.  
 
In humans, it has also been shown that patients that undergo a surgical 
thyroidectomy are less likely to gain weight when compared to those patients 
that first undergo I131 and then have a surgical thyroidectomy performed 
(Schneider et al., 2014).  
 
In this study there was no definitive effect of sequential treatments e.g. surgical 
thyroidectomy then I131 on weight gain, as weight gain between pre-referral 
treatments was not significant; however, only weight changes over the three 
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week period were assessed rather than weight changes since diagnosis and 
the start of treatment in cats, which may have affected this finding.  
 
The vast majority of cases in this study that had received pre-referral treatment 
had been treated with anti-thyroidal medication (n = 58). Ideally, the findings 
from this study assessing weight changes in patients treated first with anti-
thyroidal medication and then I131 would be compared to findings in the human 
field. However, permanent remission using anti-thyroidal drugs is rarely 
achieved in toxic nodular goiter in humans, so surgery or I131 treatment are the 
preferred treatment modalities, unless there are contraindications to their use 
(van Soestbergen et al., 1992; De Leo et al., 2016). Due to this there are not 
many studies assessing the use of anti-thyroidal treatment prior to the use of I131 
in humans and those that have, have not assessed weight changes 
(Kartamihardja & Massora, 2016). Therefore, comparisons between this study 
and the human field cannot be made. 
 
2.7 Limitations 
 
2.7.1 Case exclusions 
 
The main limitation to this study was due to its retrospective nature. Lack of 
post isolation weight recording resulted in 15.4 % of the originally identified 
cases having to be excluded. Further investigations into this suggested it was 
likely these cats were weighed following treatment but unfortunately at the 
time of discharge the weight was not recorded.  
 
2.7.2 Appetite variability 
 
The cats’ appetites were variable within the unit on a daily basis and therefore 
appetite was not a consistent parameter in the statistical analysis and this may 
have acted as a limitation. In order to limit the nurses’ exposure to radiation the 
cats were only fed once daily; however, large quantities of food were offered at 
this point. The food fed was a mixture of dry and wet food, which was 
dependent on the individual cat’s preference.  
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As discussed previously, the variability in appetite may have been an 
indicator of stress in the study cats; however, an attempt was made to negate 
this by hospitalizing them prior to administration of I131. Due to the radiation 
health and safety concerns regarding limiting the nurses’ exposure to radiation, 
provision of more frequent meals to the cats while they were in the isolation 
unit was not possible. Should fresh wet food have been offered more frequently, 
it is possible that some cats may have eaten larger amounts each day, which 
could have resulted in further weight gain. 
 
2.7.3 Previous control and severity of hyperthyroidism 
 
Another limitation in this study was the variability in the study population’s 
length of hyperthyroidism control if they were pre-treated, as well as the 
severity of disease. A previously well-controlled hyperthyroid cat with mild 
disease would not be expected to have lost as much weight as a severely 
affected cat that had been poorly stabilised. In the study population only 28 cats 
were injected with a dose of I131 > 150 MBq, suggesting that most of the study 
cats were only mildly to moderately affected by hyperthyroidism and therefore 
may have had less weight to gain. However, statistical analysis did not identify 
the dose of I131 to have a significant effect on the weight gained by the study 
cats, demonstrating that the severity of hyperthyroidism was unlikely to have 
had a major effect. Unfortunately, regulating the length and control of 
hyperthyroidism in the study population before referral was not possible and 
therefore this effect could not be avoided.  
 
2.7.4 Azotaemia 
 
Development of azotaemia was not identified to have a significant effect on 
weight gain in this study. However, only eight of the study cats were detected to 
be azotaemic post-treatment and this number of cases may have been too small 
to enable a significant effect to be identified.   
 
The definition of azotaemia in this study was a post-treatment serum creatinine 
concentration > 180 µmol/l, which is the upper limit of the laboratory reference 
interval. Although serum creatinine is a crude marker of renal dysfunction this 
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was a retrospective study and this value provided a clear cut-off point for 
identification of cases with potential post-treatment renal disease. However, 
this definition may have resulted in cases that had developed renal insufficiency 
being missed, as cats with chronic kidney disease can have serum creatinine 
concentrations < 180 µmol/l, as per the IRIS guidelines (IRIS, 2013). Previous 
studies have reported incidence rates of renal disease post-treatment of 28-63 % 
which is markedly higher than in this study and the definition used to identify 
cases of renal disease may be the cause of this (Rogers et al., 2000; Milner et 
al., 2006).  
 
Unfortunately, post-treatment analysis of urine is not routinely performed in 
treated cats, partly due to the concern of radiation levels in the urine following 
treatment (Lamb et al., 2013). Therefore, it was not possible to evaluate if 
some of the study cats had developed a reduced urine concentrating ability 
during the isolation period nor was it possible to completely exclude a pre-renal 
cause of the azotaemia in cases included in the azotaemic group. To avoid this 
limitation in future studies a post-treatment urine analysis could be obtained in 
all cases to further assess the azotaemia but this should be postponed until four 
weeks following administration due to concerns of radiation levels in the urine 
(Lamb et al., 2013).  
 
An alternative method to assess for the development of renal dysfunction would 
be to measure the GFR pre- and post-treatment in these cases as was performed 
in van Hoek et al., (2009); however, as iohexol can decrease the absorbed dose 
of I131 if given within 24 hours of its administration, this should be taken into 
consideration (Peremans et al., 2008). Measurement of serum symmetric 
dimethylarginine could also be considered; however this was not commercially 
available at the time of the study dates (Braff et al., 2014; Hall et al., 2014). 
 
2.7.5 Method of defining weight changes 
 
Percentage body weight change was used as the marker for changes in weight in 
this study population, whilst in human studies they have also assessed changes in 
absolute body weight (kg) and body mass index (De La Rosa et al., 1997). 
Unfortunately, body condition scores were not recorded in the study population 
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and so they could not also be evaluated. Although absolute body weight 
changes were recorded in this study, percentage body weight changes were used 
instead. This was because this value was less likely to be impacted by the 
variation in the different body statures and builds of the study cats, as previous 
studies have shown a marked variation in the body weights of hyperthyroid cats, 
with a weight range from two to seven kg (Slater et al., 2001).  
 
Another potential method to assess the weight changes of hyperthyroid patients 
undergoing treatment is with the use of DEXA scans (Lönn et al., 1998; Finch et 
al., 2012). These scans assess if weight changes are due to alterations in the fat 
mass or the fat-free mass and they have already been used within the human 
field for this purpose (Lönn et al., 1998). Recently, DEXA scans have also been 
used in a small number of cats with hyperthyroidism (Finch et al., 2012). 
Unfortunately, DEXA scans are not available at the SAH and therefore could not 
be used in this study.  
 
2.8 Further studies 
 
This study only evaluated weight gain in hyperthyroid cats treated with I131 but in 
human medicine weight gain between patients treated either with anti-thyroidal 
medication, thyroidectomy or with I131 have been compared (Pears et al., 1990; 
Dale et al., 2001). Future studies could therefore evaluate the weight gain in 
hyperthyroid cats treated medically, surgically, with I131 or with iodine-
restricted diets to assess if the use of different treatment modalities has an 
effect on the amount of weight gained. It would also enable the assessment of 
whether weight gain can be used as an indicator of the reversal of the 
hyperthyroid state in other treatment modalities, as has been shown in the use 
of I131 in this study.  
 
The weight gain following achievement of a euthyroid state in humans has been 
documented to last for many years following treatment (Dale et al., 2001). 
Although Boag et al., (2007) previously documented the longer-term weight 
changes in cats treated with I131 by assessing the weight changes at six-months 
post-treatment, a longitudinal study assessing weight changes over the first 
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year, including the short-term weight changes has not yet been performed in 
cats.  
 
Future studies on weight changes in hyperthyroidism could also include the use 
of DEXA scans given the findings of the small study by Finch et al., (2012). These 
scans would enable the weight changes seen in these patients to be directly 
attributed to changes in fat or fat-free mass. It would be interesting to compare 
these findings in hyperthyroid cats treated with the different treatment 
modalities currently available to assess if differences exist. In the human field of 
hyperthyroidism, DEXA scans have also been used to document the long-term 
changes in body composition of these patients (Lönn et al., 1998). This is an area 
that could also be explored in cats.  
 
2.9 Conclusions 
 
The findings of this study show that hyperthyroid cats treated with subcutaneous 
I131 that become biochemically euthyroid or hypothyroid three weeks following 
treatment gain significantly more weight than those cats that remain 
biochemically hyperthyroid. However, percentage weight gain cannot be used as 
a replacement for measurement of serum T4 or serum creatinine concentrations 
as it cannot differentiate cats with biochemical euthyroidism from those cats 
with biochemical hypothyroidism, nor can it be used to differentiate cats that 
have developed post-treatment azotaemia from those that have not.  
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CHAPTER 3 
3 GAMMA (γ) RADIATION EMISSIONS DURING THE THREE-
WEEK ISOLATION PERIOD FOLLOWING ADMINISTRATION 
OF I131 IN CATS WITH HYPERTHYROIDISM 
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3.1 Introduction 
 
Hyperthyroid cats treated with I131 remain in isolation for a variable time period 
following I131 administration, dependent on the centre at which they are treated 
and the local radiation legislation (Puille & Peremans, 2011; Lamb et al., 2013; 
Boland et al., 2014). In some centres this isolation period varies on a case-by-
case basis, depending on the individual cat and the radiation levels they are 
emitting (Meric et al., 1986). However, at other centres the isolation period is 
fixed, regardless of the dose of I131 that is administered (Boland et al., 2014). 
 
The original isolation period of hyperthyroid cats treated with I131 at the SAH was 
28 days in length. This was based on unpublished work carried out at the SAH in 
the 1990’s under the guidance of the Scottish Environment Protection Agency. 
This isolation period was subsequently reduced to 21 days for cases administered 
doses of I131 ≤ 200 MBq, following the results of the study performed by Lamb et 
al., (2013). 
 
Within the UK there are legal dose limits of ionising radiation in place that 
members of the public can be exposed to, to prevent members of the public 
being placed at undue risk (Ionising radiations regulations, 1999). Therefore, it is 
important that the level of ionising radiation that is emitted by people or cats 
treated with I131 be measured, to ensure that these limits are not exceeded. In 
the UK the legal dose limit is currently one mSv (1000 microsieverts (µSv))/year, 
which is averaged over a five-year period (Ionising radiations regulations, 1999; 
Environment Agency, 2012). There is also a constraint for a single new source of 
ionising radiation, which is limited to 0.3 mSv (300 µSv) (Environment Agency, 
2012). 
 
Despite these limits, there is some room for flexibility by regulating bodies for 
ionising radiation in that they can allow a public dose commitment of 20 µSv, 
which is 1/50th of the annual dose commitment for members of the public, 
without having to impose major restrictions (Environment Agency, 2012).  
Recommendations by the International Commission on Radiological Protection 
(ICRP) in 2005 also advised that a public dose commitment of 100 µSv, which is 
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1/10th of the annual limit for members of the public, should be the minimal 
dose constraint of an effective dose of ionising radiation that should be 
considered for application in any situation (ICRP, 2005). Taking this information 
a dose commitment < 100 µSv could therefore be allowed, as long as there are 
certain restrictions in place. These restrictions include: 
1) The radiation exposure is a one-off. 
2) The dose commitment is restricted to a small group of the public. 
3) That the as low as reasonably practical (ALARP) procedures are followed. 
  
The γ radiation emitted by treated hyperthyroid cats has been previously 
assessed using surface exposure at the level of the thyroid gland itself (Feeney 
et al., 2003). Feeney et al., (2003) assessed surface emissions from treated cats 
at several time points during their isolation period using a calibrated Geiger-
Müller counter, as well as measuring the radioactivity of the urine from the 
same cats. That study found that surface emission rates from treated cats were 
useful in determining upper thresholds of urine radioactivity. The conclusion 
from the study was that the use of surface emission rates was a valid method of 
assessing whether the level of γ radiation emitted from the cats was low enough 
to enable exit from isolation. Therefore, due to these study findings this 
methodology is used at some institutions to dictate when cats can be released 
from isolation following treatment of hyperthyroidism using I131, which allows a 
variable isolation period to be used. However, a potential concern of using this 
methodology for radiation monitoring is that it requires staff to be in close 
proximity to the treated cats to allow the surface emission to be measured at 
the level of the thyroid gland, increasing their exposure to radiation. This 
methodology is also operator dependent and could therefore be affected by the 
orientation of the counter towards the thyroid gland and also by the variability 
in the location of the thyroid gland itself between individual cats.  
 
In the human field of radiation, EPDs are used by workers in medical 
laboratories, nuclear power plants and nuclear research facilities to monitor 
their exposure to radiation (Mirion Technologies, 2010). These dosimeters 
monitor workers exposure to ionising radiation, which includes γ, β and neutron 
radiation, as well as x-ray radiation in real-time. The dosimeters can have both 
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audible and visual alarms that are activated when a dose rate level of 
radiation is exceeded. These alarms act to alert the personnel wearing them, so 
that appropriate action can be taken. These dosimeters are capable of not only 
detecting a specific dose rate level but also of recording radiation exposure over 
time. 
 
There are many companies that currently manufacture and supply EPDs for 
radiation workers. One particular company, Mirion Technologies, Berkshire, 
manufacture a battery operated EPD used by radiation workers (Mirion 
Technologies, 2010). One of the EPD models used, the MGP DM2000X, is an 
energy compensated silicon diode detector. It has flat energy responses to x-ray 
and γ-rays from 50 keV to 6 megaelectronvolts (MeV) and linear responses to 
dose-rate fields from natural background up to more than 10 Sv/hour. These 
monitors are front facing with an accuracy better than ± 20 % over an angular 
range of −75° to +75°(Mirion Technologies, 2010). These EPDs are calibrated 
with caesium (Cs137), which has been shown to have a similar energy range to the 
isotope I131 that is used for radioactive iodine treatment in hyperthyroid cats 
(Delacroix et al., 1998).  
 
Within the human field of radiation EPDs are commonly used and studies have 
been performed using them to assess the radiation exposure of caregivers and 
family members of people with hyperthyroidism treated with I131 (Barrington et 
al., 1999; Marriott et al., 2007). However, they have only recently been 
evaluated in the field of feline hyperthyroidism (Roberts et al., 2015).  
 
A pilot study assessing the use of an EPD in the monitoring of γ radiation in 
feline hyperthyroidism has already been performed at the SAH between 
December 2011 and September 2014 (Roberts et al., 2015). However, as this 
study only assessed the γ radiation emissions from 12 cats treated with I131, it 
was decided to expand the study to include more cases, whilst keeping the 
original aims the same for this part of the thesis.  
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3.2 Aims and hypotheses 
 
1) To assess if an EPD could be used to measure the γ radiation emitted from 
hyperthyroid cats treated with radioactive iodine at the SAH, by assessing 
if it could be used to determine the effective half-life of the radioisotope 
used (I131). It was hypothesized that the EPD could be used to measure the 
γ radiation.  
2) To assess if an EPD could be used to determine the release time of 
treated hyperthyroid cats, as well as ascertain if a fixed isolation period 
could be used for these cats treated with I131. It was hypothesized that 
the EPD could be used to determine the release time of treated 
hyperthyroid cats. 
 
3.3 Materials and methods 
 
This prospective study was carried out at the SAH of the University of Glasgow 
between December 2011 and April 2016 and involved cats that had been referred 
to the SAH for the treatment of feline hyperthyroidism using I131. This study 
included cases that had previously been part of the pilot study (Roberts et al., 
2015).  
 
Cats referred for I131 have been previously diagnosed with hyperthyroidism in 
general practice. Dependent on the individual case, previous treatment for 
hyperthyroidism using anti-thyroidal medication (methimazole or carbimazole), 
surgery (thyroidectomy) or an iodine-restricted diet may have been trialed.  
 
3.3.1 Inclusion criteria 
 
Any cat that had been referred to the SAH for I131 treatment of their previously 
diagnosed hyperthyroidism and remained in the isolation unit for three weeks 
following I131 administration was eligible for inclusion into this study.  
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3.3.2 Exclusion criteria 
 
1) Any cat that was due to receive a dose of I131 > 200 MBq and therefore be 
required to remain in the isolation unit for more than the standard 21-day 
period. 
2) Any cat that had an incomplete data set recorded by the EPD i.e. did not 
have full data recorded for all days they were in the isolation unit for. 
 
3.3.3 Standard protocol for cases referred for I131  
 
This protocol is the same as described in chapter 2.3.3 of this thesis. See 
chapter 2.3.3 for details.  
 
3.3.4 The monitor kennel  
 
Within the I131 unit there are eight available kennels for treated cats. During this 
study all cats that were enrolled were placed in the same kennel during their 
isolation period, which was designated as the monitoring kennel. This particular 
kennel was chosen because it was the furthest kennel from the lead lined 
radioactive waste bin, which housed used sharps and previously emptied vials 
that had contained/been contaminated with I131, in the I131 unit. The dimensions 
of the monitoring kennel were: height 86 cm, width 86 cm and depth 71 cm. To 
minimize the impact of other treated cats in the unit on readings from the 
monitor kennel and to standardize the methodology, the three kennels 
surrounding the monitor kennel were kept empty (Figure 7). Due to this the 
minimum possible distance between a cat in the monitor kennel and the next 
treated cat was 133 cm.  
 
The EPD (model MGP DM2000X) used for this study was clipped onto the monitor 
kennel door in exactly the same position for all cats included in the study, which 
was 42 cm above the kennel floor. Whilst in the isolation unit the daily position 
of the cat within the monitor kennel was observed subjectively when the 
veterinary nurses cleaned them out. Each cat was cleaned out on a daily basis 
and this involved the removal of the cats’ faeces and urine. This meant that 
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data recorded by the EPD was not affected by the previous days urine and 
faecal waste, as excreted faeces and urine from treated cats have previously 
been shown to act as sources of radiation exposure (Lamb et al., 2013). 
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MONITORING 
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Figure 7. A diagrammatic representation of the eight kennels in the I131 isolation 
unit, illustrating which kennel was used as the monitoring kennel for cats 
enrolled in this study and had the EPD attached to the kennel door, which 
kennels were kept empty and which kennels were available to be used by other 
cats undergoing treatment that were not enrolled in the study. 
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3.3.5 Data recorded by the electronic personal dosimeter (EPD) 
 
The EPD recorded radiation exposure events, which were measured in Sieverts. 
This data was downloaded onto a computer database system (Dosimass 
Software; Mirion Technologies, Berkshire) at the end of the isolation period once 
the cat had been removed from the I131 isolation unit (Mirion Technologies, 
2010). The EPD was then reset and placed back onto the monitor kennel when 
the next cat in the study was placed into the monitor kennel. The downloaded 
data was then transferred into a separate database (Microsoft Excel), to enable 
the dose of γ radiation that was emitted by the monitored cat each day to be 
calculated. This was then converted into grays so that radiation exposure could 
be evaluated. This was performed by using the calculation that one Sievert is 
the equivalent of one gray.  
 
As there were other potential sources of radiation within the isolation unit, 
which included other treated cats and the bins used for radioactive waste, a 
second MGP DM2000X EPD was placed into the isolation unit to take these factors 
into account. This EPD was placed in two separate locations within the unit 
during the study. Location one was the ledge of the viewing window into the 
unit, which was 252 cm away from the monitor kennel and location two, which 
was 346 cm from the monitor kennel, was the windowsill of the isolation unit. 
These specific locations were chosen as they were locations where the EPD 
would not be interfered with and therefore the monitor would not be moved by 
accident. Background daily radiation was recorded from one of the two 
locations, for the same 21-day period that the cats were being monitored for. 
The location of the second EPD alternated between the two locations during the 
study period. For odd case numbers e.g. one, three, five and seven, it was 
placed in location one, and for even case numbers e.g. two, four, six and eight, 
it was placed into location two. The recorded readings from these two locations 
were then used to calculate an average background radiation level/day. This 
background radiation was then subtracted from the daily monitor kennel 
readings so that these background variables, which would not be present in the 
home of the treated cats, could be taken into account.  
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3.4 Statistical analysis 
 
The Pearson correlation coefficients of the measured half-lives against 
exponential models were calculated and expressed as r2. The effective half-life 
of I131 for all cats was calculated using the equation t1/2 = t x ln (2)/ln 
(Svfirst/Svlast) where t1/2 = calculated effective half-life, t = number of days from 
the first full day of readings to the last day of detectable radiation, Svfirst is the 
radiation measured on the first full day of readings and Svlast is the radiation 
measured on the last day of detectable readings (Roberts et al., 2015). 
 
The potential additional γ radiation exposure emitted by the cats was then 
calculated had they left the isolation unit earlier than the current 21-day 
period. This was assessed at three separate time points: after seven, 14 or 17 
days of isolation. The daily γ radiation emission of the cats involved in the study 
was then assessed using a multilevel linear regression model. This was 
performed to assess if the daily γ radiation emissions were associated with the 
dose of I131 administered. Dose, which was a categorical variable and days since 
administration, which was used as a continuous variable, were both entered into 
the multivariable model. A cat identifier was included as a random effect to 
account for clustering within each cat. Explanatory variables were retained if 
their respective P-values were < 0.05. These analyses were conducted using 
STATA/SE V.12.1 (STATA, College Station, Texas, USA) (Roberts et al., 2015). 
 
Due to the dose constraints discussed previously, the data obtained in this study 
was also analysed in regards to both the 20 µSv and 100 µSv dose commitments, 
to assess how many cats would be emitting radiation levels within these dose 
constraints had they been released following seven, 14 or 17 days of isolation. 
To enable this to be done the radiation data for dose equivalent was changed 
into dose exposure. This was done using the calculation that one microgray 
(µGy) of radiation exposure is approximately equal to one µSv of radiation dose 
equivalent.  
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3.5 Results 
 
3.5.1 Exclusions 
 
When the study was first started several cases were excluded. This was due to 
either the alarm of the dosimeter being triggered or poor battery life of the 
EPD. As the EPD is manufactured for use by radiation workers it comes with a 
preset alarm of 10 µSv/hour, which alerts the workers when this level has been 
reached due to safety concerns of radiation levels higher than this. The 
dosimeter alarm was triggered in the first four cases in this study shortly after 
the I131 was injected and resulted in incomplete data being recorded. As the 
alarm was not necessary for this study it was subsequently disabled. Once the 
alarm had been disabled no further cases were excluded due to this issue. In an 
additional two cases, incomplete data sets were recorded due to a battery 
failure during the monitoring period and these cases were also excluded.  
 
One of the cases that had been included in the pilot study did not have data 
recorded for the first two days of isolation due to the dosimeter not being 
placed on the kennel door. Due to the incomplete data set it was elected to 
remove this case from the expanded study. This resulted in 11/12 cases that had 
been used in the pilot study being included in the expanded study.  
 
One further case was excluded from the study as another treated cat was 
accidentally placed into the kennel next to the monitor kennel during the 
monitoring period. This resulted in a sudden increase in the level of γ radiation 
recorded by the dosimeter on day 13 of the isolation period onwards. 
 
3.5.2 Study cats 
 
Following these eight case exclusions, 20 cats that were treated with I131 and 
had their daily γ radiation emissions recorded during the 21-day isolation period 
were used in this study. The age of the cats in the study ranged from seven 
years of age up to 16 years of age, with a mean age of 12.5 years. There were 
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eight male neutered cats and 12 female neutered cats and they were all 
domestic shorthaired cats. The dose of I131 injected in these cases was 80 MBq  
(n = 5), 120 MBq (n = 7), 150 MBq (n = 4), 175 MBq (n = 1) and 200 MBq (n = 3) 
(Table 5).  
 
None of the cats included in this study were found to be azotaemic, defined as a 
serum creatinine concentration greater than the laboratory reference interval of 
91-180 µmol/l, on their pre-treatment blood work (Table 5), nor were they 
known to have concurrent illnesses e.g. congestive heart failure.  
  
Eleven of the 20 cats were biochemically hypothyroid three weeks following 
their treatment with I131, with post-isolation serum T4 concentrations < 15 
nmol/l and six of the 20 cats were biochemically euthyroid with post-isolation 
serum T4 concentrations ≥ 15 nmol/l and ≤ 50 nmol/l. Three of the 20 cats had 
post-isolation serum T4 concentrations > 50 nmol/l at the three week point post-
treatment and were classified as biochemically hyperthyroid (Table 5). 
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Case 
(MBq) 
Serum 
creatinine 
concentration 
pre-treatment  
Serum 
creatinine 
concentration 
post-treatment  
Serum T4 
concentration 
post-
treatment  
1 (80) 135 164 14.9 
2 (120) 85 109 33.5 
3 (175) 65 91 104 
4 (120) 82 59 459 
5 (120) 84 121 27.9 
6 (200) 143 158 6.5 
7 (80) 100 167 < 3.2 
8 (150) 67 103 7.04 
9 (80) 66 98 17.6 
10 (120) 80 113 7.6 
11 (200) 95 81 144 
12 (120) 143 201 3.37 
13 (120) 117 128 44.1 
14 (200) 66 117 11.9 
15 (150) 78 87 12.6 
16 (150) 105 130 24.3 
17 (80) 102 148 15.1 
18 (150) 90 142 5.8 
19 (120) 79 154 6.7 
20 (80) 101 116 8.3 
 
Table 5. The dose of I131 used in each case in MBq, the serum creatinine 
concentration (in µmol/l) before and three weeks after treatment with I131 
(laboratory reference interval 91 – 180 µmol/l) and the serum T4 concentration 
(in nmol/l) three weeks post-treatment.
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3.5.3 EPDs 
 
The EPDs were attached to the monitor kennel cage door with ease. Once 
attached to the cage door, using the clip on the back of the dosimeter, the EPD 
remained in place during the whole monitoring period for each cat. The 
dosimeters were not noted to be interfered with by any of the cats during the 
study period. 
 
During the three-week isolation period the cats were subjectively noted to move 
around the monitor kennel freely. They were therefore at variable distances 
from the dosimeter during the period of study. Due to this variable movement 
within the monitor kennel, the average distance of the study cats from the EPD 
was presumed to be ~50 cm. However, cats could have been as far as 100 cm 
away from the dosimeter. 
 
3.5.4 Effective half-life of I131 
 
The first aim of this study was to ascertain if the EPD could be used to measure 
the γ radiation emitted by the hyperthyroid cats following administration of I131. 
 
It was found that the rate of decrease in radioactivity of the study cats was 
found to follow an exponential decay pattern very closely, with correlation 
coefficients (r2) of more than 0.93 in 19 of the cats and 0.84 in the remaining 
cat (Table 6) (Figures 8-27).  
 
Following this, the effective half-lives of I131 were calculated and the mean 
value was found to be 2.60 ± 0.65 days with a range of 1.40 to 4.16 days (Table 
6). The mean effective half-life of I131 was very similar to the data previously 
described by Puille et al., (2002), which found the effective half-life of I131 to be 
2.5 ± 0.7 days. The similarity between the effective half-life of I131 in the Puille 
et al., (2002) study and the effective half-life in this study, suggested that the 
data could be used to assess the γ radiation emissions from the cats in this 
study, which was the second aim.  
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Case 
(MBq) t1/2 t r2 7-Day  14-Day  17-Day  
1 (80) 2.22 15 0.99 74 3 0 
2 (120) 3.08 19 0.97 354 79 32 
3 (175) 4.16 19 0.97 542 115 41 
4 (120) 3.27 19 0.95 236 34 12 
5 (120) 2.91 18 0.99 403 69 24 
6 (200) 2.20 19 0.97 393 33 7 
7 (80) 1.85 15 0.97 207 6 0 
8 (150) 2.18 18 0.97 318 22 5 
9 (80) 3.08 19 0.98 149 31 11 
10 (120) 2.15 18 0.98 264 29 6 
11 (200) 2.97 19 0.96 271 65 27 
12 (120) 2.64 19 0.95 380 34 16 
13 (120) 2.81 19 0.95 240 34 12 
14 (200) 2.72 19 0.96 951 89 34 
15 (150) 3.24 19 0.99 617 110 43 
16 (150) 2.45 19 0.97 442 36 8 
17 (80) 2.74 19 0.96 86 18 9 
18 (150) 1.40 7 0.93 28 0 0 
19 (120) 1.53 11 0.84 86 0 0 
20 (80) 2.47 12 0.97 150 0 0 
 
Table 6. The dose of I131 administered (in MBq), the effective half-life of I131 
(t1/2), the number of days from the first full day of readings to the last day of 
detectable radiation (t) and the Pearson correlation coefficients of the 
measured half-lives against exponential models (r2) in each case. Also shown is 
the potential additional dose exposure in micrograys (µGy) to owners if the 
treated cats had left the isolation unit following a seven, 14 or 17-day isolation 
period after administration of I131. 
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Figure 8. r2 = 0.99, t1/2 = 2.22 
 
 
Figure 9. r2 = 0.97, t1/2 = 3.08 
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Figure 10. r2 = 0.97, t1/2 = 4.16 
 
 
Figure 11. r2 = 0.95, t1/2 = 3.27 
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Figure 12. r2 = 0.99, t1/2 = 2.91 
 
 
Figure 13. r2 = 0.97, t1/2 = 2.20 
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Figure 14. r2 = 0.97, t1/2 = 1.85 
 
 
Figure 15. r2 = 0.97, t1/2 = 2.18 
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Figure 16. r2 = 0.98, t1/2 = 3.08 
 
 
Figure 17. r2 = 0.98, t1/2 = 2.15 
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Figure 18. r2 = 0.96, t1/2 = 2.97 
 
 
Figure 19. r2 = 0.95, t1/2 = 2.64 
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Figure 20. r2 = 0.95, t1/2 = 2.81 
 
 
Figure 21. r2 = 0.96, t1/2 = 2.72 
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Figure 22. r2 = 0.99, t1/2 = 3.24 
 
 
Figure 23. r2 = 0.97, t1/2 = 2.45 
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Figure 24. r2 = 0.96, t1/2 = 2.74 
 
 
Figure 25. r2 = 0.93, t1/2 = 1.40 
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Figure 26. r2 = 0.84, t1/2 = 1.53 
 
 
Figure 27. r2 = 0.97, t1/2 = 2.47 
 
Figures 8-27. These figures show the logarithmic regression line for each of the 
20 cases in the study. The blue line in each graph represents the logarithmic 
regression line and the black line shows the trend line. r2 is displayed for each 
graph and represents the Pearson correlation coefficient of the measured half-
lives against exponential models. t1/2 is displayed for each graph and shows the 
effective half-life of I131 in each case. The x-axis shows the days of isolation and 
the y-axis the decrease in radioactivity.  
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3.5.5 Background radiation exposure 
 
The EPD recorded background daily radiation exposure readings in the range of 
1-9 µGy from the first location (location one) and 1-8 µGy from the second 
location (location two). The daily background radiation readings from the two 
locations used for the background exposure were then combined and averaged 
to calculate the mean daily background radiation reading, which was 5 µGy. To 
remove the effect of background radiation on the cage-side data, this value (5 
µGy), was then subtracted from all daily cage-side readings.  
 
3.5.6 Cage-side radiation exposure readings 
 
Once the subtraction of background radiation exposure from the cage-side 
radiation exposure readings was performed, the potential additional radiation 
exposures that owners may have been exposed to, had the study cats been 
released at an earlier period than 21 days were calculated. Three new isolation 
lengths in this study were assessed: seven days, 14 days and 17 days (Table 6). 
To give an example of the calculations: 
• For an isolation period reduction to seven days, the daily radiation 
exposures from days eight to 21 were added together for each study cat. 
This calculated value was the total additional radiation exposure that the 
owners would hypothetically have been exposed to over that time period, 
assuming they were constantly in close contact with their cat.  
 
From the data collected, the additional radiation dose exposure to owners 
following a reduction of the isolation period to seven days would have had a 
mean value of 310 µGy, with a range of 28-951 µGy. Had the isolation period 
been shortened to 14 days, the mean value of the additional radiation dose 
exposure to owners would have been 40 µGy, with a range of 0 to 115 µGy and 
following a 17 day isolation period the mean additional radiation dose exposure 
would have been 14 µGy, with a range of 0-43 µGy (Table 6). On the 21st (final) 
day of the isolation period, the mean radiation exposure recorded by the EPD 
was 3 µGy/day, with a range of 0 to 11 µGy.  
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Had a 17-day isolation period been used, all cats would have emitted < 100 
µGy over the remainder of the 21-day isolation period but only 14/20 cats would 
have emitted < 20 µGy. Had the isolation period been reduced to 14 days, 18/20 
(90%) cats would have emitted < 100 µGy and 5/20 cats would have emitted < 20 
µGy over the remainder of the isolation period. However had a seven day 
isolation period been used, only 4/20 cats would have emitted < 100 µGy and 
none of the study cats would have emitted < 20 µGy over the following 14 days.  
 
Therefore, using these results of γ radiation emission, 14/20 cats would be 
within the 1/50th of the annual limit criteria i.e. < 20 µSv if using a 17-day 
isolation period but this would reduce to no cats if using a seven day isolation 
period. However, all cats would be within the 1/10th of the annual limit criteria 
using a 17-day isolation period i.e. < 100 µSv, compared to only 4/20 (20 %) cats 
if using a seven day isolation period.  
 
Due to insufficient statistical power in the pilot study it was not possible to 
assess if the dose of I131 had a significant effect on the additional dose exposures 
to owners using a seven, 14 or 17-day isolation period. An expansion of the study 
population from 12 cases to 20 cases did enable this to be assessed; however, no 
statistical significance was found (P-values > 0.05). 
 
In regards to the dose of I131 administered, the EPD measured 53.2 µGy of γ 
radiation/day more from cats injected with 200 MBq compared to cats who had 
been injected with doses < 200 MBq. This difference was found to be statistically 
significant (P = 0.002). However, there were no significant differences found 
between the daily γ radiation emitted by cats treated with doses of 80, 120, 150 
or 175 MBq.  
 
3.5.7 Renal disease 
 
Previous studies have shown that I131 is excreted through the kidneys of treated 
cats, as the urine from these cats has been found to emit radiation (Feeney et 
al., 2003; Lamb et al., 2013). It was therefore possible that renal disease in the 
study cats may have affected the rate of excretion of I131 in their urine. Due to 
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this the study group was evaluated to assess for the development of overt 
renal disease following I131 treatment. The study cats were followed up for 
varying time periods, ranging from zero to 24 months.  
 
Of the 20 cats in the study only three were known to develop renal disease 
following treatment; however, only one of these cases had renal disease 
unmasked immediately following resolution of their hyperthyroidism. As only one 
case developed renal disease during the three week isolation period post-
treatment, the statistical evaluation of the impact of renal disease on the 
excretion of I131 in urine was underpowered and therefore not performed.  
 
Of the three cases that developed renal azotaemia in the follow up period, the 
first case had persistent increases in their serum creatinine concentration, with 
values consistently > 200 µmol/l (laboratory reference interval 91-180 µmol/l) 
following I131 treatment. These increases in serum creatinine concentrations 
were in the absence of known pre-renal or post-renal causes of azotaemia and 
the cat had a USG of 1.017, indicating a reduced concentrating ability. This cat 
had been administered 120 MBq of I131 and was calculated to have had radiation 
emissions of < 100 µGy at both the 14-day and 17-day isolation points (Case 12, 
Tables 5 and 6).  
 
The second cat was diagnosed with renal disease five months following 
treatment with I131 when it was found to have persistent increases in its serum 
creatinine concentration > 180 µmol/l and a USG of 1.026 in the absence of pre- 
and post-renal causes. This cat had been injected with 80 MBq of I131 and also 
had total radiation emissions < 100 µGy at both the 14-day and 17-day isolation 
points (Case 7, Tables 5 and 6). This cat was also found to remain hypothyroid 
following treatment with a low serum T4 concentration and a high serum cTSH 
concentration and was subsequently started on levothyroxine supplementation. 
Despite the start of levothyroxine supplementation the cat remained azotaemic.  
 
The third cat was diagnosed with renal disease 21 months following I131 
treatment. The diagnosis of renal disease at its referring veterinary practice was 
based on an azotaemia (blood urea nitrogen concentration 33.2 mmol/l, serum 
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creatinine concentration 316 µmol/l) and hyperphosphataemia (3.09 
mmol/l); however, a USG was not recorded. This cat had received 200 MBq of 
I131 and had total radiation exposures of < 100 µGy at both the 14-day and 17-day 
isolation points (Case 11, Tables 5 and 6). This cat was euthanized 10 weeks 
after the detection of its renal azotaemia due to deterioration in quality of life 
secondary to renal disease. 
 
3.5.8 Continuation of hyperthyroidism following I131 
 
Three of the 20 cats in this study continued to be biochemically ± clinically 
hyperthyroid following I131 treatment. The first case was originally treated with 
120 MBq of I131 and had a higher post-isolation serum T4 concentration (459 
nmol/l) than pre-treatment (210 nmol/l) (Case 4, Table 5). This cat was 
subsequently treated again with I131 two months later using a higher dose of 250 
MBq. This resulted in resolution of the hyperthyroidism; however, the cat 
became persistently biochemically hypothyroid and was started on levothyroxine 
supplementation.  
 
The second case that had a serum T4 concentration still above the reference 
interval following treatment received 175 MBq of I131. The serum T4 
concentration had reduced from 278 nmol/l pre-treatment to 104 nmol/l post-
treatment (Case 3, Table 5). On follow-up this cat’s serum T4 concentration was 
found to have normalized four months post-treatment.   
 
The final cat was treated with 200 MBq of I131 and had a serum T4 concentration 
pre-treatment of 257 nmol/l that reduced to 144 nmol/l post-treatment (Case 
11, Table 5). This cat was followed up and similar to case three, the serum T4 
concentration returned to within the reference interval by four months post-
treatment. 
 
Due to insufficient statistical power it was not possible to assess if the mean 
radiation emissions of the three cats that remained biochemically hyperthyroid 
were significantly different from the 17 cats that became biochemically 
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euthyroid/hypothyroid, had they been discharged following a seven-day, 14-
day or 17-day period of isolation. 
 
3.6 Discussion 
 
There are currently several institutions within the UK that offer I131 as a 
treatment option for feline hyperthyroidism. However, following administration 
of I131 the isolation period of treated cats varies between them (Lamb et al., 
2013; Boland et al., 2014). This variability in isolation periods is due to a 
combination of factors. These include local radiation rules and radiation 
legislation and the dose of I131 that is administered, as some centres use a 
variable dose of I131 dependent on the severity of hyperthyroidism, where as 
other centres use a fixed dose of I131 (Boland et al., 2014). 
 
This study has shown that EPDs can be used as a monitoring option for measuring 
the γ radiation emitted from hyperthyroid cats treated with I131, proving the first 
hypothesis of this study to be correct. These dosimeters also offer an advantage 
over other monitoring options as they continuously monitor radiation emissions. 
This is compared to other modalities that only assess spot sample radiation 
emissions e.g. Geiger-Müller counters.  
 
As these monitors can be clipped onto the cage door and be easily removed and 
therefore do not involve holding the monitoring equipment whilst readings are 
taken, they could also reduce the γ radiation levels that staff are exposed to and 
are less operator dependent. This is in comparison to other methods such as the 
Geiger-Müller counter, which require a staff member to hold the counter at a 
set distance from the treated cat to obtain readings (Feeney et al., 2003).   
 
3.6.1 Length of isolation following treatment with I131 
 
As discussed, there are dose limits put in place to limit the radiation exposure 
that members of the public are exposed to; however, regulating bodies can 
allow public dose commitments of 20 µSv and 100 µSv (ICRP, 2005; Environment 
Agency, 2012). For a public dose commitment of 100 µSv, restrictions must be 
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put in place including the dose commitment being restricted to a small group 
of the public, which for the use of I131 in cats would be the restriction of this to 
the owners of the cats.  
 
This study found that none of the cats were within the 1/50th of the annual limit 
criteria had a seven day isolation period been used, only 25 % (5/20) cats were 
within it had a 14-day isolation period been used but 70 % (14/20) cats were 
within it had a 17-day isolation period been used. In comparison, 20 % (4/20) 
cats were within the 1/10th of the annual limit criteria with a seven day isolation 
period, 90 % (18/20) cats with a 14-day isolation period and 100 % (20/20) cats 
were within this limit using a 17-day isolation period. These results would 
suggest that the isolation period of hyperthyroid cats be reduced from the 
current 21-day period at the SAH, to at least 17 days following treatment with 
I131. However, this would only apply to cats treated with doses ≤ 200 MBq of I131. 
These findings also support the second hypothesis of this study, as they show 
that the EPD can be used to determine the release time of treated hyperthyroid 
cats.  
 
In this study, 35 % (7/20) of the cats were no longer emitting detectable γ 
radiation by the time of exit from the isolation unit, with one cat no longer 
emitting radiation as early as day nine of isolation. After day 14 of isolation 
three cats were no longer emitting radiation and after day 17, five cats were no 
longer emitting radiation. The last two cats in this group were no longer 
emitting radiation on the last day of isolation i.e. day 21. 
 
The radiation data recorded by the EPD, which was located ~ 50 cm away from 
the study cats, was dependent on the cats’ precise location within the kennel at 
any point. The γ radiation that was recorded would have included both external 
and internal radiation hazards from the treated cats. This was due to the fact 
that the EPD will have recorded γ radiation emissions from the treated cats as 
well as from their urine, faeces and saliva. Therefore, the radiation exposure 
that owners of the treated cats would have been exposed to, as documented in 
this study, took both of these factors into consideration.  
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Despite these findings, it is very unlikely that owners are going to be 50 cm 
away from their cats at all times following the cats discharge from the hospital, 
especially as it is currently recommended by the SAH that there be limited 
contact between the owner and treated cat for a two week period following 
discharge. However, to assess this further, by averaging the daily γ radiation 
emissions from all the study cats during days 15 to 21 of isolation, the additional 
dose exposure to the owner would have been 1.84 µGy/hour. Due to this level of 
dose exposure, combined with the fact that only 20 % of the cats emitted 
potential additional dose commitments to the owners > 100 µSv following day 14 
of isolation, a reduction of the SAH isolation period to 14 days is also feasible. It 
would still be advised that owners limit contact with their treated cat post-
treatment with this new isolation length; however, this period of limited contact 
could be shortened to one week.  
 
A reduction of the isolation period following injection of I131 at the SAH, to lower 
than 14 days is not recommended. This is due to the findings from a previous 
study, which was also based at the SAH that assessed the radioactivity of the 
faeces and urine excreted by cats treated with I131. In that study it was found 
that the faeces and urine of the cats treated with doses of I131 ≤ 200 MBq were 
only able to be designated for disposal as ‘very low level waste’ two weeks 
following administration of I131 (Lamb et al., 2013). Due to the concerns 
highlighted by that study regarding the disposal of the urine and faeces from 
treated cats in the home environment for the immediate 14 days following 
treatment, isolation periods should not be reduced to a shorter time period than 
two weeks.  
 
Reducing the current length of hospitalization for hyperthyroid cats following 
treatment with I131 could result in this treatment modality being more commonly 
utilized, as well as making it potentially more affordable for some owners. 
Previous work assessing factors that may influence owners decisions when 
choosing a treatment option for their hyperthyroid cat, has found that owners do 
have concerns regarding the length of hospitalization following treatment with 
I131 and this factor could actually deter some owners from pursuing this option 
(Boland et al., 2014). Costs associated with I131 treatment have also been shown 
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to effect the frequency with which practitioners consider this as their 
preferred treatment option for hyperthyroid cats in the UK (Higgs et al., 2014). 
A reduction of the isolation period and therefore the costs associated with this 
treatment may negate some of these concerns. 
 
A previous study identified that the only factor that could be used to determine 
isolation duration following administration of I131 was the dose administered 
(Weichselbaum et al., 2003). It was therefore suggested that the lowest dose of 
I131 should be used in each case. Although in the current study it was found that 
cats treated with the highest doses of I131 i.e. 200 MBq, emitted more γ 
radiation/day than other doses, all three cats treated with this dose emitted  
< 100 µGy over days 15-21 of isolation. This would suggest that the dose of I131 
used does not appear to have such a marked effect on isolation times. This was 
shown even further in this study by the finding that the dose of I131 administered 
did not affect the total additional dose exposures at any of the three proposed 
time frames of a seven-day, 14-day or a 17-day isolation period. However, the 
difference in findings between this study and the Weichselbaum et al., (2003) 
study may have been due to the difference in sample size included in each study 
at 20 cases and 149 cases, respectively.  
 
In the current expanded study it was found that cats injected with 200 MBq 
emitted 10 times the amount of γ radiation/day than was detected in the pilot 
study (Roberts et al., 2015). A definitive cause for this difference was not 
apparent; however, a possible contributing cause may have been the exclusion 
of one of the cases used in the pilot study. The excluded case had incomplete 
data recorded at the beginning of the isolation period, which is the time when 
the highest radiation exposures are recorded as the I131 has only recently been 
administered. In order to explore this difference in daily γ radiation emissions 
further, the γ radiation emissions of more cats treated with 200 MBq would need 
to be assessed in a future study. 
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3.6.2 Effect of renal disease on I131 excretion 
 
One of the main routes of I131 excretion in cats has previously been shown to be 
via the urine (Lamb et al., 2013). It has also been shown that following 
treatment with I131, the GFR of the kidneys decreases, with the maximum drop 
in GFR being detected at four weeks post-treatment (Boag et al., 2007; van 
Hoek et al., 2009). Due to this there is a possibility that the unmasking of, or 
development of, renal disease in these cats during the isolation period may 
affect the excretion rate of the γ radiation. In this study there was only one cat 
that developed overt renal azotaemia during the isolation period so it was not 
possible to draw conclusions on the impact of this on the study results. This cat 
had γ radiation emissions of < 100 µGy at both the 14-day and 17-day isolation 
points, which would suggest that the excretion of radiation had not been 
significantly affected by the development of azotaemia. However, to draw more 
definitive conclusions, larger numbers of cats with immediate unmasking of 
renal disease following treatment would need to be included in a future study. 
 
3.7 Limitations 
 
3.7.1 Lack of comparison 
 
In this study only the data collected from the EPD was evaluated and a direct 
comparison of this data with another radiation recording modality e.g. a Geiger–
Müller counter was not performed. However, as the data recorded by the EPD 
resulted in the calculation of similar effective half-lives of I131 when compared 
to Puille et al., (2002), it was concluded that the EPD could reliably assess the γ 
radiation emitted by the cats in the study. Although it would have been ideal to 
perform a direct comparison of the data collected by the EPD to data collected 
using an alternative technique, it was not possible to do this. The original 
unpublished data collected at the SAH in the 1990’s, which forms the basis of 
the current local radiation rules at the SAH, can no longer be accessed. The 
studies performed for the Scottish Environment Protection Agency in the 1990’s 
were performed to address their concerns regarding environmental 
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contamination from urine and faeces from treated cats; however, no 
assessment was made of the radiation hazards posed to the owners of treated 
cats.  
 
The current local radiation rules at the SAH reduce the exposure of staff to 
radiation by reducing the need for monitoring of radiation emissions. Therefore, 
for the purposes of this study, the exposure rate of staff to radiation could not 
be increased by starting to monitor the cats in a more intensive manner i.e. by 
use of a Geiger-Müller counter. This combination of factors resulted in it not 
being possible to obtain radiation data using other radiation monitoring 
methodology to compare the data collected from the EPD to. 
 
3.7.2 Case numbers 
 
Although this was an expansion of a previously published study, a main limitation 
of this study was still the sample size (Roberts et al., 2015). Unfortunately, the 
small sample size included in this study, despite the study being carried out over 
several years, was in part due to the hyperthyroid case load at the hospital, 
combined with the fact that only one cat could be included every three weeks 
due to the need for them to be in a specific monitoring kennel. A further 
expansion of the study group may have allowed additional statistical analyses to 
be performed e.g. evaluation of the development of renal disease on the 
excretion of radiation.  
 
3.7.3 Assessment of renal insufficiency 
 
Whilst considering the topic of renal azotaemia, it is possible that cats with 
early IRIS stage renal disease i.e. stages I or II may have been overlooked in this 
study. This was because urine samples were not routinely collected post-
treatment to assess the USG nor did assessment of GFR occur before or after 
treatment. Therefore, this is also a limitation of this study.  
 
Of the 20 cats included in the study, seven cases had post-treatment serum 
creatinine concentrations > 140 µmol/l, which is the current lower reference 
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limit for IRIS stage II chronic renal disease (IRIS, 2013).  Unfortunately, only 
two of these cases had post-treatment urine samples collected following 
isolation, with one of these cases being the case diagnosed with renal 
azotaemia. The other case had a USG of 1.046, suggesting sufficient renal 
concentrating ability.  
 
Ideally, in future studies, the GFR ± serum symmetric dimethylarginine would be 
assessed before and after I131 treatment to correctly identify cases that may 
have renal disease unmasked, rather than solely relying on the development of 
overt azotaemia as this may miss cases of early renal disease i.e. IRIS stage I and 
II cases (Hall et al., 2014).  
 
3.7.4 Battery life of the EPD 
 
The other main limitation of this study, which was only relevant at the start, 
was the battery life of the dosimeter. A battery failure during the recording 
period resulted in four cases having data incompletely recorded and these cases 
were therefore excluded from the study group. However, following these case 
exclusions, it was found that complete data sets would be obtained as long as 
the battery in the EPD was replaced after every third cat in the monitoring 
kennel and that the battery was also removed when the dosimeter was not in 
use.  
 
3.7.5 Location of the monitor kennel dosimeter 
 
One further possible limitation in this study was the placement height of the 
dosimeter on the kennel door, when compared to the height of the cat’s thyroid 
gland, as well as the distance of the cat from the dosimeter. The dosimeter was 
placed in the same place on the cage door for all cases in this study, as this 
position was the most secure and easiest place for its attachment. This position 
was 42 cm above the floor of the kennel, which would have been above the 
height of the cats’ thyroid. However, due to the directionality of the monitor, 
which is linear over a 150° cone area, combined with the fact that there were no 
objects in the kennel that would allow the cats to climb onto higher surfaces, it 
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is unlikely that this would have had a substantial effect on the results 
obtained (Roberts et al., 2015).  
 
As the position of the dosimeter was fixed but the monitored cats position would 
vary each day, there is a potential that this may have affected the data 
collected in this study. This is due to the fact that radiation exposure obeys the 
inverse square law i.e. a doubling of the distance results in a reduction in the 
radiation exposure by a factor of four. However, as the monitored cats would 
move around the kennel daily and be noted to be in variable positions within the 
kennel, the variation in the distance from the dosimeter would likely even out 
each day and therefore minimize the effect on the data collected (Roberts et 
al., 2015). 
 
3.8 Conclusion 
 
The results of this study have shown that the EPD, model MGP DM2000X, can be 
used to monitor the γ radiation emitted from hyperthyroid cats treated with I131. 
The data obtained in this study is suggestive that the current isolation period of 
21 days following administration of I131 could be safely reduced to a maximum 
period of 17 days at the SAH. The data also suggests that the isolation period 
could be further shortened to 14 days, which would be within both current UK 
and ICRP guidelines. However, should a 14-day isolation period be used, it is 
important that the time owners spend in close contact with their cats post-
treatment be limited for the following week. A shortening of the isolation period 
for cats treated with I131 could result in this treatment option being chosen more 
frequently by owners of hyperthyroid cats.  
 
It is advised that additional assessment of this method of radiation monitoring 
be performed at other centres that currently offer I131 as a treatment option for 
feline hyperthyroidism, as well as at centres that use doses > 200 MBq, to assess 
if this method would assist radiation monitoring in their cases as well. 
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CHAPTER 4 
4 CONCLUSIONS 
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4.1 I131 as a treatment modality 
 
Feline hyperthyroidism has become the most common endocrine disease in cats 
and, therefore, it is a relatively frequent condition seen by veterinarians in 
general practice (Peterson, 2012). Multiple treatment options exist for this 
condition, including anti-thyroidal medication, surgery, an iodine-restricted diet 
and I131. According to a survey of general practitioners, the preferred treatment 
options currently within the UK are those of anti-thyroidal medication and 
surgery (Higgs et al., 2014). This preference is most likely influenced by the 
costs associated with I131 treatment and also the lack of inclusion of an iodine-
restricted diet as an option in the survey, due to the diet only just being 
launched prior to the time of the survey in 2012 (Higgs et al., 2014).  
 
Although I131 is not currently the preferred treatment option of general 
practitioners in the UK, it is viewed as the gold standard treatment option for 
this condition (Mooney, 1994; Higgs et al., 2014). Unfortunately, the availability 
of this treatment option is limited within the UK to University environments and 
some private referral practices and this may contribute to the reasons why it is 
not opted for as a first-line treatment, as has been shown in Australia (Kopecny 
et al., 2016).  
 
There is a notable difference between Australia and the UK in regards to the 
preference of practitioners opting to use I131 for treatment of hyperthyroidism in 
cats. In Australia, I131 is the preferred treatment choice of 38 % of general 
practitioners, compared to only 5.5 % in the UK and this difference has been 
partly shown to be due to the increased availability of I131 in Australia (Higgs et 
al., 2014; Kopecny et al., 2016). In the Kopecny et al., (2016) study it was 
identified that a greater number of facilities offering I131 treatment were 
available in Australia compared to the UK. It was also found that the availability 
of centres providing I131 and therefore the time needed to travel to the centre 
had an effect on how often I131 was offered; if the centre was less than two 
hours away 87 % of general practitioners were likely to offer it, compared to 
only 64 % if the centre was more than two hours away. This concern regarding 
distance to a treatment centre was highlighted even further in the same study, 
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by the finding that 48 % of participants marked this factor as a great concern 
caused to owners of hyperthyroid cats (Kopecny et al., 2016). The findings of 
the Kopecny et al., (2016) study would suggest that the availability of I131 
treatment does have an effect on the frequency that it is utilized. Should more 
centres capable of providing I131 treatment be available, then more cats could 
be treated with this modality in the UK. 
 
Treatment with I131 in the short-term is a more expensive option when compared 
to the costs associated with anti-thyroidal medication. However, for cost-
effectiveness in the long-term, I131 treatment is superior to anti-thyroidal 
medication where the costs of medication combined with associated blood 
monitoring are spread out over many months to years (Trepanier, 2007; Daminet 
et al., 2014). Costs of I131 treatment have been shown to have an effect when 
choosing a treatment option for hyperthyroidism, both by general practitioners 
and owners and it is one of the main reasons why anti-thyroidal treatment is 
preferred in the UK (Boland et al., 2014; Higgs et al., 2014).  
 
In both the Higgs et al., (2014) and Kopecny et al., (2016) studies, the 
preference of utilizing I131 as a treatment option by general practitioners was 
shown to be influenced by costs. In both studies when costs were eliminated as a 
consideration factor, the utilization of I131 as the preferred treatment option was 
found to increase by 40 % (Higgs et al., 2014; Kopecny et al., 2016). Costs 
associated with I131 are also thought to be a great concern for 82 % of owners 
when deciding on treatment options, as viewed by general practitioners 
(Kopecny et al., 2016). Despite the findings in Kopecny et al., (2016), an owners 
decision was not found to be impacted by costs in 51.3 % of cases when the 
views of owners were directly assessed, but this may have been influenced by 
whether or not their cat was insured (Boland et al., 2014). 
 
The study by Boland et al., (2014) specifically set out to identify factors that 
may affect owners’ treatment choices when deciding on what option to choose 
for their cats’ hyperthyroidism. They also assessed the owners’ experiences of 
I131 treatment, which were found to be very good, with > 90 % of owners being 
happy in their decision to pursue I131 treatment in their cat. The study also 
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showed that owners perceived a marked improvement in the quality of life of 
their cat following treatment with I131 (Boland et al., 2014). The study 
highlighted that one of the main factors as to why I131 is not chosen by some 
owners, is due to the fact that many owners are not made aware of this as a 
treatment option. The finding that owners are not made aware of all the 
possible treatment options for their hyperthyroid cat has also been corroborated 
by the findings of other studies (Caney, 2013; Kopecny et al., 2016). In Caney 
(2013), owners of cats receiving anti-thyroidal medication were surveyed and ~ 
30 % of owners had only been made aware of anti-thyroidal medication as a 
treatment option for their cat. In Kopecny et al., (2016), only 39 % of 
practitioners were found to routinely offer I131 to owners of hyperthyroid cats. 
These study findings would suggest that I131 could become a more popular 
treatment option in the UK, if owners are made more aware of it. They also 
highlight the point that veterinary surgeons should be making owners aware of 
all possible treatment options available for the treatment of hyperthyroidism in 
their cat. 
 
Boland et al., (2014) also found that owners do have concerns about the length 
of hospitalization associated with I131 treatment. Those concerns (in decreasing 
frequency) included their cat being unhappy, the owner missing the cat, the cat 
developing inappetance, other pets missing the cat, the development of co-
morbid disease, and side effects caused by the treatment (Boland et al., 2014). 
In Australia, where hospitalization times are generally shorter than the UK at 
five to seven days, I131 is also a more popular option (Kopecny et al., 2016). As 
there is no requirement for hospitalization for sustained periods of time with the 
use of anti-thyroidal medication, an iodine-restricted diet or surgery (unless 
hypocalcaemia occurs post-thyroidectomy), this factor will contribute to reasons 
why these treatment options are preferentially pursued over I131 in the UK 
(Boland et al., 2014). This combination of findings would suggest that more 
owners in the UK would opt for I131 treatment in their cat, if hospitalization 
periods associated with the treatment were reduced.  
 
These previous studies highlight several concerns associated with the use of I131 
as a treatment option in cats with hyperthyroidism, including the concerns 
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associated with cost and length of hospitalization (Boland et al., 2014; Higgs 
et al., 2014; Kopecny et al., 2016). The length of hospitalization following I131 
treatment in the UK is quite variable, from as little as five days up to six weeks 
(Lamb et al., 2013; The Hyperthyroid Cat Centre, 2015). This is due to local 
radiation rules and legislation, as well as the dose of I131 that is administered. 
The longest periods of hospitalization following treatment i.e. six weeks, are 
used when high doses of I131 (1100 MBq) are administered in cases of thyroid 
carcinoma (Hibbert et al., 2009; Lamb et al., 2013). The costs associated with 
I131 treatment, which in part are due to the costs associated with hospitalization 
times, can have a marked effect on the decision as to whether I131 is pursued 
(Higgs et al., 2014; Kopecny et al., 2016). Therefore, if a shorter isolation 
period could be used following administration of I131, this could result in a 
reduction of associated costs. If this was achieved it could make I131 a more 
popular treatment option, as this would negate two of the concerns voiced by 
general practitioners and owners.  
 
For some diseases in veterinary medicine, direct comparisons can be drawn from 
similar diseases in human medicine and this can aid the understanding and 
treatment of such conditions. Feline hyperthyroidism has been shown to be one 
of these conditions, as it has been compared to the condition toxic nodular 
goiter in humans (Peterson, 2014). Anti-thyroidal medication is the most popular 
treatment choice in cats with hyperthyroidism (Higgs et al., 2014). In contrast, 
in humans with toxic nodular goiter, it is actually advised not to use this 
treatment option long-term and instead they advise surgery or the use of I131 (De 
Leo et al., 2016). Therefore, if these two conditions are seen as being similar, 
then this would suggest that I131 as a treatment option in cats should be pursued 
more often.  
 
Hyperthyroidism in cats has been shown to be a progressive disease, with 
increases in disease severity, tumour size, prevalence of multifocal disease and 
thyroid carcinomas seen with increasing disease duration (Peterson et al., 
2016a). The use of I131 in the treatment for feline hyperthyroidism has been 
shown to be associated with longer survival times post-treatment, when 
compared to the use of methimazole alone (Milner et al., 2006). These findings 
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would suggest that definitive treatment of this condition with I131 should be 
pursued at the earliest time point in cats with hyperthyroidism, to prevent 
progression of the disease and also result in longer survival times when 
compared to anti-thyroidal medication. This may be an easier task to achieve if 
hospitalization periods are shorter and therefore associated costs are lower as 
well.  
 
4.2 Ionising radiation 
 
The main reason why isolation periods exist following treatment with I131 is due 
to the concerns regarding the γ radiation emitted by the treated cats and the 
risks that this radiation poses to humans. However, this study has shown that the 
level of γ radiation that owners would be exposed to, should the treated cats be 
released from the isolation unit one week earlier i.e. following 14 days of 
isolation, is within an acceptable limit, as long as certain precautions are taken.  
 
Humans are exposed to ionising radiation on a daily basis from many natural and 
man-made sources. These sources include exposure from cosmic radiation, 
terrestrial radiation from sources in the earths crusts e.g. uranium, exposure 
through inhalation e.g. inhalation of radon from soil/bedrock, exposure through 
ingestion of radiation sources, x-rays and working or living with people that are 
being medically treated with radiation. These ionising radiation sources also 
come in different forms including alpha (α) radiation, β radiation, γ radiation, x-
rays and neutron radiation and the penetration of these types of radiation also 
differ (Canadian Nuclear Safety Commission, 2015).  
 
Ionising radiation can cause radiation damage to human tissues, depending on 
the amount of radiation that they are exposed to, the time period over which it 
occurs and the individual tissue/organ sensitivity to radiation. There is also a 
concern that exposure to ionising radiation, depending on the dose and dose 
rate, can result in cancer in the long-term, as voiced by the World Health 
Organization (World Health Organization, 2016).  
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Due to this, there are legal limits in place for members of the public in 
regards to the level of ionising radiation that they can be exposed to. These 
limits include a yearly exposure of one mSv and a one-off exposure of 300 µSv 
(Ionising radiations regulations, 1999; Environment Agency, 2012). Therefore, 
there is a requirement and duty of care to ensure that humans are not put at 
undue risk by exposing them to levels of ionising radiation that are higher than 
legal levels.  
 
Exposure of owners to ionising radiation above these levels should therefore be 
avoided. By shortening the current isolation time post-treatment for 
hyperthyroid cats treated with I131, it was important to ensure that this would 
not result in owners being unnecessarily exposed to unacceptable levels of 
ionising radiation. The EPD used in this study documented that the level of 
potential ionising radiation that owners would be exposed to, should the 
isolation period be shortened to 14 days, was within an acceptable level. This 
was as long as certain precautions were put in place for the following week after 
the cat was discharged from hospital, which are already part of the standard 
practice at the SAH. These precautions include: 
• Owners being asked to limit their contact with the treated cat to short 
periods of time, i.e. < 10 minutes/day. 
• Owners avoiding face-to-face contact with their cat. 
• Owners not allowing the cat to sleep on their bed. 
• Owners washing their hands after handling the cat and using non-
absorbable, disposable gloves to dispose of the cats’ urine and faeces. 
• Keeping the cat indoors for the week following discharge from the 
hospital. This precaution prevents other members of the public from 
being exposed to ionising radiation from the treated cat. 
• Keeping the cat away from food preparation areas. 
• Using litter tray liners for the first week and placing these and the used 
litter they contain into a black plastic bin bag which is then placed into a 
shed/garage. In the second week following the cats’ discharge from 
hospital, the black bin bag can be sealed and disposed of in the normal 
dustbins.  
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Studies have been performed in the human field that have documented and 
measured the external radiation exposure that family members, members of the 
public, caregivers and even pets are exposed to following I131 treatment in 
humans (Grigsby et al., 2000; Pant et al., 2006; Marriott et al., 2007; Ostinelli 
et al., 2015). In particular, the study by Grigsby et al., (2000) assessed the 
radiation exposure to household members and household pets during the 10-day 
period following administration of I131 to a family member. The average 
radiation dose to household members was 240 µSv and to household pets was 370 
µSv and these doses were deemed to be safe according to the local radiation 
legislation. Those mean values were much higher than the radiation exposure 
owners would be exposed to should a 14-day isolation period be used at the SAH, 
as documented by the data recorded by the EPD. 
 
In humans, to ensure that the dose of radiation that family members are 
exposed to remains less than one mSv following treatment with I131, it is advised 
that a time period of 15 days be put in place during which in contact time with 
family members should be restricted (IAEA, 2009). This includes the requirement 
that the treated patient sleep apart from their partner, which is defined as 
equal or greater than one metre apart, for up to eight hours. These 
recommendations are specific for when doses of 200 MBq are used. This is also 
the maximum dose that is usually administered to cats at the SAH, unless a cat is 
being specifically treated for a thyroid carcinoma (Hibbert et al., 2009). 
Therefore, the proposed reduction of the post-isolation period to 14 days in cats 
treated with ≤ 200 MBq of I131 at the SAH, combined with the advised precautions 
that are put in place for the week following discharge, would result in owners 
being exposed to levels of radiation that are within the radiation safety limits 
currently advised by the IAEA and ICRP.   
 
The isolation period of treated cats would ideally be reduced to the shortest 
time possible. Although data from this study has shown that the current isolation 
period of 21 days can be reduced to 14 days, it would not be feasible to reduce 
this isolation period any further. This is due to the levels of γ radiation present 
in the excreted faeces and urine of these cats during the first two weeks of the 
isolation period, following injection of I131 (Lamb et al., 2013).  
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The results of this study have allowed the current isolation period at the SAH 
to be reduced, whilst ensuring that this reduction will not lead to owners being 
exposed to levels of ionising radiation above that allowed by radiation 
legislation.  
 
4.3 Weight changes in hyperthyroidism 
 
There are similarities drawn between hyperthyroidism in cats and 
hyperthyroidism in humans (Peterson, 2014). The overall prevalence of 
hyperthyroidism in humans is 0.8 to 1.3 %, dependent on geographical location, 
compared to an even higher prevalence in cats of 3 % and in both species this 
prevalence has been found to increase with age (Garmendia Madariaga et al., 
2014; O’Neill et al., 2014; De Leo et al., 2016). One of the main concerns voiced 
by human patients undergoing treatment for hyperthyroidism is the weight gain 
that may ensue (Dale et al., 2001).  
 
This weight gain can be excessive, with a prevalence of obesity as high as 32 % 
documented in some cases (Brunova et al., 2003). It has been found that the 
amount of weight that is gained by patients following treatment for 
hyperthyroidism can be affected by a multitude of different factors, including 
the treatment modality used, gender, ethnicity and age of the patient, as well 
as the amount of weight loss experienced by the patient prior to treatment 
(Dale et al., 2001; Ariza et al., 2010; Lang et al., 2016). 
 
Although weight gain is commonly seen in hyperthyroid cats following treatment, 
there are only a limited number of studies that document the actual values seen 
in their study findings (Boag et al., 2007; Jaillardon et al., 2012). In contrast, 
there are several studies in the human field that have broached this subject 
more extensively (Ariza et al., 2010; van Veenendaal & Rivkees, 2011; Lang et 
al., 2016). Therefore, one of the aims of this study was to add to the current 
literature on this topic in cats, by specifically assessing the weight changes in a 
feline hyperthyroid population when treated with I131.  
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The results of the study concurred with previous studies findings that weight 
gain does occur following treatment and subsequent reversal of hyperthyroidism 
(Finch et al., 2012; Jaillardon et al., 2012). Although the weight changes of cats 
over the three-week period following I131 treatment had already been 
documented by Finch et al., (2012), their study had only included a very small 
number of cases (n = 10), compared to the larger study size of 114 cases in this 
study.  
 
This study also specifically assessed whether factors such as age or gender of the 
cat had an effect on the weight changes seen in this population of treated cats. 
These factors had not been previously assessed in studies on feline 
hyperthyroidism, despite these factors being examined in the human field (Ariza 
et al., 2010; Lang et al., 2016).  
 
The cats included in this study were all treated with I131 and weight changes 
using other treatment modalities were not assessed. Due to this it cannot be 
ascertained whether the weight changes of cats treated with other modalities 
(e.g. anti-thyroidal medication) may be similar to those seen in this study, 
especially given the findings from studies assessing iodine-restricted diets that 
have shown minimal weight gain to occur (Hui et al., 2015; Scott-Moncrieff et 
al., 2015). The preferred treatment of choice for hyperthyroidism by general 
practitioners in the UK is currently anti-thyroidal medication (Jaillardon et al., 
2012; Higgs et al., 2014). Therefore, future studies should be performed to 
assess the weight changes seen in cats treated this way in more detail. 
 
This study also only assessed the weight changes over a short-time frame 
following treatment for hyperthyroidism in cats; however, the main amount of 
weight gain in humans has been shown to occur over a longer time period 
(Brunova et al., 2003). Although Boag et al., (2007) and van Hoek et al., (2009) 
have assessed the weight changes in cats treated with I131 up until the six month 
period post-treatment, there have yet to be any studies assessing the weight 
changes of cats treated with I131 past this point. Should the assessment of 
longer-term weight changes be investigated in cats, the impact of comorbid 
disease on this would also need to be evaluated due to the previous findings that 
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many hyperthyroid cats develop renal disease or neoplasia on follow-up 
(Slater et al., 1994).  
 
4.4 Is assessment of serum T4 concentration all that is needed to assess the 
control of hyperthyroidism? 
 
Although assessment of serum T4 concentration is the gold standard for assessing 
control of hyperthyroidism in cats, one of the study aims was to assess whether 
percentage weight gain could be used as a predictor of the achievement of 
reversal of overt hyperthyroidism (Daminet et al., 2014). The results of this 
study have shown that percentage weight gain can be used as an indicator of the 
serum T4 concentration reducing to either within or below the reference 
interval, therefore showing that it could be used as an additional factor when 
assessing the efficacy of treatment for hyperthyroidism using I131. The 
advantages of using percentage weight gain include the ease with which this 
information can be collected and the lack of cost associated with it. However, as 
the study identified that percentage weight gain could not differentiate 
between the achievement of biochemical euthyroidism and biochemical 
hypothyroidism, the measurement of serum T4 concentration should still be 
performed.  
 
4.4.1 Subclinical/physiological hyperthyroidism 
 
A recent study has also supported the need to assess weight gain when assessing 
a cats’ response to treatment for hyperthyroidism, as well as the serum T4 
concentration (Hui et al., 2015). The study by Hui et al., (2015) showed 
contrasting findings when assessing control of hyperthyroidism in a hyperthyroid 
population treated with an iodine-restricted diet. Although the serum T4 
concentration reduced to within the reference interval in 83 % of cats treated 
with the specific diet, their body weight did not significantly increase (nor did 
their heart rate significantly decrease), which was unexpected. Two reasons 
were proposed for this lack of weight gain, the first of which was the presence 
of undetected concurrent illnesses. The second proposed reason was that some 
of these cats were actually still physiologically hyperthyroid despite having a 
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normal serum T4 concentration. This reason would also support the lack of 
evidence of the cats’ heart rates decreasing despite effective treatment.  
 
This syndrome of subclinical/physiological hyperthyroidism has been described in 
humans and is classified by a low or undetectable serum TSH concentration in 
the face of normal serum fT4 and fT3 concentrations (Biondi & Cooper, 2008). 
This syndrome has also been associated with an increased heart rate and weight 
loss, as well as having a potential association with increased cardiovascular and 
skeletal risks in humans (Biondi et al., 1999; Santos Palacios et al., 2012; Biondi 
et al., 2015). 
 
Unfortunately, the use of serum cTSH concentration in cats with thyroid disease 
is limited in that the current assay of serum cTSH concentration cannot 
distinguish low-normal values from low or suppressed values (Peterson et al., 
2015). Due to this, the use of serum TSH concentration cannot be relied on for 
detecting subclinical hyperthyroidism in cats to the same degree that it is in 
humans (Biondi et al., 2015).  
 
There could be potential concerns of subclinical hyperthyroidism occurring in 
cats despite apparently effective treatment being reported given the findings in 
humans (Biondi et al., 1999; Hui et al., 2015). However, due to the inability of 
serum cTSH concentration to definitively differentiate low-normal from 
suppressed values, a definitive diagnosis of subclinical hyperthyroidism is 
difficult to obtain in cats and it highlights the need to consider more than just 
blood tests when assessing control of hyperthyroidism in this species (Peterson 
et al., 2015). Indeed in the current study, 10/101 (9.9 %) cases that became 
biochemically euthyroid/hypothyroid did not gain weight during the three-week 
isolation period, raising suspicion as to whether these cases could have still been 
physiologically hyperthyroid as proposed by Hui et al., (2015).  
 
This concern regarding physiological hyperthyroidism opens up the possibilities 
for further research in this field. Potential future studies could involve assessing 
weight changes both in the short and long-term in hyperthyroid cats being 
treated with the different treatment modalities-surgery, anti-thyroidal 
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medication, I131 and an iodine-restricted diet, as well as assessing the control 
of hyperthyroidism in more detail. This would include not only measurement of 
their serum T4 concentration but also of their serum fT4, fT3 and cTSH 
concentrations (taking into account the caveats associated with measurement of 
serum cTSH concentration), and physical examination findings such as heart rate 
(Hui et al., 2015; Peterson et al., 2015). 
 
4.5 Concluding thoughts 
 
The findings of the two studies in this thesis add to the current literature on I131 
treatment in hyperthyroid cats. They have illustrated the weight changes that 
occur in the three-week isolation period following the administration of I131 on a 
larger scale than previously documented. They have also shown that these 
changes can be used as an additional factor when assessing the efficacy of 
treatment of the cats’ hyperthyroid state; however, they do not replace the 
requirement for assessment of serum T4 concentration.  
 
The studies have also shown that the level of γ radiation emitted by these 
treated cats can be detected using EPDs. This method of detecting γ radiation 
allows for a more continuous recording of data from these treated cats, which 
has now enabled the current isolation period at the SAH to be reduced. The 
reduction in hospitalization time could result in I131 treatment being more 
commonly used. 
 
The findings of the γ radiation study in this thesis will also directly benefit future 
studies on the weight changes in hyperthyroid cats treated with I131. The 
isolation period for cats injected with I131 is now to be reduced to two weeks at 
the SAH. This will permit the weight changes that occur in this population over 
the first two weeks following treatment to be assessed and compared to the 
weight changes seen at the three week point post-treatment documented in this 
study. This will add further data to the current literature on weight changes in 
hyperthyroid cats, improving our knowledge and understanding of this disease in 
cats.  
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